<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003839.pub3" GROUP_ID="VASC" ID="680902051013042636" MERGED_FROM="" MODIFIED="2016-06-30 21:47:23 +0100" MODIFIED_BY="Abigail Baldridge" REVIEW_NO="0122" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2016-06-30 21:46:22 +0100" MODIFIED_BY="Abigail Baldridge">
<TITLE MODIFIED="2009-03-27 09:06:17 -0500" MODIFIED_BY="Joey Kwong">Self-monitoring and self-management of oral anticoagulation</TITLE>
<CONTACT MODIFIED="2016-06-30 21:46:22 +0100" MODIFIED_BY="Abigail Baldridge"><PERSON ID="19493" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Carl</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Heneghan</LAST_NAME><SUFFIX>MA, MRCGP, DPhil</SUFFIX><POSITION>Director, Centre for Evidence Based Medicine</POSITION><EMAIL_1>Carl.heneghan@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>New Radcliffe House</ADDRESS_1><ADDRESS_2>Radcliffe Observatory Quarter</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289 299</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2016-06-30 21:46:22 +0100" MODIFIED_BY="Abigail Baldridge"><PERSON ID="19493" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Carl</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Heneghan</LAST_NAME><SUFFIX>MA, MRCGP, DPhil</SUFFIX><POSITION>Director, Centre for Evidence Based Medicine</POSITION><EMAIL_1>Carl.heneghan@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>New Radcliffe House</ADDRESS_1><ADDRESS_2>Radcliffe Observatory Quarter</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289 299</PHONE_1></ADDRESS></PERSON><PERSON ID="z1407021554075699752988771908891" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Josep M</FIRST_NAME><LAST_NAME>Garcia-Alamino</LAST_NAME><POSITION>DPhil student</POSITION><EMAIL_1>josepmariagarciaa@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>New Radcliffe House. 2nd floor.</ADDRESS_1><ADDRESS_2>Walton Street, Jericho.</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6NW</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1301311744198809228299018104699" ROLE="AUTHOR"><FIRST_NAME>Elizabeth</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Spencer</LAST_NAME><POSITION>Epidemiologist</POSITION><EMAIL_1>elizabeth.spencer@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>01865289300</PHONE_1></ADDRESS></PERSON><PERSON ID="BCD2748682E26AA20046B372AAB618A0" ROLE="AUTHOR"><FIRST_NAME>Alison</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Ward</LAST_NAME><EMAIL_1>alison.ward@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16596" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Rafael</FIRST_NAME><LAST_NAME>Perera</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>rafael.perera@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>Radcliffe Observatory Quarter</ADDRESS_1><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289308</PHONE_1><FAX_1>+44 1865 289287</FAX_1></ADDRESS></PERSON><PERSON ID="BCD12BD982E26AA20046B372B1B473CF" ROLE="AUTHOR"><FIRST_NAME>Clare</FIRST_NAME><LAST_NAME>Bankhead</LAST_NAME><EMAIL_1>clare.bankhead@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_2>Woodstock Road</ADDRESS_2><CITY>Oxford</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="62B6005E82E26AA200991D56D1FC64D0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pablo</FIRST_NAME><LAST_NAME>Alonso-Coello</LAST_NAME><POSITION>Associate Researcher</POSITION><EMAIL_1>palonso@santpau.cat</EMAIL_1><EMAIL_2>alonsocoello@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_2>Sant Antoni Maria Claret 171 - Edifici Casa de Convalescencia</ADDRESS_2><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 932 919 527</PHONE_1><FAX_1>+34 932 919 525</FAX_1></ADDRESS></PERSON><PERSON ID="CCD1CE0082E26AA2005274A3A8179DCA" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Fitzmaurice</LAST_NAME><EMAIL_1>d.a.fitzmaurice@bham.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Primary Care Clinical Sciences</DEPARTMENT><ORGANISATION>Clinical Sciences Building, University of Birmingham</ORGANISATION><CITY>Birmingham</CITY><ZIP>BI5 2TT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 (0)121 414 7420</PHONE_1><FAX_1>+44 (0)121 414 3759</FAX_1></ADDRESS></PERSON><PERSON ID="6969AEAE82E26AA20125F76B37735DDF" ROLE="AUTHOR"><FIRST_NAME>Kamal</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Mahtani</LAST_NAME><EMAIL_1>kamal.mahtani@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>New Radcliffe House</ADDRESS_1><ADDRESS_2>Radcliffe Observatory Quarter</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX2 6GG</ZIP><REGION>Oxfordshire</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="z1311172319374121243819729310285" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Igho</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Onakpoya</LAST_NAME><POSITION>Senior Research Fellow in Evidence Based Practice and Pharmacovigilance</POSITION><EMAIL_1>igho.onakpoya@phc.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Nuffield Department of Primary Care Health Sciences</DEPARTMENT><ORGANISATION>University of Oxford</ORGANISATION><ADDRESS_1>New Radcliffe House</ADDRESS_1><ADDRESS_2>Radcliffe Observatory Quarter</ADDRESS_2><CITY>Oxford</CITY><ZIP>Oxon</ZIP><REGION>OX2 6GG</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 289 672</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2016-06-21 04:21:01 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="1" MONTH="7" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="7" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-06-27 08:48:46 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-06-27 05:30:15 -0500" MODIFIED_BY="Heather Maxwell">
<DATE DAY="1" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>The search was updated in July 2015. Ten new trials were found for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2016-06-27 08:48:46 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="1" MONTH="6" YEAR="2016"/>
<DESCRIPTION>
<P>The original review reported a reduction in mortality with self-management or self-monitoring; in this update, with the addition of the 10 new trials (adding 4227 participants) this risk reduction was no longer statistically significant; however, after the removal of low-quality studies, the original finding of a reduction in all-cause mortality was found.</P>
<P>Secondly, the original review found that trials of self-monitoring alone did not result in a statistically significant reduction in thromboembolic events; the new finding is a statistically significant reduction.</P>
<P>Thirdly, in the original review, self-monitoring significantly reduced major haemorrhage; in this update, self-monitoring did not reduce major haemorrhage, but removal of studies with low quality resulted in a statistically significant reduction.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-07-16 09:33:19 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-09 13:19:24 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Feedback added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-10-09 13:19:21 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>Add information about external funding sources. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-07-16 09:33:19 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="5" YEAR="2010"/>
<DESCRIPTION>
<P>Amended <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> - GRADE table.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-03-07 07:47:42 -0600" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2009-03-25 04:21:51 -0500" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-03-25 04:21:45 -0500" MODIFIED_BY="[Empty name]">
<NAME>NIHR School of Primary Care Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The University Department of Primary Health Care is part of the NIHR School of Primary Care Research which provides financial support for senior staff who contributed to this paper.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-03-25 04:21:51 -0500" MODIFIED_BY="[Empty name]">
<NAME>NIHR HTA</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The HTA has provided financial support as part of a Monitoring in Chronic diseases project grant for the analysis and write-up of this review.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-03-25 04:21:51 -0500" MODIFIED_BY="[Empty name]">
<NAME>Hospital de la Santa Creu i Sant Pau</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2012-03-07 07:47:42 -0600" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-03-07 07:47:42 -0600" MODIFIED_BY="[Empty name]">
<NAME>Instituto de Salud Carlos III, European Regional Development Fund (PI07/90406)</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<P>This work was partially funded by the Instituto de Salud Carlos III, co-financed by the European Regional Development Fund (PI07/90406).</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-06-30 12:57:09 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2016-06-27 05:33:37 -0500" MODIFIED_BY="Heather Maxwell">
<TITLE MODIFIED="2010-02-21 05:22:22 -0600" MODIFIED_BY="[Empty name]">Self-monitoring and self-management of oral anticoagulation therapy</TITLE>
<SUMMARY_BODY MODIFIED="2016-06-27 05:33:37 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Background</B>
</P>
<P>Point-of-care testing devices have made it possible for people on long-term oral anticoagulation to monitor their blood clotting time, measured as the international normalized ratio (INR). Patients who self-test can either adjust their medication dose according to a pre-determined dose-INR schedule (self-management) or they can call a clinic to be told the appropriate dose adjustment (self-monitoring). Several published studies and systematic reviews have suggested these methods of monitoring anticoagulation therapy may be equal to or better than standard monitoring by a physician.</P>
<P>
<B>Study characteristics</B>
</P>
<P>This is an update of the original review published in 2010. We performed a new search and found 10 new studies (with 4227 participants) to add to the original review, which changed some of the findings.</P>
<P>
<B>Main results</B>
</P>
<P>In total, we found 28 randomised trials including 8950 participants that compared self-monitoring and self-management with standard monitoring. The quality of the evidence was generally low to moderate. The combined results of the 28 trials showed a halving of thromboembolic events with self-monitoring and self-management and no reduction in the number of major bleeds. Self-management had similar reductions in thromboembolic events and mortality to the overall benefit, with no effect on major bleeds. Self-monitoring halved the number of major haemorrhages that occurred but did not significantly reduce the rates of thrombotic events or all-cause mortality.</P>
<P>
<B>Conclusion</B>
</P>
<P>In conclusion, self-monitoring or self-management can improve the quality of oral anticoagulant therapy, leading to fewer thromboembolic events and lower mortality, without a reduction in the number of major bleeds. Self-monitoring and self-management are not feasible for all patients, which requires the identification and education of suitable patients.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-06-27 05:32:25 -0500" MODIFIED_BY="Heather Maxwell">
<ABS_BACKGROUND MODIFIED="2016-06-27 05:31:33 -0500" MODIFIED_BY="Heather Maxwell">
<P>The introduction of point-of-care devices for the management of patients on oral anticoagulation allows self-testing by the patient at home. Patients who self-test can either adjust their medication according to a pre-determined dose-INR (international normalized ratio) schedule (self-management), or they can call a clinic to be told the appropriate dose adjustment (self-monitoring). Increasing evidence suggests self-testing of oral anticoagulant therapy is equal to or better than standard monitoring. This is an updated version of the original review published in 2010.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-19 10:03:09 -0600" MODIFIED_BY="[Empty name]">
<P>To evaluate the effects on thrombotic events, major haemorrhages, and all-cause mortality of self-monitoring or self-management of oral anticoagulant therapy compared to standard monitoring.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-27 05:32:10 -0500" MODIFIED_BY="Heather Maxwell">
<P>For this review update, we re-ran the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), 2015, Issue 6, the Cochrane Library, MEDLINE (Ovid, 1946 to June week 4 2015), Embase (Ovid, 1980 to 2015 week 27) on 1 July 2015. We checked bibliographies and contacted manufacturers and authors of relevant studies. We did not apply any language restrictions .</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-02-21 05:00:39 -0600" MODIFIED_BY="[Empty name]">
<P>Outcomes analysed were thromboembolic events, mortality, major haemorrhage, minor haemorrhage, tests in therapeutic range, frequency of testing, and feasibility of self-monitoring and self-management.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-03-08 09:28:25 -0600" MODIFIED_BY="[Empty name]">
<P>Review authors independently extracted data and we used a fixed-effect model with the Mantzel-Haenzel method to calculate the pooled risk ratio (RR) and Peto&#8217;s method to verify the results for uncommon outcomes. We examined heterogeneity amongst studies with the Chi<SUP>2</SUP> and I<SUP>2</SUP> statistics and used GRADE methodology to assess the quality of evidence. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-27 05:32:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>We identified 28 randomised trials including 8950 participants (newly incorporated in this update: 10 trials including 4227 participants). The overall quality of the evidence was generally low to moderate. Pooled estimates showed a reduction in thromboembolic events (RR 0.58, 95% CI 0.45 to 0.75; participants = 7594; studies = 18; moderate quality of evidence). Both, trials of self-management or self-monitoring showed reductions in thromboembolic events (RR 0.47, 95% CI 0.31 to 0.70; participants = 3497; studies = 11) and (RR 0.69, 95% CI 0.49 to 0.97; participants = 4097; studies = 7), respectively; the quality of evidence for both interventions was moderate. No reduction in all-cause mortality was found (RR 0.85, 95% CI 0.71 to 1.01; participants = 6358; studies = 11; moderate quality of evidence). While self-management caused a reduction in all-cause mortality (RR 0.55, 95% CI 0.36 to 0.84; participants = 3058; studies = 8); self-monitoring did not (RR 0.94, 95% CI 0.78 to 1.15; participants = 3300; studies = 3); the quality of evidence for both interventions was moderate. In 20 trials (8018 participants) self-monitoring or self-management did not reduce major haemorrhage (RR 0.95, 95% CI, 0.80 to 1.12; moderate quality of evidence). There was no significant difference found for minor haemorrhage (RR 0.97, 95% CI 0.67 to 1.41; participants = 5365; studies = 13). The quality of evidence was graded as low because of serious risk of bias and substantial heterogeneity (I<SUP>2</SUP> = 82%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-06-27 05:32:25 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants who self-monitor or self-manage can improve the quality of their oral anticoagulation therapy. Thromboembolic events were reduced, for both those self-monitoring or self-managing oral anticoagulation therapy. A reduction in all-cause mortality was observed in trials of self-management but not in self-monitoring, with no effects on major haemorrhage.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-06-30 12:57:09 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2016-06-27 05:35:35 -0500" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="2">Terminology</HEADING>
<UL>
<LI>Point-of-care testing (POC): diagnostic testing performed in a clinic, home, or other site of patient care (rather than in standard reference laboratory)</LI>
<LI>Point-of-care device: portable monitor used by a healthcare provider (physician, nurse, or other) or patient to determine a clinical measure</LI>
<LI>Self-monitoring: the trained participant uses point-of-care testing to perform the international normalized ratio (INR) test and inform his or her healthcare provider of the result. The physician or another healthcare provider adjusts the anticoagulant dose using the results obtained by the participant</LI>
<LI>Self-management: trained participant uses point-of-care testing to perform the INR test, interpret the result, and adjust the dosage of anticoagulant accordingly (adapted from <LINK REF="REF-Brown-2007" TYPE="REFERENCE">Brown 2007</LINK>)</LI>
</UL>
</SUBSECTION>
<CONDITION MODIFIED="2016-06-27 05:34:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Oral anticoagulation therapy has been shown to reduce thromboembolic events in atrial fibrillation, treatment of deep-vein thrombosis, prosthetic heart valves, and acute myocardial infarction (<LINK REF="REF-Connolly-1991" TYPE="REFERENCE">Connolly 1991</LINK>; <LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>; <LINK REF="REF-SPAF-1996" TYPE="REFERENCE">SPAF 1996</LINK>). Optimal anticoagulation with warfarin or other vitamin K antagonists like acenocoumarol or phenprocoumon could potentially prevent more than half of the strokes related to atrial fibrillation and heart valve replacements with a relatively low risk of major bleeding complications (<LINK REF="REF-Buckingham-2002" TYPE="REFERENCE">Buckingham 2002</LINK>; <LINK REF="REF-Hart-2007" TYPE="REFERENCE">Hart 2007</LINK>); however, much of this potential is still not obtained because of under and suboptimal use (<LINK REF="REF-Stafford-1998" TYPE="REFERENCE">Stafford 1998</LINK>).</P>
<P>The number of patients receiving oral anticoagulant drugs has been increasing. Reasons include improvements in clinical outcomes, increasing common disease indications for their use (<LINK REF="REF-Manotti-2001" TYPE="REFERENCE">Manotti 2001</LINK>), and improvements in anticoagulant safety (<LINK REF="REF-Ansell-2001" TYPE="REFERENCE">Ansell 2001</LINK>). In 1994, 250,000 patients in the UK were receiving anticoagulant therapy (<LINK REF="REF-Baglin-1994" TYPE="REFERENCE">Baglin 1994</LINK>); 10 years later this had increased to around 950,000 patients (<LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>). Vitamin K antagonist (warfarin, acenocoumarol, or phenprocoumon) treatment usually requires regular monitoring of prothrombin time (PT) with dose-adjustment by a specialised hospital service, primary care physician, registered nurse, nurse practitioner, or pharmacist (<LINK REF="REF-Hirsh-1998" TYPE="REFERENCE">Hirsh 1998</LINK>).</P>
<P>Numerous obstacles to the use of warfarin exist; including practical, patient, physician, and healthcare system-related barriers. Due to the complex pharmacokinetics of warfarin, continuous monitoring and dose adjustments are required. Different values and preferences amongst physicians and patients about the relative importance of bleeding and thromboembolic events, non-adherence to drug treatment, drug interactions, and increased costs of monitoring have significant roles to play in the management of anticoagulation therapy (<LINK REF="REF-Heneghan-2008" TYPE="REFERENCE">Heneghan 2008</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2016-06-27 05:35:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>Vitamin K antagonists belong to the drug class known as coumarins and produce their anticoagulant effect by interfering with the metabolism of vitamin K. There are various different types of coumarins but warfarin is the most prescribed. Warfarin has a high bioavailability (<LINK REF="REF-Breckenridge-1978" TYPE="REFERENCE">Breckenridge 1978</LINK>), and is rapidly absorbed from the gastrointestinal tract, with maximal blood concentrations reached 90 minutes after oral administration. Warfarin has a half-life of 36 to 42 hours; in the blood it is bound to plasma proteins (mainly albumin). It accumulates in the liver where the two isomers are metabolically transformed by different pathways (<LINK REF="REF-Ansell-2004" TYPE="REFERENCE">Ansell 2004</LINK>). An anticoagulation effect generally occurs within 24 hours of treatment imitation, and peak effect for warfarin takes two to five days.</P>
<P>Another vitamin K antagonist is acenocoumarol, which has a similar action to warfarin but differs in some pharmacological properties (for example, it has a shorter half-life <LINK REF="REF-Barcellona-1998" TYPE="REFERENCE">Barcellona 1998</LINK>). Phenprocoumon is another vitamin K antagonist that has traditionally been the oral anticoagulant of choice in Europe. It has similar actions to other vitamin K antagonists but has a half-life of 144 hours. As a result of their pharmacokinetic properties, these agents interact with many other drugs and their blood levels are affected by vitamin K intake in the diet, changes in metabolism, and concomitant illnesses, which makes the levels difficult to control (<LINK REF="REF-Greenblatt-2005" TYPE="REFERENCE">Greenblatt 2005</LINK>).</P>
<P>The pharmacodynamics of warfarin are subject to genetic and environmental variability (<LINK REF="REF-Hirsh-2001" TYPE="REFERENCE">Hirsh 2001</LINK>), such that there is considerable variation in the action of these drugs both between different individuals (inter-individually) and within the same individual (intra-individually). A 'therapeutic target range' has been established to deal with this variability and is expressed as the international normalized ratio (INR). This INR was established as a standard way of reporting the prothrombin time (PT). Furthermore, using the INR formula (INR = patient PT/mean normal PT) the ratio between patient PT and normal PT is calculated to the power of the ISI (International Sensitivity Index), which is the conversion factor for the used thromboplastin against the World Health Organization (WHO) standard.</P>
<P>The &#8216;therapeutic range&#8217; for anticoagulants is narrow. INR values over 4.5 increase the risk of major bleeding and an INR less than 2 increases the risk of thromboembolism (<LINK REF="REF-Cannegieter-1995" TYPE="REFERENCE">Cannegieter 1995</LINK>; <LINK REF="REF-Hylek-1996" TYPE="REFERENCE">Hylek 1996</LINK>; <LINK REF="REF-Kearon-2003" TYPE="REFERENCE">Kearon 2003</LINK>). The inter- and intra-individual variability and the narrow target range generally requires frequent testing and appropriate adjustment of the drug dose. In addition, time within the therapeutic INR target range is highly dependent on the frequency of testing (<LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>). Different values and preferences amongst patients and physicians have also been described with the former willing to accept a much higher risk of bleeding for an associated reduction in risk of stroke (<LINK REF="REF-Devereaux-2001" TYPE="REFERENCE">Devereaux 2001</LINK>).</P>
<P>An economic model analysed the cost of suboptimal oral anticoagulation and showed the following. If 50% of those not receiving warfarin prophylaxis had optimal anticoagulation, 19,380 emboli would be prevented and 1.1 billion US dollars could be saved. If 50% of those currently receiving warfarin as part of routine medical care had optimal anticoagulation, 9852 emboli would be prevented and 1.3 billion US dollars could be saved (<LINK REF="REF-Caro-2004" TYPE="REFERENCE">Caro 2004</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-06-27 05:35:30 -0500" MODIFIED_BY="Heather Maxwell">
<P>Current models of oral anticoagulation management within the UK include the traditional hospital outpatient model and various forms of community-based models, all requiring patient attendance at a clinic (<LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>). In other countries, such as Canada, a primary care physician monitors the INR and adjusts the warfarin dose (<LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>).</P>
<P>The introduction of point-of-care devices allows the patient to self-test at home with a drop of whole blood. Portable monitors for monitoring long-term oral anticoagulation were introduced in the 1990s. Devices have proved to be reliable with regard to analytical accuracy, although INR measurements tend to be lower with the portable coagulometers compared to laboratory analysers (<LINK REF="REF-Christensen-2009" TYPE="REFERENCE">Christensen 2009</LINK>; <LINK REF="REF-Poller-2006" TYPE="REFERENCE">Poller 2006</LINK>), and have proved to be reliable devices for monitoring INR when checked regularly (<LINK REF="REF-Barcellona-2009" TYPE="REFERENCE">Barcellona 2009</LINK>).</P>
<P>Generally, patients receive a structured educational programme given by the nurses or physicians responsible for their care. In addition, they receive training in self-testing, instructions to prevent bleeding and thromboembolic complications, and are made aware of the effects of diet and medications. Patients who self-test can either adjust their therapy according to a pre-determined dose-INR schedule (self-management) or they can call a clinic to be told the appropriate dose adjustment (self-monitoring).</P>
</THEORY>
<IMPORTANCE MODIFIED="2016-06-27 05:35:35 -0500" MODIFIED_BY="Heather Maxwell">
<P>In some countries, such as Germany, self-monitoring and self-management with portable monitors are established therapeutic methods. There are several available point-of-care devices and the most well known is the CoaguChek® monitor. Other available monitors are the ProTime® Microcoagulation System, INRatio® Monitor, Hemochron Junior Signature, and the TAS near-patient test system. Potential advantages of self-monitoring and self-management include improved convenience for patients, better treatment adherence, more frequent monitoring, and fewer thromboembolic and haemorrhagic complications (<LINK REF="REF-Taborski-1999" TYPE="REFERENCE">Taborski 1999</LINK>). Near-patient testing devices have made self-testing of anticoagulation therapy with vitamin K antagonists possible. Guidelines generally do not endorse self-monitoring or self-management (<LINK REF="REF-Fitzmaurice-2001" TYPE="REFERENCE">Fitzmaurice 2001</LINK>), despite several authors of trials suggesting this approach may be equal to or better than standard monitoring (<LINK REF="REF-Anderson-1993" TYPE="REFERENCE">Anderson 1993</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>). A recent study suggested that self-monitoring and self-management are cost-effective strategies for those receiving long-term oral anticoagulation (<LINK REF="REF-Regier-2006" TYPE="REFERENCE">Regier 2006</LINK>). In addition, newer oral anticoagulants that do not require monitoring have not been established in heart valve patients (<LINK REF="REF-Eikelboom--2013" TYPE="REFERENCE">Eikelboom 2013</LINK>) and are not suitable for all because of the numerous exclusion and individuals who cannot tolerate these drugs (<LINK REF="REF-DiNicolantonio-2012" TYPE="REFERENCE">DiNicolantonio 2012</LINK>).</P>
<P>To establish the current strength of the available evidence, we updated our systematic review of the impact of patient self-monitoring or self-management on treatment with oral anticoagulation therapy.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2016-06-27 05:35:41 -0500" MODIFIED_BY="Heather Maxwell">
<P>To evaluate the effects on thrombotic events, major haemorrhages, and all-cause mortality of self-monitoring or self-management of oral anticoagulation compared with standard monitoring.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-06-30 12:55:27 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2016-06-27 05:35:57 -0500" MODIFIED_BY="Heather Maxwell">
<CRIT_STUDIES MODIFIED="2014-03-10 08:18:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) assessing the therapeutic effectiveness and safety of self-monitoring or self-management of oral anticoagulation therapy.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2016-06-27 05:35:51 -0500" MODIFIED_BY="Heather Maxwell">
<P>All patients, adults and children, on long-term anticoagulant therapy (treatment duration longer than two months), irrespective of the indication for treatment (for example, valve replacement, venous thromboembolism, atrial fibrillation).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2016-06-27 05:35:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>Self-monitoring or self-management of oral anticoagulation compared with:</P>
<UL>
<LI>control of and dosage by personal physician;</LI>
<LI>anticoagulation managed services (hospital anticoagulation service);</LI>
<LI>anticoagulation clinics (management conducted by registered nurses, nurse practitioners, or pharmacists using dosage-adjustment protocols).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-06-21 04:41:36 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-06-21 04:41:36 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Thromboembolic events</LI>
<LI>All-cause mortality</LI>
<LI>Major haemorrhage (e.g. haemorrhage requiring hospital admission or transfusion)</LI>
<LI>Time in range, and proportion of measurements within the therapeutic range for each particular condition</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-10-09 13:30:11 -0500" MODIFIED_BY="[Empty name]">
<UL>
<LI>Minor haemorrhage (e.g. bleeding after minor trauma, nose bleed)</LI>
<LI>Frequency of testing</LI>
<LI>Feasibility of testing: participant factors (e.g. physical limitations), and non-participant factors (e.g. inability to attend training)</LI>
<LI>Quality of life and general satisfaction with treatment</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-06-30 12:55:27 -0500" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2016-06-30 12:55:27 -0500" MODIFIED_BY="[Empty name]">
<P>The searches for the initial review were run in November 2007 (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). We re-ran the searches on 27 November 2013 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We updated the searches on 1 July 2015 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>) with exception of CINAHL which was last searched on 27 November 2013 (an updated search of CINAHL was not mandatory):</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 6, the Cochrane Library,</LI>
<LI>MEDLINE (Ovid, 1946 to June week 4 2015),</LI>
<LI>Embase (Ovid, 1980 to 2015 week 27), and</LI>
<LI>CINAHL (EBSCO, 1982 to November 2013).</LI>
</UL>
<P>We limited our searches to randomised controlled trials by using a maximally sensitive strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>; <LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK> in 2007 and <LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK> in 2015).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-06-27 05:46:01 -0500" MODIFIED_BY="Heather Maxwell">
<P>We also searched for ongoing trials on the UK National Research Register (webarchive.nationalarchives.gov.uk), Trials Central, Current Controlled Trials (<A HREF="http://www.controlled-trials.com/mrct/">www.controlled-trials.com/mrct/</A>) (November 2013) and handsearched reference lists of all retrieved papers. We contacted Roche<SUP>® </SUP>Diagnostics (one manufacturer of PT and INR monitors) in order to identify further published and unpublished studies. There were no language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-06-27 05:40:52 -0500" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">Data extraction</HEADING>
<P>Two review authors (EAS and IJO) screened studies for inclusion and retrieved all potentially relevant studies. Three review authors (JM, PA, CH) independently extracted data on study population, intervention, pre-specified outcomes, methodology, and quality from eligible trials. The authors were not blinded to any aspect of the studies (for example, journal type, authors' names, institution). We resolved disagreements by consensus. If needed, we sought additional information from trial authors. We used Cohen&#8217;s kappa to assess agreement between the two authors on the selection of articles for inclusion.</P>
<P>We extracted information on disease characteristics and training provided to the different groups. In the self-management group, we extracted information on the actions participants subsequently undertook. We extracted the characteristics of the population studied, including the number of, and reasons for, participants not entering the trial (for example, refusal or exclusion). Additionally, we sought information on the reasons for discontinuation by participants allocated to the intervention.</P>
<P>In the case of cross-over studies, the outcomes of interest are potentially confounded by the cross-over and we only used data from the first part of the trial (before cross-over).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment</HEADING>
<P>Three review authors (EAS, IJO, CH) independently extracted methodological information for the assessment of risk of bias. They used the following five components: method of randomisation, concealment of allocation, intention-to-treat, number of, and reasons for, participant losses to follow-up, and blinding. We performed a sensitivity analyses for study quality by including only those studies with clear methods of randomisation and concealment of allocation (high-quality studies). We also used the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) (<LINK REF="REF-GRADE-2008" TYPE="REFERENCE">GRADE 2008</LINK>) to assess the quality of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quantitative data synthesis</HEADING>
<P>For the analysis we used Review Manager (RevMan) Version 5.3. For the statistical analysis we calculated risk ratios (RRs) and 95% confidence intervals (CIs) as summary statistics. We used a fixed-effect model with the Mantzel-Haenzel method to calculate the pooled odds ratio; and Peto&#8217;s method to verify the results in uncommon outcomes.  We examined heterogeneity amongst studies with the Chi<SUP>2</SUP> and I<SUP>2</SUP> statistics (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Where significant heterogeneity existed, we used the random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>).</P>
<P>We examined publication bias by constructing a funnel plot of precision (SE of the log RR) against RR for the endpoints of major haemorrhage and thromboembolic episodes. We performed a sensitivity analysis by excluding studies with high risk of bias and pre-specified subgroup analyses according to clinical indication (mechanical valve replacement or atrial fibrillation), and self-monitoring or self-management therapy. We performed a post-hoc subgroup analysis according to who provided the control group care (specialist anticoagulation clinic, family physician). Meta-regression in STATA tested any subgroup interaction on the outcomes. The ratio of the average test frequency per individual patient/year between intervention and control groups was calculated and linear regression was used to assess the association with study duration. Pooling of the mean percentage of tests in the therapeutic range was not possible; results were summarised using means and ranges. We tested subgroup interactions using meta-regression (Intercooled STATA 9.1 for Windows). </P>
<P>To provide further insight into the adequacy of the total sample size across all trials, we calculated a posteriori the optimal information needed for our meta-analysis (<LINK REF="REF-Pogue-1997" TYPE="REFERENCE">Pogue 1997</LINK>)<I>.</I> To determine this optimal information size, we assumed a 2% risk of thromboembolism (median control event rate from trials in the review) and a 50% RR reduction with a power of 95% and a two-sided alpha = 0.01.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-06-30 12:57:09 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2016-06-27 09:21:44 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2016-06-27 09:21:44 -0500" MODIFIED_BY="[Empty name]">
<P>The search for the initial review retrieved 463 citations, which included 18 relevant trials. The updated searches in November 2013 and July 2015 identified 5136 new citations and identified an additional 10 trials (with 4227 participants) for inclusion.</P>
<P>In total, we identified 5894 citations through database searching as well as one additional unpublished citation (<LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>). Of these, we excluded 758 duplicate records, leaving 5136 potentially relevant studies. A further 5067 citations were removed after being deemed irrelevant to our research question. We independently assessed 69 full-text articles for eligibility. Of these, 22 articles were excluded and 20 articles were secondary publications of primary studies already included in the review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-06-27 05:41:28 -0500" MODIFIED_BY="Heather Maxwell">
<P>A total of 27 included publications provided data on 28 trials including 8950 participants (one publication, <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>, contained data on two trials that compared self-monitoring or self-management of oral anticoagulation with standard monitoring). Trials were published between 1989 and 2013 and were largely undertaken in Europe (five each in UK and Germany; three each in the Netherlands and Denmark; one in each of Ireland, France, Spain and Austria); seven were undertaken in United States and Canada; and one was conducted in Australia. In total, 4723 participants on long-term anticoagulation were included in our analysis. Three trials (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>) used a cross-over design. The remaining 25 trials were parallel design; this included the unpublished study for which we were given access to the complete data by the authors (<LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>).</P>
<P>One trial (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>) presented results on four groups. One group used self-management therapy (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>), one used self-monitoring therapy (<LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>). The two other arms with no self-monitoring were combined (trained and untrained participants) to provide an overall control group and were then subdivided for the independent comparisons.</P>
<P>Six trials included only participants on life-long anticoagulation therapy following mechanical valve insertion (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>); two trials included participants on long-term anticoagulation for atrial fibrillation (<LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>); 20 trials included participants on long-term anticoagulation for any indication (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). In 15 trials the intervention group used self-management (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>) and 12 trials used self-monitoring (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). One further study (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>), reported information on both self-management and self-monitoring groups. Eleven trials used primary care for the control group (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>); 13 studies used specialist anticoagulation clinics (<LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>); and one trial (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>) used a medical analysis laboratory. In the three remaining trials participants in the control group could use either primary care or specialist clinics (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>). Duration of studies varied from two months (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>) to more than 24 months (<LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>); the mean duration was 12 months.</P>
<P>Analysis of publication bias using funnel plots of major haemorrhage and thromboembolic events showed no evidence of asymmetry (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-06-27 09:23:43 -0500" MODIFIED_BY="[Empty name]">
<P>The reported risk of bias was generally low to moderate. The nature of the intervention made blinding of the allocation of intervention to the participants impossible, although blinding of study staff and outcome assessment was possible. We contacted nine authors of the 27 included trials for additional details of randomisation process, concealment of allocation, and blinding. The additional information provided generally raised our ratings of the quality of the trial, indicating that authors had met methodological criteria. We also obtained valuable validity information from the ACP Journal Club structured reviews on two occasions. ACP reviews contact study authors when needed and are a valuable source of additional information for validity issues.</P>
<P>After the addition of extra information supplied by authors, 11 trials were judged to be of high risk of bias (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>) and were removed in the sensitivity analysis. These 11 trials did not perform intention-to-treat analyses and randomisation and/or allocation concealment was unclear. Overall, the available evidence was judged to be moderate according to the GRADE Working Group grades of evidence (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). This was due to flaws in study design; most commonly there was an absence of information about the allocation concealment procedure or blinding and the number of events was less than 300 for the primary outcomes (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The overall risk of bias graph and summary table are shown in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="3">Randomisation and allocation concealment</HEADING>
<P>Twenty-one trials reported adequate information about the randomisation process (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>) and were therefore judged to be of low risk of bias in this domain.</P>
<P>However, the method of allocation concealment was generally not reported in the published papers. After contacting authors for additional information, 14 of the 28 trials had an appropriate method of concealment (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>). Four studies used both concealment of allocation and intention-to-treat (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>) (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>Participant blinding was not possible due to the nature of the intervention. Seven studies included information about blinding. Two trials blinded data collectors (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>), three blinded healthcare providers (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>), and six trials blinded outcome assessors (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>) (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow-up</HEADING>
<P>Of those assigned to the intervention, 25% (range 0% to 57%) stopped self-monitoring or self-management by the end of the trial. Nine trials used an intention-to-treat analysis (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>). All included studies described appropriate participant follow-up (see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> and <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Financial support</HEADING>
<P>Eight studies (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>) did not describe financial support. Six studies were supported by grants from professional associations or national agencies (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). Twelve studies (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>) were part funded by an unrestricted research grant from industry or received the coagulometer and strips for utilisation during the study. One study was funded by a private hospital (<LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>); and two by a combination of government and private agencies (<LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>).<BR/>
</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-06-30 12:57:09 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary endpoints</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Thromboembolic events</HEADING>
<P>Twenty-six trials reported thromboembolic outcomes; however, eight trials showed no events in either the intervention or control arm (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>), and were therefore not included in the pooled analysis (chapter 16.9.3, <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Eighteen trials provided the information to calculate the overall effect size (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>).</P>
<P>Compared to standard therapy, self-monitoring or self-management reduced thromboembolic events (risk ratio (RR) 0.58, 95% confidence interval (CI) 0.45 to 0.75; participants = 7594; studies = 18) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The overall quality of evidence was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The findings were not affected by the removal of the five trials deemed to have high risk of bias (RR 0.50, 95% CI 0.36 to 0.69; participants = 4558; studies = 13) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>In those groups that self-managed (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>), the effect was larger (RR 0.47, 95% CI 0.31 to 0.70; participants = 3497; studies = 11; <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>) than in the groups that self-monitored (RR 0.69, 95% CI 0.49 to 0.97; participants = 4097; studies = 7); <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>) (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). In either group, the quality of the evidence was downgraded from high to moderate because of serious risk of bias. However, the subgroup interaction was non-significant (P = 0.66).</P>
<P>Compared to standard therapy, self-monitoring or self-management in patients with mechanical valves (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>) resulted in a significant effect on thromboembolic events (RR 0.53, 95% CI 0.32 to 0.90; participants = 1816; studies = 6) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The post-hoc subgroup analysis for specialised care (RR 0.63, 95% CI 0.44 to 0.90; participants = 4947; studies = 8) and family physician care (RR 0.56, 95% CI 0.38 to 0.84; participants = 2397; studies = 8) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) showed both to be significant (subgroup interaction P = 0.33).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>Twenty-two trials reported information on mortality; 11 trials did not report any deaths in the intervention and control groups and are therefore excluded form the pooled analysis (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>) (chapter 16.9.3, <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Eleven trials (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>) reported all-cause mortality events. No reduction in all-cause mortality was found (RR 0.85, 95% CI 0.71 to 1.01; participants = 6358; studies = 11) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The overall quality of evidence was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Removal of three studies deemed to have high risk of bias resulted in no difference of the effect (RR 0.85, 95% CI 0.71 to 1.02; participants = 6160; studies = 8) (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). In three studies of participants with mechanical valves (<LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>) self-monitoring or self-management showed a significant reduction in mortality (RR 0.50, 95% CI 0.29 to 0.86; participants = 1295; studies = 3) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
<P>Two studies (<LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>) reported on participants with atrial fibrillation, no deaths were reported. A reduction in mortality occurred in participants who self-managed (<LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>) compared to standard therapy (RR 0.55, 95% CI 0.36 to 0.84; participants = 3058; studies = 8) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). The overall quality of evidence was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). No effect was found for the self-monitoring only trials (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>) (RR 0.94, 95% CI 0.78 to 1.15; participants = 3300; studies = 3) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>); The overall quality of evidence was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The subgroup interaction was significant (P = 0.02). The post-hoc subgroup analysis for specialised care (RR 0.92, 95% CI 0.75 to 1.13; participants = 4387; studies = 5) and family physician care (RR 0.62, 95% CI 0.43 to 0.90; participants = 1776; studies = 5) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>) showed only family physician care to be significant; however the subgroup interaction was not significant (P = 0.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Major haemorrhage</HEADING>
<P>Twenty-four trials reported major haemorrhage outcomes, four of which did not report any events (<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). Twenty trials provided the information to calculate the overall effect size (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>). Compared to standard therapy, self-monitoring or self-management were associated with no reduction in major haemorrhage (RR 0.95, 95% CI 0.80 to 1.12; participants = 8018; studies = 20) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The overall quality of evidence was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). After removal of the six studies deemed to have high risk of bias, the result remained similar (RR 0.96, 95% CI 0.81 to 1.14; participants = 7337; studies = 14) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). In terms of clinical condition, four studies (<LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>) included participants with mechanical valves only and two studies (<LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>) reported on participants with atrial fibrillation. No significant differences were found.The inability to distinguish between the two conditions in the remaining trials meant there was insufficient power to determine significance by clinical condition (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>).</P>
<P>In those who self-monitored (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>), there was no significant reduction in the number of events that occurred compared to standard therapy (RR 0.90, 95% CI 0.74 to 1.09; participants = 4038; studies = 7). The quality of the evidence was downgraded from high to low because of serious risk of bias and strong suspicion of publication bias (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). Self-management (<LINK REF="STD-Dignan-2013" TYPE="STUDY">Dignan 2013</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>) was comparable with standard therapy (RR 1.08, 95% CI 0.79 to 1.47; participants = 3980; studies = 13) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). The subgroup interaction for this outcome, between the two groups, was not significant (P = 0.32). The quality of the evidence was downgraded from high to low because of serious risk of bias and imprecision of effect estimate (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). The post-hoc subgroup analysis for specialised care (RR 0.98, 95% CI 0.80 to 1.19; participants = 5054; studies = 9) and family physician care (RR 0.93, 95% CI 0.66 to 1.30; participants = 2267; studies = 8) showed no effect (subgroup interaction P = 0.79).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Tests in range</HEADING>
<P>Sixteen trials reported results of mean international normalized ratio (INR) within target range (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). All studies but one (<LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>), reported improvements in the self-monitoring or self-management groups; six were statistically significant (<LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). Pooling of the mean percentage of tests in range was not possible as information was collected in two different ways: as the percentage of overall tests in range (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>), and the percentage of tests for each individual in range (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>). Improvements ranged from 3% to 21%. Eighteen trials reported the percentage time within range (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>). Seven studies (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>) reported a significant improvement in the time in therapeutic range in the self-monitoring or self-management groups (see additional tables, <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P>
<P>The method used to estimate the time within therapeutic INR target range in 16 studies was linear interpolation (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>; <LINK REF="STD-Ryan-2009" TYPE="STUDY">Ryan 2009</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary endpoints</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Minor haemorrhage</HEADING>
<P>Eighteen trials reported minor haemorrhage outcomes, with 13 reporting events (<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>; <LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). Compared to standard therapy, self-monitoring or self-management there was no difference in minor haemorrhage (RR 0.97, 95% CI 0.67 to 1.41; participants = 5365; studies = 13) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>), but results varied considerably (I<SUP>2</SUP> = 82%). The overall quality of evidence was downgraded from high to low because of serious risk of bias and substantial heterogeneity (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>There was no reduction in minor haemorrhage with self-management (RR 0.91, 95% CI 0.47 to 1.76; participants = 1862; studies = 7), or with self-monitoring (RR 1.16, 95% CI 0.95 to 1.42; participants = 3503; studies = 6) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The quality of the evidence for self-monitoring was downgraded from high to moderate because of serious risk of bias (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The quality of evidence for self-management was downgraded from high to low because of serious risk of bias and high heterogeneity (82%) (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Only one trial (<LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>) showed a significant effect on minor haemorrhage with self-management (RR 0.41, 95% CI 0.31 to 0.54).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Frequency of testing</HEADING>
<P>Fourteen studies reported on the total number of tests performed throughout the study (<LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>; <LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>; <LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). Maximum test frequency occurred in the study with the shortest duration (<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>). The ratio of tests in the self-monitoring or self-management groups compared to the control groups ranged from 1.00 to 4.98; this ratio increased with duration of study (test for linear trend P &lt; 0.002). Due to inadequate data, we were unable to rate the quality of the evidence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Feasibility of testing</HEADING>
<P>A population of 11,738 was sampled in 15 trials (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>; <LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>; <LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>; <LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>). Of that population, 7974 were either excluded or decided not to take part. The average proportion of people that could not (or would not) take part in the trials was 68% (range 31% to 88%). In trials which included older populations (<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>), the exclusion rates were much higher. Of the participants assigned to the intervention 24.9% (range 0% to 57.3%) were unable to complete self-monitoring or self-management. The main reasons for the dropouts were: problems with the device, physical limitations preventing self-testing and problems with attending the training assessments or failing the assessment. Due to inadequate data, we were unable to rate the quality of the evidence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcomes</HEADING>
<P>Thirteen studies evaluated quality of life outcomes. These included ease of use (<LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>), anxiety caused by testing (<LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>), beliefs specific to warfarin (<LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>), and quality of life (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>; <LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>; <LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK> ). <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK> evaluated health status and quality of life using a validated tool, the 36-item United Kingdom Short Form Health Survey (UKSF-36) and the European Quality of Life questionnaire (Euroqol). <LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK> used the individual quality of life (SEIQoL) tool for estimating quality of life and reported on results of participant interviews (<LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>). <LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK> used a treatment-related satisfaction survey measuring five categories; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK> used the Health Utilities Index Mark; <LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK> used the SF-36v2 questionnaire; and <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK> used a validated questionnaire including 32 statements covering five socio-psychological topics: general treatment satisfaction, self-efficacy, daily hassles, psychological distress, and strained social network. Four trials (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>) used a questionnaire designed by Sawicki on patients' feelings towards anticoagulation therapy. Six studies (<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>; <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>; <LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>; <LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>) showed a significant difference in treatment satisfaction. In addition, one study (<LINK REF="REF-Gadisseur-2004" TYPE="REFERENCE">Gadisseur 2004</LINK>) (one of the articles from <LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>) reported quality of life outcomes showing greater treatment satisfaction in the self-monitoring group compared to the self-management group. One study (<LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>), reported that there were no adverse events resulting from physical interaction with the testing device. Due to inadequate data, we were unable to rate the quality of the evidence for quality of life and satisfaction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Optimal information size</HEADING>
<P>The calculated optimal information size needed for a reliable and conclusive treatment effect was 5150 in each arm. This assumed a 2% thromboembolic event rate in the control group, a 50% RR reduction, a power of 95%, and a two-sided alpha = 0.01. The current meta-analysis has approximately 4000 in each arm, which would give a 78% power using the same assumptions.</P>
<P>One of the main trials included in the meta-analysis showed a clear absence of correlation between the benefits observed and the degree of control (<LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>). We therefore questioned the influence of this study by performing a post hoc sensitivity analysis that removed the trial; the beneficial effects observed for all the major outcomes remained similar.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-06-27 05:44:47 -0500" MODIFIED_BY="Heather Maxwell">
<P>To our knowledge the present review is the most comprehensive review to date. We identified 28 randomised controlled trials (RCTs) trials (8950 participants). Self-monitoring or self-management of oral anticoagulation leads to a significant 50% reduction in thromboembolism but no reduction in all-cause mortality. However, trials of self-management led to a significant reduction in all-cause mortality. Self-management did not reduce major haemorrhages nor did self-monitoring.</P>
<SUBSECTION>
<HEADING LEVEL="2">Quality of the evidence</HEADING>
<P>The GRADE approach was employed to interpret result findings and the GRADE profiler (GRADEPRO) allowed us to import data from Review Manager to create 'Summary of findings' tables. The overall quality of the evidence for the effect of self-monitoring or self-management of oral anticoagulation on major haemorrhage was moderate; the quality was downgraded because of serious risk of bias across the studies. The quality of the evidence for trials of self-management was downgraded from high to low because of serious risk of bias and imprecision of effect estimate (i.e. large confidence intervals). The quality of the evidence for trials of self-monitoring was downgraded from high to low because of serious risk of bias across the studies and strong suspicion of publication bias.</P>
<P>The overall quality of the evidence for thromboembolic events was moderate; downgraded because of serious risk of bias across the included studies. The quality of the evidence for trials of either self-monitoring or self-management were downgraded from high to moderate because of serious risk of bias. The overall quality of the evidence for mortality was moderate; downgraded because of serious risk of bias across the included studies. The quality of the evidence for trials of either self-monitoring or self-management were downgraded from high to moderate because of serious risk of bias.</P>
<P>The overall quality of the evidence for minor haemorrhage of the evidence was low; downgraded because of serious risk of bias and substantial heterogeneity in the meta-analysis result. The quality of the evidence for trials of self-management was downgraded from high to low because of serious risk of bias and substantial heterogeneity. The quality of the evidence for trials of self-monitoring was downgraded from high to moderate because of serious risk of bias across the included studies. Due to inadequate data, we were unable to rate the quality of the evidence for the following outcomes: (i) Frequency of testing; (ii) Feasibility of testing; and (iii) Quality of life and satisfaction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Comparison with other reviews</HEADING>
<P>This systematic review provides information additional to a substantial body of evidence from previously published reviews of self-monitoring or self-management of oral anticoagulation (<LINK REF="REF-Bazian-2005" TYPE="REFERENCE">Bazian 2005</LINK>; <LINK REF="REF-Bloomfield-2011" TYPE="REFERENCE">Bloomfield 2011</LINK> <LINK REF="REF-Christensen-2007" TYPE="REFERENCE">Christensen 2007</LINK>; <LINK REF="REF-Connock-2007" TYPE="REFERENCE">Connock 2007</LINK>; <LINK REF="REF-de-Sol_x00e0__x002d_Morales-2005" TYPE="REFERENCE">de Solà-Morales 2005</LINK>; <LINK REF="REF-Heneghan-2006a" TYPE="REFERENCE">Heneghan 2006a</LINK>; <LINK REF="REF-_x00d8_degaard-2004" TYPE="REFERENCE">Ødegaard 2004</LINK>; <LINK REF="REF-Siebenhofer-2004" TYPE="REFERENCE">Siebenhofer 2004</LINK>) and a meta-analysis of individual patient data (<LINK REF="REF-Heneghan-2012" TYPE="REFERENCE">Heneghan 2012</LINK>).</P>
<P>The main results of this review are consistent with previous reviews. The <LINK REF="REF-Christensen-2007" TYPE="REFERENCE">Christensen 2007</LINK> review of 10 trials showed that self-management was associated with a reduced risk of mortality and major complications with increased time being spent within the therapeutic INR target range. A 2004 review of eight trials (<LINK REF="REF-_x00d8_degaard-2004" TYPE="REFERENCE">Ødegaard 2004</LINK>) identified a significant reduction in major clinical events and a 2004 review of four trials (<LINK REF="REF-Siebenhofer-2004" TYPE="REFERENCE">Siebenhofer 2004</LINK>) concluded that patient self-management is safe and can improve the quality of anticoagulation control. A 2005 review of 12 trials (seven RCTs and five quasi-experimental trials) (<LINK REF="REF-de-Sol_x00e0__x002d_Morales-2005" TYPE="REFERENCE">de Solà-Morales 2005</LINK>), reported no difference between participants undertaking self-management and those receiving usual care in the time spent in the therapeutic range and in the incidence of adverse effects. Bazian's review (which was less comprehensive) also did not show a difference between self-management and routine care (<LINK REF="REF-Bazian-2005" TYPE="REFERENCE">Bazian 2005</LINK>). In the <LINK REF="REF-Bloomfield-2011" TYPE="REFERENCE">Bloomfield 2011</LINK> review, patients assigned to self-monitoring or self-management had significantly lower total mortality, lower risk for major thromboembolism, and no increased risk in major haemorrhage.</P>
<P>An individual patient data meta-analysis (<LINK REF="REF-Heneghan-2012" TYPE="REFERENCE">Heneghan 2012</LINK>), which included 11 trials with data for 6417 participants and 12,800 person-years of follow-up, reported a significant reduction in thromboembolic events in the self-monitoring group (Hazard Ratio (HR) 0.51; 95% CI 0.31 to 0.85), but not for major haemorrhagic events (HR 0.88, 95% CI, 0.74 to 1.06) or mortality (HR 0.82, 95% CI 0.62 to 1.09). In this review patients, younger than 55 years showed marked reductions in thrombotic events (HR 0.33, 95% CI 0.17 to 0.66), as did patients with mechanical heart valve (HR 0.52, 95% CI, 0.35 to 0.77). The greater reduction in mortality with self-management compared with self-monitoring observed in this review might be related to the higher frequency of thromboembolic events seen in the latter group. Also, reduced mortality might be affected by increased patient empowerment, whereby self-management influences other aspects of a patient's lifestyle (i.e. adherence to treatments) as they take on more of a locus of control for their condition.</P>
<P>A 2015 Health Technology Assesment (HTA) systematic review (<LINK REF="REF-Sharma-2015" TYPE="REFERENCE">Sharma 2015</LINK>) on the clinical effectiveness and cost-effectiveness of point-of-care tests of people receiving long-term vitamin K antagonist therapy reported that self-monitoring significantly prevented thromboembolic events and reduced all-cause mortality in people with artificial heart valves, and similarly to this current review, reported greater reductions in thromboembolic events and all-cause in those self-managing. In addition, the review reported net UK health and social care costs, which over a 10-year period were equivalent to standard monitoring costs.</P>
<P>Intrinsic limitations to self-monitoring and self-management include the reluctance of individuals to participate in self-management and the extensive training required to do so. Self-monitoring is not feasible for up to half of the patients requiring anticoagulation. Factors influencing patient participation within trials included problems with the device; physical limitations; attending training sessions; or failing the assessment. An additional problem with adoption in clinical practice will be the relatively high cost of the test strips. The reliability of self-testing devices can affect test results; however, available devices give INR results which are comparable with those obtained in laboratory testing (<LINK REF="REF-Ansell-2005" TYPE="REFERENCE">Ansell 2005</LINK>). Self-monitoring and self-management are also associated with a rate of testing that is higher than with usual care. In effect self-managed warfarin dosing is analogous to self-adjusted insulin dosing according to a pre-specified sliding scale (<LINK REF="REF-Ansell-1996" TYPE="REFERENCE">Ansell 1996</LINK>). Such self-managed treatment has been practiced for years by people with diabetes (<LINK REF="REF-Ansell-1996" TYPE="REFERENCE">Ansell 1996</LINK>), and the use of self-monitoring or self-management offers independence and freedom to travel for selected patients.</P>
<P>Our review has some potential limitations. First, our search was comprehensive, making serious publication bias less likely, but it remains a concern. Therefore, the results may represent an overestimate of the true effect of treatment. Second, variability in the quality of care in the control groups can affect the rate of testing and hence the benefit and safety of standard anticoagulation monitoring. Specialist programmes may improve outcomes by the same mechanism as self-monitoring or self-management, that is improving the time in therapeutic range and lessening the frequency of adverse outcomes. However, our post hoc subgroup analysis did not verify this effect. A further modifying factor is education and training. The two trials in which patients consented to participate and received education alone had better results than did those patients allocated to routine care (<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>; <LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>). Third, for all the major outcomes of this review, limitations in the published reports led to an absence of information about the allocation concealment procedure or blinding. However, several authors were successfully contacted and the additional information that they provided generally raised the assessed quality of the trials. This finding is in agreement with recent empirical evidence suggesting that authors fail to report concealment of randomisation and blinding (<LINK REF="REF-Devereaux--2004" TYPE="REFERENCE">Devereaux 2004</LINK>). Finally, for all the major outcomes there was a low numbers of events. Overestimates are likely in trials with fewer than 500 events and large overestimates of the effects are more likely in trials with fewer than 200 events. (<LINK REF="REF-Bassler-2010" TYPE="REFERENCE">Bassler 2010</LINK>)</P>
<P>Self-monitoring or self-management are likely to prevent thromboembolism to a greater extent than standard monitoring. The mechanism of effect is probably through increasing the number of INR values in range and therefore the longer time that patients are in the therapeutic range. Despite the limitations outlined above the apparent beneficial effects are large, and even smaller true underlying effects would probably justify widespread use of self-monitoring and self-management of oral anticoagulation in suitable candidates.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-06-27 05:45:06 -0500" MODIFIED_BY="Heather Maxwell">
<IMPLICATIONS_PRACTICE MODIFIED="2016-06-27 05:44:59 -0500" MODIFIED_BY="Heather Maxwell">
<P>Self-monitoring or self-management by patients can improve the quality of oral anticoagulation therapy compared to standard monitoring. Patients spend more time within the therapeutic range resulting in decreases in thromboembolic events with no increase in harms. Self-monitoring or self-management is potentially not feasible for half of the patients requiring anticoagulation. In addition, National Institute for Health and Care Excellence (NICE) guidance in the UK (<LINK REF="REF-NICE-diagnostics-guidance-_x005b_DG14_x005d_" TYPE="REFERENCE">NICE diagnostics guidance [DG14]</LINK>) for atrial fibrillation and heart valve disease currently recommends both the CoaguChek XS and InRatio2 PT/INR meters for patients if they are able and suitably trained. NICE also recommends not routinely offering self-monitoring to patients who have had a deep vein thrombosis or a pulmonary embolism (<LINK REF="REF-NICE-Venous-thromboembolic-diseases-_x0028_CG144_x0029_" TYPE="REFERENCE">NICE Venous thromboembolic diseases (CG144)</LINK>. The British Committee for Standards in Haematology guidance (<LINK REF="REF-Jennings-2014" TYPE="REFERENCE">Jennings 2014</LINK>) highlights the need for motivated patients to demonstrate competency and to be trained. Patients should also be reviewed at least every six months with documentation of their results and dosing, with external quality assessment to be undertaken at least every six months. The guidance also recommends that an INR &gt; 8·0 (if confirmed on a repeat sample) requires a venous sample to be analysed in a hospital laboratory and that medical advice is sought.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-27 05:45:06 -0500" MODIFIED_BY="Heather Maxwell">
<P>For the results to be generalisable to the population at large, there is a need for population-based studies that collect data on adverse event rates, time in range, and factors that impinge on successful self-monitoring and self-management (<LINK REF="REF-Nagler-2014" TYPE="REFERENCE">Nagler 2014</LINK>). The nature of this intervention lends itself to a registry to guarantee its safety and effectiveness in clinical practice. Future studies should set out to understand why people decide to use self-management (or not) and should incorporate consumer knowledge about self-management, triggers to seek care, self-efficacy or self-confidence to self-manage, and perceived or actual support. Further studies should explore components of the intervention that affect the feasibility of self-monitoring and self-management and identify means to improve uptake and effectiveness. In addition, given the low rates of adverse events in trials of self-monitoring, studies comparing its use to newer oral anticoagulants, which do not require monitoring, are warranted.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-06-21 07:46:08 -0500" MODIFIED_BY="[Empty name]"/>
<CONFLICT_OF_INTEREST MODIFIED="2016-06-21 07:46:05 -0500" MODIFIED_BY="[Empty name]">
<P>CJH: CH has received financial support from the National Institute of Health Research (NIHR) School of Primary Care Research in the UK for this update and is also part funded by the NIHR Oxford Diagnostic Evidence Co-operative (NIHR DEC). The opinions are those of the authors and not the Department of Health.</P>
<P>JMGA: None known.</P>
<P>EAS: None known.</P>
<P>AMW: None known.</P>
<P>RP: I am an investigator in the cohort study looking at estimating how successful self-monitoring is (in terms of control levels) in individuals that attempt self-monitoring (non-RCT setting). The results of this study would not be included in this Cochrane SR but could inform its discussion.</P>
<P>CB: None known.</P>
<P>PAC: None known.</P>
<P>DF: The institution I work for, The Univeristy of Birmingham, has received educational grants from Roche Diagnsotics UK to deliver on-going educational activities in the area of oral anticoagulation management.</P>
<P>KRM: None known.</P>
<P>IJO: None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-19 09:46:53 -0600" MODIFIED_BY="[Empty name]">
<P>CH: had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</P>
<P>CH, IO, ES, KM: checked and analysed the data.</P>
<P>CH, IO, ES, KM, JMG-A, RP, PA-C, AW, and CB, DF: contributed to the manuscript.</P>
<P>RP, CH and IO: Statistical analysis</P>
<P>All authors approved the final manuscript. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-06-27 05:24:40 -0500" MODIFIED_BY="Heather Maxwell">
<P>Changes were introduced between protocol and review stage to increase the scope and quality of the review. The title changed from "Self management for oral anticoagulation" to "Self-monitoring and self-management of oral anticoagulation". The authors' list changed from Garcia-Alamino JM, Martin JLR, Subirana M, Gich I to Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, Heneghan C. The type of studies changed from "Randomised controlled trials assessing the therapeutic efficacy and safety of self-management" to "Randomised controlled trials assessing the therapeutic effectiveness and safety of self-monitoring or self-management of oral anticoagulation". In the 'Types of outcome measures' mortality was added as an outcome. The quality assessment of the studies in the review now includes assessment of the evidence with the GRADE system.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-06-30 21:47:23 +0100" MODIFIED_BY="Abigail Baldridge">
<STUDIES MODIFIED="2016-06-24 04:50:28 -0500" MODIFIED_BY="Heather Maxwell">
<INCLUDED_STUDIES MODIFIED="2016-06-24 04:35:55 -0500" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Azarnoush-2009" MODIFIED="2016-06-24 04:15:12 -0500" MODIFIED_BY="Heather Maxwell" NAME="Azarnoush 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-19 07:28:20 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Azarnoush K, Camilleri L, Aublet-Cuvelier B, Geoffroy E, Dauphin C, Dubray C, et al</AU>
<TI>Results of the first randomized French study evaluating self-testing of the International Normalized Ratio</TI>
<SO>Journal of Heart Valve Disease</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>5</NO>
<PG>518-25</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417125"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-06-24 04:15:12 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dauphin C, Legault B, Jaffeux P, Motreff P, Azarnoush K, Joly H, et al</AU>
<TI>Comparison of INR stability between self-monitoring and standard laboratory method: preliminary results of a prospective study in 67 mechanical heart valve patients</TI>
<SO>Archives of Cardiovascular Diseases</SO>
<YR>2008</YR>
<VL>101</VL>
<NO>11-12</NO>
<PG>753-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417126"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417124"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beyth-2000" MODIFIED="2010-02-21 06:41:37 -0600" MODIFIED_BY="[Empty name]" NAME="Beyth 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-21 06:41:37 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beyth RJ, Quinn L, Landefeld CS</AU>
<TI>A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2000</YR>
<VL>133</VL>
<NO>9</NO>
<PG>687-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417128"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-28 17:31:23 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417127"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-2006" MODIFIED="2010-02-21 06:42:10 -0600" MODIFIED_BY="[Empty name]" NAME="Christensen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-02-21 06:42:10 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen TD, Maegaard M, Sørensen HT, Hjortdal VE, Hasenkam JM</AU>
<TI>Self-management versus conventional management of oral anticoagulant therapy: A randomized, controlled trial</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>4</NO>
<PG>260-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417130"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-28 17:31:13 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417129"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-2011" MODIFIED="2016-06-24 04:15:56 -0500" MODIFIED_BY="Heather Maxwell" NAME="Christensen 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-06-24 04:15:56 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen H, Lauterlein JJ, Sørensen PD, Petersen ERB, Madsen JS, Brandslund I</AU>
<TI>Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment</TI>
<SO>Telemedicine and e-Health</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>3</NO>
<PG>169-76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417132"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417131"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cromheecke-2000" MODIFIED="2016-06-24 04:16:43 -0500" MODIFIED_BY="Heather Maxwell" NAME="Cromheecke 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-06-24 04:16:43 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cromheecke ME, Levi M, Colly LP, de Mol BJ, Prins MH, Hutten BA, et al</AU>
<TI>Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9224</NO>
<PG>97-102</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417134"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417133"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dignan-2013" MODIFIED="2016-06-24 04:16:55 -0500" MODIFIED_BY="Heather Maxwell" NAME="Dignan 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-06-24 04:16:55 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dignan R, Keech AC, Gebski VJ, Mann KP, Hughes CF; Warfarin SMART Investigators</AU>
<TI>Is home warfarin self-management effective? Results of the randomised Self-Management of Anticoagulation Research Trial</TI>
<SO>International Journal of Cardiology</SO>
<YR>2013</YR>
<VL>168</VL>
<NO>6</NO>
<PG>5378-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4300486"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4300485"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzmaurice-2002" MODIFIED="2016-06-24 04:18:18 -0500" MODIFIED_BY="Heather Maxwell" NAME="Fitzmaurice 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-06-24 04:18:18 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD</AU>
<TI>A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management</TI>
<SO>Journal of Clinical Pathology</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>11</NO>
<PG>845-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417136"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 08:40:56 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCahon D, Murray ET, Murray K, Holder RL, Fitzmaurice DA</AU>
<TI>Does self-management of oral anticoagulation therapy improve quality of life and anxiety?</TI>
<SO>Family Practice</SO>
<YR>2011</YR>
<VL>28</VL>
<NO>2</NO>
<PG>134-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417135"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzmaurice-2005" MODIFIED="2016-06-24 04:17:24 -0500" MODIFIED_BY="Heather Maxwell" NAME="Fitzmaurice 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-06-24 04:17:24 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, et al</AU>
<TI>Self management of oral anticoagulation: randomised trial</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<NO>7524</NO>
<PG>1057</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417139"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:59:28 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCahon D, Fitzmaurice DA, Murray ET, Fuller CJ, Hobbs RF, Allan TF, et al</AU>
<TI>SMART: self-management of anticoagulation, a randomised trial</TI>
<SO>BMC Family Practice</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417140"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:59:28 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murray E, Fitzmaurice D, McCahon D, Fuller C, Sandhur H</AU>
<TI>Training for patients in a randomised controlled trial of self management of warfarin treatment</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7437</NO>
<PG>437-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417141"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417138"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadisseur-2003-Self-mge" MODIFIED="2016-06-24 04:20:36 -0500" MODIFIED_BY="Heather Maxwell" NAME="Gadisseur 2003 Self mge" YEAR="2003">
<REFERENCE MODIFIED="2010-02-26 08:02:36 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR</AU>
<TI>Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>21</NO>
<PG>2639-46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417143"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 08:03:31 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR</AU>
<TI>Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417142"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gadisseur-2003-Self-monit" MODIFIED="2010-02-26 08:04:43 -0600" MODIFIED_BY="[Empty name]" NAME="Gadisseur 2003 Self monit" YEAR="2003">
<REFERENCE MODIFIED="2010-02-26 08:02:42 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR</AU>
<TI>Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>21</NO>
<PG>2639-46</PG>
<IDENTIFIERS MODIFIED="2008-08-13 15:38:32 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417146"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 08:04:43 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR</AU>
<TI>Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417145"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gardiner-2005" MODIFIED="2016-06-24 04:23:01 -0500" MODIFIED_BY="Heather Maxwell" NAME="Gardiner 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-06-24 04:23:01 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gardiner C, Williams K, Longair I, Mackie IJ, Machin SJ, Cohen H</AU>
<TI>A randomised control trial of patient self-management of oral anticoagulation compared with patient self-testing.</TI>
<SO>British Journal of Haematolgy</SO>
<YR>2006</YR>
<VL>132</VL>
<NO>5</NO>
<PG>598-603</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417149"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-21 05:46:19 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H</AU>
<TI>Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>2</NO>
<PG>242-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417150"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417148"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grunau-2011" MODIFIED="2014-10-16 11:11:49 -0500" MODIFIED_BY="[Empty name]" NAME="Grunau 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-10-16 11:11:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grunau BE, Wiens MO, Harder KK</AU>
<TI>Patient self-management of warfarin therapy: pragmatic feasibility study in Canadian primary care</TI>
<SO>Canadian Family Physician Medecin de Famille Canadien</SO>
<YR>2011</YR>
<VL>57</VL>
<NO>8</NO>
<PG>e292-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417152"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417151"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horstkotte-1998" MODIFIED="2010-02-22 08:47:32 -0600" MODIFIED_BY="[Empty name]" NAME="Horstkotte 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-02-22 08:47:32 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horstkotte D, Piper C, Wiemer M</AU>
<TI>Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>1998</YR>
<VL>5 Suppl 1</VL>
<NO>3</NO>
<PG>19-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417154"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417153"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kaatz-Unpublished" MODIFIED="2014-10-16 11:11:59 -0500" MODIFIED_BY="[Empty name]" NAME="Kaatz Unpublished" YEAR="2001">
<REFERENCE MODIFIED="2014-10-16 11:11:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaatz S, Elston-Lafata J, Gooldy S</AU>
<TI>Anticoagulation therapy home and office monitoring evaluation study</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2001</YR>
<VL>12</VL>
<PG>111</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417156"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417155"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2004" MODIFIED="2010-02-21 06:45:47 -0600" MODIFIED_BY="[Empty name]" NAME="Khan 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-21 06:45:47 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan TI, Kamali F, Kesteven P, Avery P, Wynne H</AU>
<TI>The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation</TI>
<SO>British Journal of Haematology</SO>
<YR>2004</YR>
<VL>126</VL>
<NO>4</NO>
<PG>557-64</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417158"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417157"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00f6_rtke-2001" MODIFIED="2016-06-24 04:25:58 -0500" MODIFIED_BY="Heather Maxwell" NAME="Körtke 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-06-24 04:25:03 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eitz T, Schenk S, Fritzsche D, Bairaktaris A, Wagner O, Koertke H, et al</AU>
<TI>International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2008</YR>
<VL>85</VL>
<NO>3</NO>
<PG>949-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417160"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:57:28 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Körtke H, Körfer R</AU>
<TI>International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>1</NO>
<PG>44-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417161"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:56:52 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Körtke H, Minami K, Breymann T, Seifert D, Baraktaris A, Wagner O, et al</AU>
<TI>INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial)</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>2001</YR>
<VL>90 Suppl</VL>
<PG>6118-24</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417162"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:56:52 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Minami K, Bairaktaris A, Wagner O, Koerfer R</AU>
<TI>INR self-management following mechanical heart valve replacement</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2000</YR>
<VL>9 Suppl 1</VL>
<PG>41-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417163"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 07:56:52 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Minami K, Boethig D, Breymann TH, Seifert D, Wagner O, et al</AU>
<TI>INR self-management permits lower anticoagulation levels after mechanical heart valve replacement</TI>
<SO>Circulation</SO>
<YR>2003</YR>
<VL>108</VL>
<NO>10 Suppl 1</NO>
<PG>II-75-II-78</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417164"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-06-24 04:25:58 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Zittermann A, Minami K, Tenderich G, Wagner O, El-Arousy M, et al</AU>
<TI>Low-dose international normalized ratio self-management: a promising tool to achieve low complication rates after mechanical heart valve replacement</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>6</NO>
<PG>1909-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417165"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-16 05:33:33 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Zittermann A, Tenderich G, Wagner O, El-Arousy M, Krian A, et al</AU>
<TI>Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II</TI>
<SO>European Heart Journal</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>20</NO>
<PG>2479-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417166"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-16 05:35:41 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Zittermann A, Wagner O, Ennker J, Saggau W, Sack FU, et al</AU>
<TI>Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2010</YR>
<VL>90</VL>
<NO>5</NO>
<PG>1487-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417167"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-16 05:34:27 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koertke H, Zittermann A, Wagner O, Koerfer R</AU>
<TI>Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2007</YR>
<VL>83</VL>
<NO>1</NO>
<PG>24-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417168"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-06-28 17:30:57 -0500" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417159"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Matchar-2010" MODIFIED="2016-06-24 04:27:38 -0500" MODIFIED_BY="Heather Maxwell" NAME="Matchar 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-19 08:39:54 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matchar DB, Dolor R, Jacobson A, Love S, Edson R, Uyeda L</AU>
<TI>More frequent self-testing of prothrombin time results in improved time in target range</TI>
<SO>Circulation</SO>
<YR>2012</YR>
<VL>126</VL>
<PG>21 Suppl</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417170"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-06-24 04:27:38 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, et al; THINRS Executive Committee and Site Investigators</AU>
<TI>Effect of home testing of international normalized ratio on clinical events</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>363</VL>
<NO>17</NO>
<PG>1608-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417171"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417169"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menendez_x002d_Jandula-2005" MODIFIED="2010-02-22 09:38:03 -0600" MODIFIED_BY="Joey Kwong" NAME="Menendez-Jandula 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-02-21 06:48:45 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menéndez-Jándula B, Souto JC, Oliver A, Montserrat I, Quintana M, Gich I, et al</AU>
<TI>Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2005</YR>
<VL>142</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417173"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417172"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen-2012" MODIFIED="2014-10-16 11:12:23 -0500" MODIFIED_BY="[Empty name]" NAME="Rasmussen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-10-16 11:12:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen RS, Corell P, Madsen P, Overgaard K</AU>
<TI>Effects of computer-assisted oral anticoagulant therapy</TI>
<SO>Thrombosis Journal</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>1</NO>
<PG>17</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417175"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417174"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryan-2009" MODIFIED="2014-10-16 11:12:53 -0500" MODIFIED_BY="[Empty name]" NAME="Ryan 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-10-16 11:12:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryan F, Byrne S, O'Shea S</AU>
<TI>Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system</TI>
<SO>Journal of Thrombosis and Haemostasis : JTH</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>8</NO>
<PG>1284-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417177"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417176"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sawicki-1999" MODIFIED="2010-02-26 08:00:50 -0600" MODIFIED_BY="[Empty name]" NAME="Sawicki 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-02-26 08:00:33 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sawicki PT, Glaser B, Kleespies C, Stubbe J, Schmitz N, Kaiser T, et al</AU>
<TI>Long-term results of patients' self-management of oral anticoagulation</TI>
<SO>Journal of Clinical &amp; Basic Cardiology</SO>
<YR>2003</YR>
<VL>6</VL>
<NO>1-4</NO>
<PG>59-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417179"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 08:00:50 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sawicki PT</AU>
<TI>A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>281</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417180"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417178"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sidhu-2001" MODIFIED="2010-02-21 06:49:16 -0600" MODIFIED_BY="[Empty name]" NAME="Sidhu 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-21 06:49:16 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sidhu P, O'Kane HO</AU>
<TI>Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2001</YR>
<VL>72</VL>
<NO>5</NO>
<PG>1523-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417182"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417181"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siebenhofer-2007" MODIFIED="2016-06-24 04:33:08 -0500" MODIFIED_BY="Heather Maxwell" NAME="Siebenhofer 2007" YEAR="2007">
<REFERENCE MODIFIED="2016-06-24 04:33:08 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siebenhofer A, Hemkens LG, Rakovac I, Spat S, Didjurgeit U; SPOG 60+ Study Group</AU>
<TI>Self-management of oral anticoagulation in elderly patients - effects on treatment-related quality of life</TI>
<SO>Thrombosis Research</SO>
<YR>2012</YR>
<VL>130</VL>
<PG>e60-e6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417184"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 08:42:10 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U</AU>
<TI>Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2007</YR>
<VL>97</VL>
<NO>3</NO>
<PG>408-16</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417185"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 08:41:52 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U</AU>
<TI>Self-management of oral anticoagulation reduces major outcomes in the elderly. A randomized controlled trial</TI>
<SO>Thrombosis &amp; Haemostasis</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>6</NO>
<PG>1089-98</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417186"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417183"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soliman-Hamad-2009" MODIFIED="2014-10-16 11:13:22 -0500" MODIFIED_BY="[Empty name]" NAME="Soliman Hamad 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-10-16 11:13:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soliman Hamad MA, van Eekelen E, van Agt T, van Straten AH</AU>
<TI>Self-management program improves anticoagulation control and quality of life: a prospective randomized study</TI>
<SO>European Journal of Cardiothoracic Surgery</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>2</NO>
<PG>265-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417188"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417187"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunderji-2004" MODIFIED="2010-02-26 08:02:10 -0600" MODIFIED_BY="[Empty name]" NAME="Sunderji 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-26 08:02:10 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunderji R, Campbell L, Shalansky K, Fung A, Carter C, Gin K</AU>
<TI>Outpatient self-management of warfarin therapy: A pilot study</TI>
<SO>Pharmacotherapy</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>6</NO>
<PG>787-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417190"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-26 08:01:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sunderji R, Gin K, Shalansky K, Carter C, Chambers K, Davies C, et al</AU>
<TI>A randomized trial of patient self-managed versus physician-managed oral anticoagulation</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>11</NO>
<PG>1117-23</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417191"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417189"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-2013" MODIFIED="2016-06-24 04:35:55 -0500" MODIFIED_BY="Heather Maxwell" NAME="Thompson 2013" YEAR="2013">
<REFERENCE MODIFIED="2016-06-24 04:35:55 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JL, Burkhart HM, Daly RC, Dearani JA, Joyce LD, Suri RM, et al</AU>
<TI>Anticoagulation early after mechanical valve replacement: improved management with patient self-testing</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2013</YR>
<VL>146</VL>
<PG>599-604</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417192"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verret-2012" MODIFIED="2014-10-16 11:14:28 -0500" MODIFIED_BY="[Empty name]" NAME="Verret 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-10-16 11:14:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verret L, Couturier J, Rozon A, Saudrais-Janecek S, St-Onge A, Nguyen A, et al</AU>
<TI>Impact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial</TI>
<SO>Pharmacotherapy</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>10</NO>
<PG>871-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417195"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417194"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Voller-2005" MODIFIED="2010-02-21 06:52:41 -0600" MODIFIED_BY="[Empty name]" NAME="Voller 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-02-21 06:52:41 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Völler H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K</AU>
<TI>Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study)</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>2005</YR>
<VL>94</VL>
<NO>3</NO>
<PG>182-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417197"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417196"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-White-1989" MODIFIED="2010-02-21 06:53:08 -0600" MODIFIED_BY="[Empty name]" NAME="White 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-02-21 06:53:08 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>White RH, McCurdy SA, von Marensdorff H, Woodruff DE Jr, Leftgoff L</AU>
<TI>Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1989</YR>
<VL>111</VL>
<NO>9</NO>
<PG>730-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417198"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-06-24 04:50:28 -0500" MODIFIED_BY="Heather Maxwell">
<STUDY DATA_SOURCE="PUB" ID="STD-Bauman-2010" MODIFIED="2014-10-16 11:14:53 -0500" MODIFIED_BY="[Empty name]" NAME="Bauman 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-10-16 11:14:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauman ME, Black K, Bauman ML, Bruce AA, Kuhle S, Bajzar L, et al</AU>
<TI>EMPoWarMENT: Edmonton pediatric warfarin self-management pilot study in children with primarily cardiac disease</TI>
<SO>Thrombosis Research</SO>
<YR>2010</YR>
<VL>126</VL>
<NO>2</NO>
<PG>e110-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417201"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417200"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bussey-2010" MODIFIED="2016-06-24 04:46:35 -0500" MODIFIED_BY="Heather Maxwell" NAME="Bussey 2010" YEAR="2010">
<REFERENCE MODIFIED="2016-06-24 04:46:35 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bussey HI Jr, Frei C, Walker MB, Bussey-Smith K</AU>
<TI>Superior oral anticoagulation management with self testing and automated management; An interim analysis</TI>
<SO>Pharmacotherapy</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>10</NO>
<PG>396e</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4300488"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4300487"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bussey-2011" MODIFIED="2016-06-20 08:23:51 -0500" MODIFIED_BY="[Empty name]" NAME="Bussey 2011" YEAR="2011">
<REFERENCE MODIFIED="2016-06-20 08:23:51 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker MB, Bussey HI</AU>
<TI>Use of an interactive online information service to improve patient care in the field of anticoagulation and antithrombotic therapy</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2011</YR>
<VL>31</VL>
<PG>371:A8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-2001" MODIFIED="2010-02-21 06:57:12 -0600" MODIFIED_BY="[Empty name]" NAME="Christensen 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-21 06:57:12 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen TD, Attermann J, Pilegaard HK, Andersen NT, Maegaard M, Hasenkam JM</AU>
<TI>Self-management of oral anticoagulant therapy for mechanical heart valve patients</TI>
<SO>Scandinavian. Cardiovascular Journal</SO>
<YR>2001</YR>
<VL>35</VL>
<NO>2</NO>
<PG>107-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417205"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417204"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christensen-2003" MODIFIED="2010-02-21 06:58:20 -0600" MODIFIED_BY="[Empty name]" NAME="Christensen 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-02-21 06:58:20 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christensen TD, Andersen NT, Attermann J, Hjortdal VE, Maegaard M, Hasenkam JM</AU>
<TI>Mechanical heart valve patients can manage oral anticoagulant therapy themselves</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>292-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417207"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417206"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarkesmith-2013" MODIFIED="2014-03-11 15:52:54 -0500" MODIFIED_BY="[Empty name]" NAME="Clarkesmith 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-11 15:52:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarkesmith DE, Pattison HM, Lip GYH, Lane DA</AU>
<TI>Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial</TI>
<SO>PLOS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>9</NO>
<PG>1-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417208"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallagher-2015" MODIFIED="2016-06-24 04:48:04 -0500" MODIFIED_BY="Heather Maxwell" NAME="Gallagher 2015" YEAR="2015">
<REFERENCE MODIFIED="2016-06-24 04:48:04 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher J, Mc Carthy S, Woods N, Ryan F, O' Shea S, Byrne S</AU>
<TI>Economic evaluation of a randomized controlled trial of pharmacist-supervized patient self-testing of warfarin therapy</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2015</YR>
<VL>40</VL>
<NO>1</NO>
<PG>14-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="4300490"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="4300489"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hambleton-2003" MODIFIED="2010-02-21 06:59:09 -0600" MODIFIED_BY="[Empty name]" NAME="Hambleton 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-02-21 06:59:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hambleton J</AU>
<TI>Home monitoring of anticoagulation</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2003</YR>
<VL>16</VL>
<NO>1-2</NO>
<PG>39-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417211"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417210"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasenkam-1997" MODIFIED="2010-02-22 08:52:32 -0600" MODIFIED_BY="[Empty name]" NAME="Hasenkam 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-02-22 08:52:32 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasenkam JM, Knudsen L, Kimose HH, Gronnesby H, Attermann J, Andersen NT, et al</AU>
<TI>Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation</TI>
<SO>Thrombosis Research</SO>
<YR>1997</YR>
<VL>85</VL>
<NO>1</NO>
<PG>77-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417213"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417212"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasenkam-1998" MODIFIED="2010-02-21 07:01:39 -0600" MODIFIED_BY="[Empty name]" NAME="Hasenkam 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-02-21 07:01:39 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasenkam JM, Kimose HH, Gronnesby H, Andersen NT, Halborg J, Attermann J, et al</AU>
<TI>Self management of peroral anticoagulant therapy in patients with artificial heart valves</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>47</NO>
<PG>6811-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417215"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417214"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heidinger-2000" MODIFIED="2010-02-21 07:03:09 -0600" MODIFIED_BY="[Empty name]" NAME="Heidinger 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-21 07:03:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heidinger KS, Bernardo A, Taborski U, Muller-Berghaus G</AU>
<TI>Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis</TI>
<SO>Thrombosis Research</SO>
<YR>2000</YR>
<VL>98</VL>
<NO>4</NO>
<PG>287-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417217"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417216"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horstkotte-2004" MODIFIED="2010-02-21 07:03:34 -0600" MODIFIED_BY="[Empty name]" NAME="Horstkotte 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-21 07:03:34 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horstkotte D, Piper C</AU>
<TI>Improvement of oral anticoagulation therapy by INR self-management</TI>
<SO>Journal of Heart Valve Disease</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>3</NO>
<PG>335-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417219"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417218"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lafata-2000" MODIFIED="2010-02-21 07:09:44 -0600" MODIFIED_BY="[Empty name]" NAME="Lafata 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-21 07:09:44 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lafata JE, Martin SA, Kaatz S, Ward RE</AU>
<TI>Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis</TI>
<SO>Journal of Thrombosis and Thrombolysis</SO>
<YR>2000</YR>
<VL>9 Suppl 1</VL>
<PG>13-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417221"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417220"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurence-2008" MODIFIED="2016-06-24 04:50:28 -0500" MODIFIED_BY="Heather Maxwell" NAME="Laurence 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-06-24 04:50:28 -0500" MODIFIED_BY="Heather Maxwell" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurence C, Gialamas A, Yelland L, Bubner T, Ryan P, Willson K, et al</AU>
<TI>A pragmatic cluster randomised controlled trial to evaluate the safety, clinical effectiveness, cost effectiveness and satisfaction with point of care testing in a general practice setting - rationale, design and baseline characteristics</TI>
<SO>Trials</SO>
<YR>2008</YR>
<VL>9</VL>
<PG>50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417223"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417222"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leger-2004" MODIFIED="2010-02-21 07:11:18 -0600" MODIFIED_BY="[Empty name]" NAME="Leger 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-21 07:11:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leger S, Allenet B, Calop J, Bosson JL</AU>
<TI>Therapeutic education of patients receiving anticoagulants for thromboembolic venous disease: Description of the Educ'AVK program</TI>
<SO>Journal des Maladies Vasculaires</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>3</NO>
<PG>145-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417225"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417224"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-2001" MODIFIED="2010-02-21 07:12:10 -0600" MODIFIED_BY="[Empty name]" NAME="Levi 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-21 07:12:10 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, de Bruin TA, van der Meer FJ, Cromheecke ME, de Mol BA</AU>
<TI>Self-monitoring and self dosing of oral anticoagulant therapy with vitamin K antagonists</TI>
<SO>Tijdschrift voor Geneeskunde</SO>
<YR>2001</YR>
<VL>145</VL>
<NO>48</NO>
<PG>2313-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417227"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417226"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piso-2002" MODIFIED="2010-02-21 07:15:03 -0600" MODIFIED_BY="[Empty name]" NAME="Piso 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-02-21 07:15:03 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piso B, Jimenz-Boj E, Krinninger B, Watzke HH</AU>
<TI>The quality of oral anticoagulation before, during and after a period of patient self-management</TI>
<SO>Thrombosis Research</SO>
<YR>2002</YR>
<VL>106</VL>
<NO>2</NO>
<PG>101-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417229"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417228"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosengart-2002" MODIFIED="2010-02-21 07:15:32 -0600" MODIFIED_BY="[Empty name]" NAME="Rosengart 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-02-21 07:15:32 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosengart TK</AU>
<TI>Anticoagulation self-testing after heart valve replacement</TI>
<SO>Journal of Heart Valve Disease</SO>
<YR>2002</YR>
<VL>11 Suppl</VL>
<PG>61-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417231"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417230"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidtke-2001" MODIFIED="2010-02-21 07:20:04 -0600" MODIFIED_BY="[Empty name]" NAME="Schmidtke 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-21 07:20:04 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidtke C, Huppe M, Berndt S, Notzold A, Sievers HH</AU>
<TI>Quality of life after aortic valve replacement - Anticoagulation self-management or conventional therapy in mechanical prostheses versus pulmonary autograft</TI>
<SO>Zeitschrift fur Kardiologie</SO>
<YR>2001</YR>
<VL>90</VL>
<NO>11</NO>
<PG>860-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417233"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417232"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staresinic-2006" MODIFIED="2014-10-16 11:18:45 -0500" MODIFIED_BY="[Empty name]" NAME="Staresinic 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-10-16 11:18:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staresinic AG, Sorkness CA, Goodman BM, Pigarelli DW</AU>
<TI>Comparison of outcomes using 2 delivery models of anticoagulation care</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2006</YR>
<VL>166</VL>
<NO>9</NO>
<PG>997-1006</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417235"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417234"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sunderji-2005" MODIFIED="2010-02-21 07:22:05 -0600" MODIFIED_BY="[Empty name]" NAME="Sunderji 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-02-21 07:22:05 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sunderji R, Gin K, Shalansky K, Carter C, Chambers K, Davies C, et al</AU>
<TI>Clinical impact of point-of-care vs laboratory measurement of anticoagulation</TI>
<SO>American Journal of Clinical Pathology</SO>
<YR>2005</YR>
<VL>123</VL>
<NO>2</NO>
<PG>184-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417236"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watzke-2000" MODIFIED="2010-02-26 08:07:09 -0600" MODIFIED_BY="[Empty name]" NAME="Watzke 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-02-26 08:07:09 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B</AU>
<TI>A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>84</VL>
<NO>5</NO>
<PG>931-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3417239"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3417238"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2013-05-15 06:47:46 -0500" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-06-27 04:48:56 -0500" MODIFIED_BY="Heather Maxwell">
<ADDITIONAL_REFERENCES MODIFIED="2016-06-27 04:48:56 -0500" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Anderson-1993" MODIFIED="2010-02-21 07:22:33 -0600" MODIFIED_BY="[Empty name]" NAME="Anderson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Anderson DR, Harrison L, Hirsh J</AU>
<TI>Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1993</YR>
<VL>153</VL>
<PG>1441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-1996" MODIFIED="2010-02-21 07:22:58 -0600" MODIFIED_BY="[Empty name]" NAME="Ansell 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ansell JE, Hughes R</AU>
<TI>Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management</TI>
<SO>American Heart Journal</SO>
<YR>1996</YR>
<VL>132</VL>
<NO>5</NO>
<PG>1095-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-2001" MODIFIED="2010-02-21 07:23:53 -0600" MODIFIED_BY="[Empty name]" NAME="Ansell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, et al</AU>
<TI>Managing oral anticoagulant therapy</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119 Suppl</VL>
<NO>1</NO>
<PG>22-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-2004" MODIFIED="2010-02-21 07:24:33 -0600" MODIFIED_BY="[Empty name]" NAME="Ansell 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E</AU>
<TI>The pharmacology and management of the vitamin K antagonist</TI>
<SO>Chest</SO>
<YR>2004</YR>
<VL>126</VL>
<PG>204-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ansell-2005" MODIFIED="2010-02-21 07:25:22 -0600" MODIFIED_BY="[Empty name]" NAME="Ansell 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ansell J, Jacobson A, Levy J, Völler H, Hasenkam JM; International Self-Monitoring Association for Oral Anticoagulation</AU>
<TI>Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>1</NO>
<PG>37-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baglin-1994" MODIFIED="2010-02-21 07:27:20 -0600" MODIFIED_BY="[Empty name]" NAME="Baglin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Baglin T</AU>
<TI>Decentralization of anticoagulant control</TI>
<SO>Clinical and Laboratory Haematology</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>327-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barcellona-1998" MODIFIED="2016-06-24 04:54:31 -0500" MODIFIED_BY="Heather Maxwell" NAME="Barcellona 1998" TYPE="JOURNAL_ARTICLE">
<AU>Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F</AU>
<TI>Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?</TI>
<SO>Thrombosis and Haemostostasis</SO>
<YR>1998</YR>
<VL>80</VL>
<NO>6</NO>
<PG>899-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barcellona-2009" MODIFIED="2016-06-24 04:54:47 -0500" MODIFIED_BY="Heather Maxwell" NAME="Barcellona 2009" TYPE="JOURNAL_ARTICLE">
<AU>Barcellona D, Fenu L, Cornacchini S, Marongiu F</AU>
<TI>Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful?</TI>
<SO>Thromb Res.</SO>
<YR>2009</YR>
<VL>123</VL>
<PG>775-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bassler-2010" MODIFIED="2015-08-04 08:37:27 -0500" MODIFIED_BY="[Empty name]" NAME="Bassler 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al</AU>
<TI>Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis.</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>12</NO>
<PG>1180-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bazian-2005" MODIFIED="2010-02-21 07:27:55 -0600" MODIFIED_BY="[Empty name]" NAME="Bazian 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bazian Ltd</AU>
<TI>Self-management of oral anticoagulation</TI>
<SO>Evidence-Based Healthcare and Public Health</SO>
<YR>October 2005</YR>
<VL>9</VL>
<NO>5</NO>
<PG>334-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bloomfield-2011" MODIFIED="2014-10-16 11:20:36 -0500" MODIFIED_BY="[Empty name]" NAME="Bloomfield 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, et al</AU>
<TI>Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2011</YR>
<VL>154</VL>
<NO>7</NO>
<PG>472-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breckenridge-1978" MODIFIED="2010-02-21 07:28:48 -0600" MODIFIED_BY="[Empty name]" NAME="Breckenridge 1978" TYPE="JOURNAL_ARTICLE">
<AU>Breckenridge AM</AU>
<TI>Oral anticoagulant drugs: pharmacokinetic aspects</TI>
<SO>Seminars in Hematology</SO>
<YR>1978</YR>
<VL>15</VL>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2007" MODIFIED="2010-02-22 08:45:46 -0600" MODIFIED_BY="[Empty name]" NAME="Brown 2007" TYPE="OTHER">
<AU>Brown A, Wells P, Jaffey J, McGahan L, Poon M-C, Cimon K, et al</AU>
<TI>Point-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness</TI>
<SO>Canadian Agency for Drugs and Technologies in Health</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2009-01-18 15:41:29 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2009-01-18 15:41:29 -0600" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="www.cadth.ca"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Buckingham-2002" MODIFIED="2010-02-21 07:29:35 -0600" MODIFIED_BY="[Empty name]" NAME="Buckingham 2002" TYPE="JOURNAL_ARTICLE">
<AU>Buckingham TA, Hatala R</AU>
<TI>Anticoagulants for atrial fibrillation: why is the treatment rate so low?</TI>
<SO>Clinical Cardiology</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>10</NO>
<PG>447-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cannegieter-1995" MODIFIED="2010-02-21 07:30:31 -0600" MODIFIED_BY="[Empty name]" NAME="Cannegieter 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E</AU>
<TI>Optimal oral anticoagulant therapy in patients with mechanical heart valves</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<NO>1</NO>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caro-2004" MODIFIED="2016-06-24 04:58:30 -0500" MODIFIED_BY="Heather Maxwell" NAME="Caro 2004" TYPE="JOURNAL_ARTICLE">
<AU>Caro JJ</AU>
<TI>An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation</TI>
<SO>American Journal of Managed Care</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>14 Suppl</NO>
<PG>451-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-2007" MODIFIED="2010-02-21 07:32:19 -0600" MODIFIED_BY="[Empty name]" NAME="Christensen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM</AU>
<TI>Self-management of oral anticoagulant therapy: a systematic review and meta-analysis</TI>
<SO>International Journal of Cardiology</SO>
<YR>2007</YR>
<VL>118</VL>
<NO>1</NO>
<PG>54-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Christensen-2009" MODIFIED="2010-02-21 07:32:44 -0600" MODIFIED_BY="[Empty name]" NAME="Christensen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Christensen TD, Larsen TB, Jensen C, Maegaard M, Sørensen B</AU>
<TI>International normalised ratio (INR) measured on the CoaguChek S and XS compared with the laboratory for determination of precision and accuracy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>101</VL>
<NO>3</NO>
<PG>563-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connock-2007" MODIFIED="2016-06-24 04:59:26 -0500" MODIFIED_BY="Heather Maxwell" NAME="Connock 2007" TYPE="JOURNAL_ARTICLE">
<AU>Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al</AU>
<TI>Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling</TI>
<SO>Health Technology Assessment</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>38</NO>
<PG>ix-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connolly-1991" MODIFIED="2010-02-21 07:34:08 -0600" MODIFIED_BY="[Empty name]" NAME="Connolly 1991" TYPE="JOURNAL_ARTICLE">
<AU>Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C</AU>
<TI>Canadian Atrial Fibrillation Anticoagulation (CAFA) Study</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>2</NO>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Sol_x00e0__x002d_Morales-2005" MODIFIED="2010-02-21 07:36:21 -0600" MODIFIED_BY="[Empty name]" NAME="de Solà-Morales 2005" TYPE="JOURNAL_ARTICLE">
<AU>de Solà-Morales Serra O, Elorza Ricart JM</AU>
<TI>Portable coagulometers: a systematic review of the evidence on self-management of oral anticoagulant treatment</TI>
<SO>Medicina Clinica (Barc)</SO>
<YR>2005</YR>
<VL>124</VL>
<NO>9</NO>
<PG>321-5</PG>
<IDENTIFIERS MODIFIED="2009-01-18 12:02:13 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-02-21 07:36:53 -0600" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devereaux--2004" MODIFIED="2010-02-21 07:37:33 -0600" MODIFIED_BY="[Empty name]" NAME="Devereaux  2004" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ, Choi PT, El-Dika S, Bhandari M, Montori VM, Schünemann HJ, et al</AU>
<TI>An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2004</YR>
<VL>57</VL>
<NO>12</NO>
<PG>1232-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Devereaux-2001" MODIFIED="2010-02-21 07:37:59 -0600" MODIFIED_BY="[Empty name]" NAME="Devereaux 2001" TYPE="JOURNAL_ARTICLE">
<AU>Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al</AU>
<TI>Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2010-02-21 07:38:18 -0600" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DiNicolantonio-2012" MODIFIED="2016-06-24 05:02:33 -0500" MODIFIED_BY="Heather Maxwell" NAME="DiNicolantonio 2012" TYPE="JOURNAL_ARTICLE">
<AU>DiNicolantonio JJ</AU>
<TI>Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.</TI>
<SO>Expert Opinion in Pharmacotherapy</SO>
<YR>2012</YR>
<VL>13</VL>
<NO>8</NO>
<PG>1101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eikelboom--2013" MODIFIED="2016-06-24 05:06:24 -0500" MODIFIED_BY="Heather Maxwell" NAME="Eikelboom  2013" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ et al; RE-ALIGN Investigators</AU>
<TI>Dabigatran versus Warfarin in Patients with Mechanical Heart Valves</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>369</VL>
<NO>13</NO>
<PG>1206-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fitzmaurice-2001" MODIFIED="2010-02-21 07:39:35 -0600" MODIFIED_BY="[Empty name]" NAME="Fitzmaurice 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fitzmaurice DA, Machin SJ, for The Bristish Society of Haematology Task Force for Haemostasis and Thrombosis</AU>
<TI>Recommendations for patients undertaking self management of oral anticoagulation</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>323</VL>
<PG>985-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gadisseur-2004" MODIFIED="2010-02-21 07:40:05 -0600" MODIFIED_BY="[Empty name]" NAME="Gadisseur 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR</AU>
<TI>Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Go-2003" MODIFIED="2010-02-22 09:00:07 -0600" MODIFIED_BY="[Empty name]" NAME="Go 2003" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al</AU>
<TI>Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<NO>20</NO>
<PG>2685-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-2008" MODIFIED="2010-02-21 07:40:32 -0600" MODIFIED_BY="[Empty name]" NAME="GRADE 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, for the GRADE Working Group</AU>
<TI>Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenblatt-2005" MODIFIED="2010-02-21 07:41:52 -0600" MODIFIED_BY="[Empty name]" NAME="Greenblatt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Greenblatt DJ, von Moltke LL</AU>
<TI>Interaction of warfarin with drugs, natural substances, and foods</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>2005</YR>
<VL>45</VL>
<PG>127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-2007" MODIFIED="2016-06-24 05:07:36 -0500" MODIFIED_BY="Heather Maxwell" NAME="Hart 2007" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Pearce LA, Aguilar MI</AU>
<TI>Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2007</YR>
<VL>146</VL>
<PG>857-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heneghan-2006a" MODIFIED="2010-02-22 08:55:43 -0600" MODIFIED_BY="[Empty name]" NAME="Heneghan 2006a" TYPE="JOURNAL_ARTICLE">
<AU>Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P</AU>
<TI>Self-monitoring of oral anticoagulation: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9508</NO>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heneghan-2008" MODIFIED="2016-06-24 05:08:39 -0500" MODIFIED_BY="Heather Maxwell" NAME="Heneghan 2008" TYPE="BOOK_SECTION">
<AU>Heneghan C, Perera R</AU>
<TI>Oral anticoagulation therapy</TI>
<SO>Evidence Based Medical Monitoring</SO>
<YR>2008</YR>
<PG>229-244</PG>
<EN>1</EN>
<ED>Glasziou P, Irwig L, Aronson JK</ED>
<PB>Blackwells</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heneghan-2012" MODIFIED="2014-10-16 11:21:23 -0500" MODIFIED_BY="[Empty name]" NAME="Heneghan 2012" TYPE="JOURNAL_ARTICLE">
<AU>Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, et al</AU>
<TI>Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>379</VL>
<NO>9813</NO>
<PG>322-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-01-17 16:16:17 -0600" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-06-21 06:23:04 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1998" MODIFIED="2010-02-21 07:42:49 -0600" MODIFIED_BY="[Empty name]" NAME="Hirsh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al</AU>
<TI>Oral anticoagulation mechanism of action, clinical effectiveness, and optimal therapeutic range</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>114 Suppl</VL>
<PG>445-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-2001" MODIFIED="2016-06-24 05:09:24 -0500" MODIFIED_BY="Heather Maxwell" NAME="Hirsh 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al</AU>
<TI>Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range</TI>
<SO>Chest</SO>
<YR>2001</YR>
<VL>119 Suppl 1</VL>
<PG>8-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hylek-1996" MODIFIED="2010-02-21 07:43:58 -0600" MODIFIED_BY="[Empty name]" NAME="Hylek 1996" TYPE="JOURNAL_ARTICLE">
<AU>Hylek EM, Skates SJ, Sheehan MA, Singer DE</AU>
<TI>An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<NO>8</NO>
<PG>540-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jennings-2014" MODIFIED="2016-06-24 05:10:23 -0500" MODIFIED_BY="Heather Maxwell" NAME="Jennings 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jennings I, Kitchen D, Keeling D, Fitzmaurice D, Heneghan C; BCSH Committee</AU>
<TI>Patient self-testing and self-management of oral anticoagulation with vitamin K antagonists: guidance from the British Committee for Standards in Haematology</TI>
<SO>British Journal of Haematology</SO>
<YR>2014</YR>
<VL>167</VL>
<NO>5</NO>
<PG>600-7</PG>
<IDENTIFIERS MODIFIED="2016-03-02 05:52:44 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2016-03-02 05:52:44 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="doi: 10.1111/bjh.13070"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kearon-2003" MODIFIED="2010-02-21 07:45:13 -0600" MODIFIED_BY="[Empty name]" NAME="Kearon 2003" TYPE="JOURNAL_ARTICLE">
<AU>Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators</AU>
<TI>Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>7</NO>
<PG>631-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" NAME="Lefebvre 1996" TYPE="OTHER">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Paper presented at the Fourth International Cochrane Colloquium, 20-24 Oct 1996; Adelaide. Australia</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-10-16 10:21:27 -0500" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of InterventionsVersion 5.1.0 (updated March 2011)</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manotti-2001" NAME="Manotti 2001" TYPE="JOURNAL_ARTICLE">
<AU>Manotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG</AU>
<TI>Effect of computer-aided management on the quality of treatment in anticoagulated patients: a prospective, randomized, multicenter trial of APROAT (Automated Program for Oral Anticoagulant Treatment)</TI>
<SO>Haematologica</SO>
<YR>2001</YR>
<VL>86</VL>
<PG>1060-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagler-2014" MODIFIED="2016-06-24 05:14:26 -0500" MODIFIED_BY="Heather Maxwell" NAME="Nagler 2014" TYPE="JOURNAL_ARTICLE">
<AU>Nagler M, Bachmann LM, Schmid P, Raddatz Müller P, Wuillemin WA</AU>
<TI>Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study</TI>
<SO>PLoS one</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>4</NO>
<PG>e95761</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-diagnostics-guidance-_x005b_DG14_x005d_" MODIFIED="2016-06-24 05:15:07 -0500" MODIFIED_BY="Heather Maxwell" NAME="NICE diagnostics guidance [DG14]" TYPE="OTHER">
<AU>NICE</AU>
<TI>Atrial fibrillation and heart valve disease: self&#8209;monitoring coagulation status using point&#8209;of&#8209;care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor)</TI>
<SO>NICE diagnostics guidance [DG14]</SO>
<YR>September 2014</YR>
<IDENTIFIERS MODIFIED="2016-06-24 05:15:07 -0500" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-06-24 05:15:07 -0500" MODIFIED_BY="Heather Maxwell" TYPE="OTHER" VALUE="www.nice.org.uk/guidance/dg14"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-NICE-Venous-thromboembolic-diseases-_x0028_CG144_x0029_" MODIFIED="2016-06-24 05:15:27 -0500" MODIFIED_BY="Heather Maxwell" NAME="NICE Venous thromboembolic diseases (CG144)" TYPE="OTHER">
<AU>NICE</AU>
<TI>Venous thromboembolic diseases: diagnosis, management and thrombophilia testing</TI>
<SO>NICE</SO>
<YR>June 2012</YR>
<IDENTIFIERS MODIFIED="2016-06-24 05:15:27 -0500" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-06-24 05:15:27 -0500" MODIFIED_BY="Heather Maxwell" TYPE="OTHER" VALUE="www.nice.org.uk/guidance/CG144"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pogue-1997" MODIFIED="2010-02-21 07:48:55 -0600" MODIFIED_BY="[Empty name]" NAME="Pogue 1997" TYPE="JOURNAL_ARTICLE">
<AU>Pogue JM, Yusuf S</AU>
<TI>Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>6</NO>
<PG>580-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poller-2006" MODIFIED="2010-02-21 07:50:00 -0600" MODIFIED_BY="[Empty name]" NAME="Poller 2006" TYPE="JOURNAL_ARTICLE">
<AU>Poller L, Keown M, Ibrahim SA, van der Meer FJ, van den Besselaar AM, Tripodi A, et al; European Concerted Action on Thrombosis</AU>
<TI>Quality assessment of CoaguChek point-of-care prothrombin time monitors: comparison of the European community-approved procedure and conventional external quality assessment</TI>
<SO>Clinical Chemistry</SO>
<YR>2006</YR>
<VL>52</VL>
<NO>10</NO>
<PG>1843-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Regier-2006" MODIFIED="2016-06-24 05:17:16 -0500" MODIFIED_BY="Heather Maxwell" NAME="Regier 2006" TYPE="JOURNAL_ARTICLE">
<AU>Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA</AU>
<TI>Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy</TI>
<SO>CMAJ: Canadian Medical Jurnal Association</SO>
<YR>2006</YR>
<VL>174</VL>
<NO>13</NO>
<PG>1847-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharma-2015" MODIFIED="2016-06-27 04:48:56 -0500" MODIFIED_BY="Heather Maxwell" NAME="Sharma 2015" TYPE="OTHER">
<AU>Sharma P, Scotland G, Cruickshank M, Tassie E, Fraser C, Burton C, et al</AU>
<TI>The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2015</YR>
<VL>19</VL>
<NO>48</NO>
<IDENTIFIERS MODIFIED="2016-06-26 15:29:54 -0500" MODIFIED_BY="Heather Maxwell"><IDENTIFIER MODIFIED="2016-03-02 05:15:37 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="http://dx.doi.org/10.3310/hta19480"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siebenhofer-2004" MODIFIED="2010-02-21 07:52:47 -0600" MODIFIED_BY="[Empty name]" NAME="Siebenhofer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Siebenhofer A, Berghold A, Sawicki PT</AU>
<TI>Systematic review of studies of self-management of oral anticoagulation</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>91</VL>
<NO>2</NO>
<PG>225-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPAF-1996" MODIFIED="2010-02-22 12:16:40 -0600" MODIFIED_BY="[Empty name]" NAME="SPAF 1996" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<NO>9028</NO>
<PG>633-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stafford-1998" MODIFIED="2010-01-05 08:19:06 -0600" MODIFIED_BY="[Empty name]" NAME="Stafford 1998" TYPE="JOURNAL_ARTICLE">
<AU>Stafford RS, Singer DE</AU>
<TI>Recent national patterns of warfarin use in atrial fibrillation</TI>
<SO>Circulation</SO>
<YR>1998</YR>
<VL>97</VL>
<NO>13</NO>
<PG>1231-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taborski-1999" MODIFIED="2010-02-21 07:53:34 -0600" MODIFIED_BY="[Empty name]" NAME="Taborski 1999" TYPE="JOURNAL_ARTICLE">
<AU>Taborski U, Wittstamm FJ, Bernardo A</AU>
<TI>Cost-effectiveness of self-managed anticoagulant therapy in Germany</TI>
<SO>Seminars in Thrombosis and Hemostasis</SO>
<YR>1999</YR>
<VL>25</VL>
<NO>1</NO>
<PG>103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-_x00d8_degaard-2004" MODIFIED="2010-02-21 07:55:56 -0600" MODIFIED_BY="[Empty name]" NAME="Ødegaard 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ødegaard KJ</AU>
<TI>Self-management in anticoagulation--a meta-analysis</TI>
<SO>Tidsskrift for den Norske Laegeforening</SO>
<YR>2004</YR>
<VL>124</VL>
<NO>22</NO>
<PG>2900-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-06-24 05:21:37 -0500" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Cochrane-2010" MODIFIED="2016-06-24 05:21:37 -0500" MODIFIED_BY="Heather Maxwell" NAME="Cochrane 2010" TYPE="COCHRANE_REVIEW">
<AU>Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, et al</AU>
<TI>Self-monitoring and self-management of oral anticoagulation</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2015-02-16 06:22:04 -0600" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2015-02-16 06:22:04 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003839.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heneghan-2006b" MODIFIED="2010-02-22 08:55:28 -0600" MODIFIED_BY="[Empty name]" NAME="Heneghan 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P</AU>
<TI>Self-monitoring of oral anticoagulation: a systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<NO>9508</NO>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2010-02-26 08:03:51 -0600" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Gadisseur-2004a" MODIFIED="2010-02-26 08:03:51 -0600" MODIFIED_BY="[Empty name]" NAME="Gadisseur 2004a" TYPE="JOURNAL_ARTICLE">
<AU>Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR</AU>
<TI>Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2004</YR>
<VL>2</VL>
<NO>4</NO>
<PG>584-91</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-06-27 05:24:30 -0500" MODIFIED_BY="Heather Maxwell">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-06-27 05:24:30 -0500" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Trial identification" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Study duration" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Oral anticoagulant used">
<INCLUDED_CHAR MODIFIED="2016-06-24 07:42:31 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Azarnoush-2009">
<CHAR_METHODS MODIFIED="2016-06-24 07:42:31 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single-centre, randomised, parallel-group controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-12 09:23:56 -0500" MODIFIED_BY="[Empty name]">
<P>206 adult patients who had undergone valve replacement with a mechanical prosthesis, with or without myocardial revascularisation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:37:06 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs standard monitoring</B>
</P>
<P>Randomised to standard monitoring of INR at a laboratory including at least one monthly assay at a medical analysis laboratory (n = 103), or self-testing using either the CoaguChek® system (n = 55) or the INRatio® system (n = 48). Self-testing was performed weekly, and in addition once monthly INR measurements were carried out at the laboratory on the same day as the self-measurement. Only the results of the monthly tests for each group were compared. Education relating to VKA therapy was provided, the same to all participants in all allocation groups. The target INR and target range were determined for each participant on the basis of the type of surgery, and according to their risk factors for thromboembolic disease (target ranges were between 2 and 3.5 INR). Aspirin was prescribed to some participants according to risk factors.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-26 03:52:10 -0500" MODIFIED_BY="[Empty name]">
<P>Mean time within target range. Clinical adverse events, and serious bleeding. </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-10 05:56:59 -0500" MODIFIED_BY="[Empty name]">
<P>Clinicaltrials.gov NCT00925197</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 05:57:08 -0500" MODIFIED_BY="[Empty name]">
<P>49.0 ± 10.3 weeks</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 05:59:32 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-10 05:59:36 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-27 05:24:30 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Beyth-2000">
<CHAR_METHODS MODIFIED="2016-06-24 07:42:38 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-12 09:33:03 -0500" MODIFIED_BY="[Empty name]">
<P>325 hospitalised patients aged 65+ years (mean age 75 years) commencing warfarin therapy of at least 10 days duration. The study was based in several university hospitals (Cleveland, Ohio, USA).</P>
<P>Exclusions included: warfarin therapy within previous 6 months; admission from nursing home; too ill to give informed consent.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:38:33 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>The intervention group (n = 163) used home self-testing using Coumatrak Protime Test System<SUP>®</SUP> to self-monitor prothrombin time. 1-hour education session, patients phoned results to coach who made recommendations on dosage adjustment.</P>
<P>The conventional management group (n = 162) received medical care including management, dosing and medical information managed by primary care physician as per usual care.</P>
<P>Randomisation was stratified according to baseline risk for major bleeding.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 07:38:47 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary outcome: first major bleeding event during the 6-month intervention period.</P>
<P>Secondary outcomes: death; recurrent venous thromboembolism at 6 months; major bleeding after 6 months; percentage time INR within target range.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:01:17 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:01:21 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-06-27 05:24:30 -0500" MODIFIED_BY="Heather Maxwell">
<P>One-to-one training, lasting 30-60 minutes. Participants instructed to check prothrombin 3 times in the first week after hospital discharge and weekly in the first month, and monthly thereafter depending on the results. 100% up at 6 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:42:44 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Christensen-2006">
<CHAR_METHODS MODIFIED="2016-06-24 07:42:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, open-label, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-12 09:43:20 -0500" MODIFIED_BY="[Empty name]">
<P>100 ambulatory patients aged &gt; 18 years (mean age 63 years in intervention group, 69 years in control group) receiving oral anticoagulation therapy for &gt; 8 months. The study was based in the Center of Self-managed Oral Anticoagulation (Denmark).</P>
<P>Exclusion criteria included: previous self-management.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:40:24 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Randomisation to a) self-management (n = 50), in which participants were trained to self-monitor using a Coaguchek<SUP>® </SUP>coagulometer to measure INR once a week and also to adjust their anticoagulant dosage accordingly.</P>
<P>b) usual care (n = 50), in which conventional management included at least monthly INR testing at a hospital or physician centre and dosage adjusted by the physician.</P>
<P>In both groups an additional INR analysis was performed monthly and the participant contacted if INR was &lt; 1.5 or &gt; 4.5.</P>
<P>After 6 months intervention, the control group began training to self-manage their anticoagulation therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-12 09:59:25 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: composite of the variance of the monthly INR test plus negative score points for death, major complications, or study discontinuation. </P>
<P>Secondary outcomes: variance of INR values in the control sample; time within therapeutic INR range. </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:05:06 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-12 09:53:49 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin or phenprocoumon.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-12 09:45:53 -0500" MODIFIED_BY="[Empty name]">
<P>Training took place over 6 months, during which time the participant gradually assumed self-management of oral anticoagulation monitoring and dosing. Assessment of ability to self-manage was made at the end of 6 months. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:22:54 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Christensen-2011">
<CHAR_METHODS MODIFIED="2016-06-24 08:22:54 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised, parallel-group, controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 07:41:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>Adult participants on lifelong anticoagulation therapy receiving treatment for at least the previous 6 months, able to use the internet and demonstrate ability to use the CoaguChek XS system after a 1-hour training session.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-20 08:22:23 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Randomised to one of three groups:</P>
<P>A) self-monitoring by measurement of INR once/week at home and reporting the value via a computer system to the anticoagulation clinic</P>
<P>B) self-monitoring by measurement of INR twice/week at home and reporting the values via a computer system to the anticoagulation clinic</P>
<P>C) continuing regular visits to the anticoagulation clinic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-10 08:43:33 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: Time in treatment range appropriate to the individual participant, as measured by the Rosendaal method. </P>
<P>Secondary outcomes: number of INR measurements &lt; 1.5 or &gt; 5.0; number of adverse clinical events. </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-10 08:43:12 -0500" MODIFIED_BY="[Empty name]"/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 08:45:09 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 08:48:32 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:44:45 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Cromheecke-2000">
<CHAR_METHODS MODIFIED="2016-06-24 07:42:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised, controlled cross-over trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-13 07:34:21 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were 50 consecutive outpatients who were receiving long-term anticoagulation (mean age 42 years). The study was based in the departments of cardiology and internal medicine of the Academic Medical Centre (Amsterdam, The Netherlands).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-13 07:40:10 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Self-management vs usual care</B>
</P>
<P>The intervention group used home self-testing using Coaguchek<SUP>® </SUP>to self-monitor prothrombin time and self-dosing testing performed once a week.</P>
<P>The conventional management was done by the anticoagulation clinic. </P>
<P>INR testing was also performed in all participants at 1-2 week intervals by the central laboratory; these results were not made available to participants or managing physicians. </P>
<P>After three months patients crossed over the alternative management strategy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 07:44:08 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary outcome: no. of INR measurements within 0.5 of therapeutic target INR.</P>
<P>Secondary outcomes: Percentage time within target INR range; no. participants within target range for 0%-100% of the time; no. participants who achieved better control of anticoagulation.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2016-06-24 07:44:26 -0500" MODIFIED_BY="Heather Maxwell">
<P>3 months (followed by cross-over to alternative intervention group, for a further 3 months. The outcomes used here are those at the end of the first 3 months)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-06-24 07:44:45 -0500" MODIFIED_BY="Heather Maxwell">
<P>Phenprocoumon (35% of participants) or acenocoumarol (65% of participants)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-12 10:08:48 -0500" MODIFIED_BY="[Empty name]">
<P>All patients were educated and trained to self-manage anticoagulation during a structured educational program of two 2 hours sessions. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:47:15 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Dignan-2013">
<CHAR_METHODS MODIFIED="2016-06-17 07:53:09 -0500" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised, controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-20 08:22:29 -0500" MODIFIED_BY="[Empty name]">
<P>Patients at least 18 years of age who were receiving warfarin for at least 3 months for either atrial fibrillation or for one or more mechanical heart valves. Patients needed to have a stable INR within the therapeutic range for the 2 weeks before enrolment, without maintenance dose adjustments above 2 mg per day, so that an individual algorithm could be developed. The study was conducted at Liverpool, Royal Prince Alfred, and Strathfield Private Hospitals, all in Australia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:45:58 -0500" MODIFIED_BY="Heather Maxwell">
<P>The intervention group was trained to perform home INR testing and warfarin dosing using a validated ColourChart algorithm. Patients checked their INR at least once a week, and more frequently if required by the algorithm.</P>
<P>Patients were instructed to call the study nurse to discuss maintenance dose adjustment if the INR was less than 1.6, greater than 4.5, or out-of-range for more than 4 tests.</P>
<P>The usual-care group was also given instructions on how to complete a black-and-white chart similar to the ColourChart to record their clinical INR test results but without the algorithm instructions.</P>
<P>For 12 months, all patients had monthly outcome INRs measured at a central accredited laboratory.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 07:47:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary outcome was the proportion of out-of-range INRs.</P>
<P>Secondary endpoints included: 1. the number of times outcome INR results occurred in extreme ranges (&#8805; 4.5, &lt; 1.5); and 2. rates of serious adverse events related to bleeding or thrombosis. Subsidiary (tertiary) endpoints were: 1. the average deviation from the middle of each individual's INR target range; 2. the mean outcome INR, by treatment group allocation; and 3. time to the first INR reading in an extreme range.</P>
<P>Serious adverse events were classified as embolism, thrombosis, moderate bleeding (requiring medical evaluation or treatment, minor and nuisance bleeding excluded), severe, life-threatening, or fatal bleeding, and other events, and were adjudicated by a blinded assessor as to nature and cause.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2016-06-17 08:02:35 -0500" MODIFIED_BY="[Empty name]">
<P>ACTRN12606000019505</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-06-17 08:02:45 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2016-06-17 08:04:01 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:48:09 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fitzmaurice-2002">
<CHAR_METHODS MODIFIED="2016-06-24 07:47:40 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 07:47:50 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants were ambulatory adults aged &gt; 18 years attending an anticoagulation clinic, receiving anticoagulation therapy for &gt; 6 months, judged as capable of self-management, and with satisfactory INR control (n = 56).</P>
<P>The study was based in six general practices that used the Birmingham model of anticoagulation management (West Midlands, UK).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:48:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 30): self-testing using Coaguchek<SUP>® </SUP>device and self-adjustment of dosing. Testing was performed every 2 weeks or after 1 week following dosage adjustment.</P>
<P>b) conventional management (n = 26) in practice clinics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-13 08:07:11 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified.</P>
<P>Data were reported for: percentage time in INR range; adverse events; frequency of testing; costs; quality of life.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:22:14 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:22:20 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-13 08:10:33 -0500" MODIFIED_BY="[Empty name]">
<P>Participants in the intervention group attended two 1-2 hour duration educational workshops on anticoagulation self-management. Workshops were based within individual practices, were organised by research staff and attended by practice staff.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:49:37 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Fitzmaurice-2005">
<CHAR_METHODS MODIFIED="2016-06-24 07:49:00 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 07:49:05 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 617) were adults aged &gt; 18 years receiving long-term anticoagulation therapy at primary care centres within the Midlands Research Consortium (UK).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:49:24 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 337) comprising home self-testing using Coaguchek<SUP>® </SUP>managed anticoagulation for 12 months, testing INR very two weeks (one week after a dose change) and self-adjusting dosage according to a dosing schedule.</P>
<P>b) usual care, comprising anticoagulation management in hospital or practice based anticoagulant clinics (n = 280).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 04:55:26 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: % time within therapeutic INR range.</P>
<P>Secondary outcomes: adverse events, serious bleeding rates, serious thrombosis rates.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-17 04:55:46 -0500" MODIFIED_BY="[Empty name]">
<P>ISRCTN 19313375</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:23:09 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:22:47 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-06-24 07:49:37 -0500" MODIFIED_BY="Heather Maxwell">
<P>Intervention participants attended two training sessions. Trained anticoagulation nurses gave participants training at the practice. After the training, participants considered capable of doing self-management were given home testing equipment Coaguchek<SUP>® </SUP>managed anticoagulation for 12 months, testing INR very two weeks (one week after a dose change). Adjusted dosage by using a laminated dosing schedule.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:59:10 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<CHAR_METHODS MODIFIED="2016-06-24 07:50:06 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 07:50:33 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 320) were adults aged 18 to 75 (mean 57) years having received anticoagulation therapy for &gt; 3 months, requiring long-term anticoagulation therapy, and attending one of two anticoagulation clinics (The Netherlands).</P>
<P>Exclusion criteria included: antiphospholipid syndrome; life-threatening illness; &lt; 1 year life expectancy; diminished understanding or physical limitations preventing participation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:59:10 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring or self-management vs usual care</B>
</P>
<P>Participants were randomised to one of four groups, using a 2-step partial Zelen design.</P>
<P>Group A (n = 52): self-testing using Coagucheck<SUP>® </SUP>monitoring device.</P>
<P>Group B (n = 47): self-testing using Coagucheck<SUP>®</SUP> and self-dosing.</P>
<P>Group C (n = 60): received education alone and routine care.</P>
<P>Group D (n = 161): received only routine care. Group D did not provide informed consent for randomisation into the study and were unaware of study participation.</P>
<P>For the purposes of this review, the results of the trial are presented as Gadisseur 2003 self-management, which is group B versus group D, and separately as Gadisseur self-monitoring, which is group A versus group D.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 05:12:59 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Data were reported for: no. INR tests within target range; time spent within target range; thromboembolism or haemorrhage; ability to self-manage by adjusting anticoagulation dosage estimated by as the inverse of the no. of dosage corrections made by physicians.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:25:56 -0500" MODIFIED_BY="[Empty name]">
<P>6.5 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:25:51 -0500" MODIFIED_BY="[Empty name]">
<P>Phenprocoumon (70% participants) or acenocoumarol (30% participants)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-06-24 16:07:39 -0500" MODIFIED_BY="[Empty name]">
<P>Groups A, B and C received the same training (three sessions of 90-120 min).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 07:59:00 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<CHAR_METHODS MODIFIED="2016-06-24 07:55:00 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
<P>Participants (n = 320) were adults aged 18 to 75 (mean 57) years having received anticoagulation therapy for &gt; 3 months, requiring long-term anticoagulation therapy, and attending one of two anticoagulation clinics (The Netherlands).</P>
<P>Exclusion criteria included: antiphospholipid syndrome; life threatening illness; &lt; 1 year life expectancy; diminished understanding or physical limitations preventing participation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 07:54:21 -0500" MODIFIED_BY="Heather Maxwell">
<P>The study enrolled 320 participants. Mean age 57 years who were receiving long-term anticoagulation. The study was based in two Dutch anticoagulation clinics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 07:59:00 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring or self-management vs usual care</B>
</P>
<P>Participants were randomised to one of four groups, using a 2-step partial Zelen design.</P>
<P>Group A (n = 52): self-testing using Coagucheck<SUP>® </SUP>monitoring device.</P>
<P>Group B (n = 47): self-testing using Coagucheck<SUP>®</SUP> and self-dosing.</P>
<P>Group C (n = 60): received education alone and routine care.</P>
<P>Group D (n = 161): received only routine care. Group D did not provide informed consent for randomisation into the study and were unaware of study participation.</P>
<P>For the purposes of this review, the results of the trial are presented as Gadisseur 2003 self-management, which is group B versus group D, and separately as Gadisseur self-monitoring, which is group A versus group D.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 07:53:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary and secondary outcomes were not specified. Data were reported for: no. INR tests within target range; time spent within target range; thromboembolism or haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:26:39 -0500" MODIFIED_BY="[Empty name]">
<P>6.5 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:26:54 -0500" MODIFIED_BY="[Empty name]">
<P>Phenprocoumon (70% participants) or acenocoumarol (30% participants)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-02-08 15:28:26 -0600" MODIFIED_BY="[Empty name]">
<P>Groups A, B and C received the same training (three sessions of 90-120 min).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:01:15 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Gardiner-2005">
<CHAR_METHODS MODIFIED="2016-06-24 08:00:16 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:00:22 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 84) were adults aged &gt; 18 (mean 58) years who had received anticoagulation therapy for &gt; 8 months and had a record of good compliance.</P>
<P>The study was based in an anticoagulation clinic in University Hospital (London, UK).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:00:39 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-testing (n = 44) using the Coagucheck<SUP>® </SUP>monitoring device once per week</P>
<P>b) control (n = 40), receiving usual care by visiting the hospital anticoagulation clinic for testing every 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 08:01:15 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary and secondary outcomes were not specified. Data were reported for:</P>
<P>Major and minor bleeding, thromboembolism and mortality, percentage of time within target range, and acceptability.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:27:14 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:27:18 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-06-27 09:35:55 -0500" MODIFIED_BY="[Empty name]">
<P>The intervention group attended two training sessions.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:02:19 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Grunau-2011">
<CHAR_METHODS MODIFIED="2016-06-24 08:01:38 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, open-label randomised, cross,over trial, feasibility study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:01:47 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 11) were adults aged &gt; 18 (mean 73) years receiving warfarin therapy for &gt; 3 months from a private family practice in British Columbia (Canada), and competent to use drug-adjustment nomograms.</P>
<P>Exclusions included: severe psychiatric disease; serious language barrier, poor physical acuity; primary care physician judgement of unsuitability.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:02:19 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 6): written instructions on how to adjust dosage of anticoagulant, including a dose-adjustment nomogram. Participants were asked to contact the study centre by phone/in person if they were having difficulty with the self-management or if their INR value &gt; 5.</P>
<P>b) usual care (n = 5): physician anticoagulation management at the clinic.</P>
<P>Measurement of INR among all participants was done by community laboratories and the results communicated by mail or in person.</P>
<P>Participants were followed for 4.5 months, then allocation was reversed.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 07:29:28 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: proportion of INR values in therapeutic range.</P>
<P>Secondary outcomes: number of days in therapeutic range. Feasibility end points included proportion of eligible participants consenting, preferred management strategy of participants at the end of the study, a treatment-related satisfaction survey and additional office visits and phone calls pertaining to anticoagulation. Safety endpoints were bleeding or thromboembolic events.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-10 08:57:18 -0500" MODIFIED_BY="[Empty name]">
<P>Clinicaltrials.gov NCT00925028</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-17 07:31:17 -0500" MODIFIED_BY="[Empty name]">
<P>9 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:28:07 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-10 08:58:17 -0500" MODIFIED_BY="[Empty name]">
<P>Feasibility study: only 11 participants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:02:57 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Horstkotte-1998">
<CHAR_METHODS MODIFIED="2016-06-24 08:02:51 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:02:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 150) were adults who had received aortic or mitral valve Implantation, presenting consecutively at a single medical centre, Free University of Berlin (Germany).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-17 08:50:49 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>a) self-monitoring using Coagucheck device to measure INR twice weekly</P>
<P>b) usual care: INR testing and dosage adjustment by home physician</P>
<P>All participants had outpatient evaluation once every 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-22 06:49:09 -0600" MODIFIED_BY="[Empty name]">
<P>Major haemorrhage, thromboembolic events, mortality.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:29:04 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:29:08 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-21 03:50:52 -0600" MODIFIED_BY="[Empty name]">
<P>It is unclear whether participants were adjusting their own dose of anticoagulation therapy (self-management) in addition to self-monitoring.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:45:08 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Kaatz-Unpublished">
<CHAR_METHODS MODIFIED="2016-06-24 08:03:30 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:03:43 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 201) were individuals receiving long-term anticoagulation therapy. The study was based in three anticoagulation clinics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:45:08 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-testing (n = 101) using the Coagucheck<SUP>® </SUP>monitoring device.</P>
<P>b) usual care (n = 100) comprising point-of-care testing at the anticoagulation clinics.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 08:52:56 -0500" MODIFIED_BY="[Empty name]">
<P>Major and minor bleeding; thromboembolic events; percentage of time within the therapeutic range; participant convenience, satisfaction and worry.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:29:30 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:29:25 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-17 08:53:15 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were trained by the anticoagulation clinic research nurse to use Coagucheck<SUP>®</SUP>. </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:05:17 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Khan-2004">
<CHAR_METHODS MODIFIED="2016-06-24 08:04:24 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:04:30 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 125) were adults aged &gt; 65 (mean 73) years with atrial fibrillation receiving oral anticoagulation for &gt; 12 months previously for atrial fibrillation.</P>
<P>Exclusion criteria included: inability to use the Coagucheck system due to general frailty, poor hearing or eyesight, impairment of hand function, dementia, residence in care home.</P>
<P>The study was based in a university based anticoagulation service (Newcastle, UK).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:04:55 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) Group A (n = 44) used home weekly self-testing using the Coagucheck<SUP>® </SUP>monitoring device. Weekly dosage adjustment was advised by telephone by the study co-ordinator.</P>
<P>b) Group B (n = 41) received education alone and clinical care.</P>
<P>c) Group C (n = 40) received usual care.</P>
<P>All study participants attended the anticoagulation clinic for INR measurement at intervals determined by the stability of their INR and with dosage changes determined through a computerised dosage program.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-17 09:19:11 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Data were reported for:</P>
<P>Percentage of time within target range; major and minor bleeding; thromboembolism; death; number of dosage changes; quality of life.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:30:11 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:30:14 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-06-24 08:05:17 -0500" MODIFIED_BY="Heather Maxwell">
<P>Groups A and B received one training session (2 hours) attended in groups of 2-3 people. Sessions were based on educational materials and led by a doctor, 4.8% of participants were lost to follow-up. Control group C participants were unaware of their participation in the study. Adverse events were not monitored in the control group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:06:10 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-K_x00f6_rtke-2001">
<CHAR_METHODS MODIFIED="2016-06-24 08:05:38 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:05:49 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participant (n = 600) were adults (mean age 63 years) receiving life long-term oral anticoagulation after mechanical heart valve replacement.</P>
<P>The study was based in Ruhr University (Germany).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:06:10 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 305): self-testing using Coagucheck<SUP>® </SUP>system, and self-adjustment of dosage. In addition, monthly INR measurements were reviewed by the anticoagulation clinic.</P>
<P>b) control (n = 295): outpatient cardiologic check up and coagulation controls every 6 months. It is unclear if these participants adjusted their anticoagulation dosage themselves.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-19 08:42:07 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Data were reported for:</P>
<P>Percentage of INR within therapeutic range; haemorrhagic events; thromboembolic events.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-19 08:38:46 -0500" MODIFIED_BY="[Empty name]">
<P>ESCAT </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:31:06 -0500" MODIFIED_BY="[Empty name]">
<P>&#8804; 51 months.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:30:53 -0500" MODIFIED_BY="[Empty name]">
<P>Phenprocoumon</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-21 03:51:11 -0600" MODIFIED_BY="[Empty name]">
<P>No details about training. It is unclear if participants in the control group adjusted their own anticoagulation dosages or whether this was done by clinic or study staff.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:23:09 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Matchar-2010">
<CHAR_METHODS MODIFIED="2016-06-24 08:23:09 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multi-centre, randomised, parallel-group, controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:07:05 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 2,992) were adults with atrial fibrillation, a mechanical heart valve, or both, requiring long-term warfarin therapy and competent in self-testing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:07:44 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Randomisation was within strata of anticoagulation duration (&lt; 3 or &#8805; 3 months) and indication for warfarin (atrial fibrillation with or without mechanical heart valve) within each site.</P>
<P>Participants were randomised to</P>
<P>a) self-testing (n = 1465): participants measured their INR once a week and recorded the results via an interactive voice-response reporting system with web-based local monitoring. If the participant reported a measurement outside the assigned INR range or reported having been hospitalised, the system directed the participant to contact study staff.</P>
<P>b) usual care (n = 1457): approximately once monthly clinic testing of INR</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 08:07:55 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary outcome: time to a first major event (stroke, major bleeding episode, or death).</P>
<P>Secondary outcomes: time within the INR target range, participant satisfaction with anticoagulation, quality of life, utilisation and costs of services.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-10 06:32:57 -0500" MODIFIED_BY="[Empty name]">
<P>Clinicaltrials.gov NCT00032591</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2016-06-24 08:08:01 -0500" MODIFIED_BY="Heather Maxwell">
<P>2.0 to 4.75 years, giving 8730 participant-years of follow-up.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:33:08 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-05-15 06:47:45 -0500" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:08:51 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<CHAR_METHODS MODIFIED="2016-06-24 08:08:35 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-19 08:51:07 -0500" MODIFIED_BY="[Empty name]">
<P>Participants (n=737) were ambulatory adults aged &gt; 18 (mean 66) years, receiving long-term anticoagulation therapy for &gt; before the study for at least 3 months.</P>
<P>The study was based in a University Hospital (Barcelona, Spain).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:08:51 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 368): home self-testing using the Coagucheck<SUP>®</SUP> ,self-adjustment of dosage of oral anticoagulant, and self-determination of time to next INR test.</P>
<P>b) usual care (n = 369): visited the hospital for every four weeks to have their INR checked.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-19 09:00:20 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: percentage of INR values within target range; time within target range.</P>
<P>Secondary outcomes: major thromboembolic or haemorrhagic complications; minor bleeding; death.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-19 09:00:59 -0500" MODIFIED_BY="[Empty name]">
<P>ACOA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:34:10 -0500" MODIFIED_BY="[Empty name]">
<P>Up to 17 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:34:21 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin or acenocoumarol</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-06-27 11:03:46 -0500" MODIFIED_BY="[Empty name]">
<P>Training: two 2-hour sessions in consecutive days run by a trained nurse.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:23:23 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rasmussen-2012">
<CHAR_METHODS MODIFIED="2016-06-24 08:23:23 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single-centre, parallel-group, randomised controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:09:35 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants were individuals requiring oral anticoagulation therapy (n = 54).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:09:57 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to self-testing with computer aided decision making, two different algorithms (computer algorithm group A n = 19, computer algorithm group B n = 18), or to usual care (monitoring and treatment by physicians) (n = 17).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-10 09:20:41 -0500" MODIFIED_BY="[Empty name]">
<P>Time to therapeutic range, time in therapeutic range, INR.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:35:17 -0500" MODIFIED_BY="[Empty name]">
<P>Mean 28 week follow-up</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:35:20 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-06-26 06:48:25 -0500" MODIFIED_BY="[Empty name]">
<P>Authors reported that there were insufficient data to provide valid measurements of thromboembolic events and severe bleeding. in this study it is difficult to estimate the individual effects of self-testing and of computer dosage calculation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:11:20 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Ryan-2009">
<CHAR_METHODS MODIFIED="2016-06-24 08:10:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:10:31 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants were individuals receiving ongoing warfarin therapy for &gt; 2 months and who had internet access, and were able to use a home INR meter (n = 162).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:11:20 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to supervised self-testing or to usual care (conventional clinic management) for 6 months; subsequently the allocation was reversed for a further 6 months.</P>
<P>In the self-testing group, participants initially self-tested INR twice weekly. Once the INR was therapeutic for 2-3 consecutive readings, the interval between tests was increased to a maximum of every 2 weeks. Participants accessed a web-based system to enter signs and symptoms and INR and receive instant automated guidance on dose and testing; if INR deviation was serious the participant was asked to take a bolus dose of warfarin (&lt; 1.5) or hold their warfarin (&gt; 5.0) and/or to log in later the same day for additional instructions. If a participant reported a symptom suggestive of a bleed or an embolus they were told to seek immediate medical advice.<BR/>The research pharmacist accessed the caregiver interface of the program at least once daily to review participant problems. Any participant who failed to test their INR or log in to the program as scheduled was contacted by telephone the same day. All new dosage recommendations were reviewed and adjusted if necessary. All extreme INRs (&lt;1.5 or &gt;5.0) were discussed by the<BR/>research pharmacist with a consultant haematologist.</P>
<P>Participants attended the anticoagulation clinic every 2 months to give a venous blood sample for laboratory analysis of INR, which was compared with the self-tested value.</P>
<P>The comparison group received conventional clinic management.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-13 08:15:00 -0500" MODIFIED_BY="[Empty name]">
<P>Time to therapeutic range, proportion of participants within therapeutic range, testing frequency, number of extreme INRs recorded, participant satisfaction, thrombotic events, bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:39:06 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:39:19 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:12:16 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sawicki-1999">
<CHAR_METHODS MODIFIED="2014-03-19 09:04:01 -0500" MODIFIED_BY="[Empty name]">
<P>Multicentre, partially blinded, randomised study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:11:49 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 179) were individuals (mean age 55 years), receiving long term oral anticoagulation. The study was based in 5 referral centres (Germany).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:12:16 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to</P>
<P>a) self-management (n = 90): home self-testing and self-dosing using a Coagucheck<SUP>® </SUP>monitor, measuring INR 1-2 times per week and adjusting their anticoagulant according to their INR values. Participants recorded INR values routinely, recorded the results and anticoagulation dosages in their logbook.</P>
<P>b) usual care (n = 89): conventional management via twice monthly clinic visits for INR testing with dosage adjustment advised by the general practitioner.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-19 09:12:46 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Data were reported for: squared INR deviation from the mean of the individual INR target range; percentage participants with INR within target range at 3 months and at 6 months; major bleeding; minor bleeding; thromboembolic events; treatment satisfaction. </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:40:08 -0500" MODIFIED_BY="[Empty name]">
<P>6 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:40:15 -0500" MODIFIED_BY="[Empty name]">
<P>Phenprocoumon</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-19 09:13:31 -0500" MODIFIED_BY="[Empty name]">
<P>Participants randomised to the self-management group received a structured educational program comprising three consecutive weekly teaching sessions of 60-90 minutes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:13:29 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sidhu-2001">
<CHAR_METHODS MODIFIED="2016-06-24 08:12:54 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:13:02 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 100) adults aged &lt; 85 years (mean age 61 years) who had undergone a heart valve operation and had been prescribed life-long anticoagulation.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:13:29 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to</P>
<P>a) self-management (n = 51): home self-testing using the Coagucheck<SUP>® </SUP>and self-dosing. INR testing performed once a week, participants were encouraged to perform more frequent INR measurements if they were necessary. They adjusted their anticoagulant dosage according to a protocol. Participants recorded the results of their INR measurements in a standard book.</P>
<P>b) usual care (n = 49) : conventional management by hospital anticoagulant clinic or family physician care.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-20 09:23:07 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Data were reported for:</P>
<P>Time within therapeutic range; minor bleeding events; major bleeding events; minor thromboembolic events; major thromboembolic events; death.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:40:48 -0500" MODIFIED_BY="[Empty name]">
<P>24 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:40:52 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-20 09:24:17 -0500" MODIFIED_BY="[Empty name]">
<P>For participants in the self-management group, training comprised two 3-hour sessions (in groups of 2-5 participants).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:14:48 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Siebenhofer-2007">
<CHAR_METHODS MODIFIED="2016-06-24 08:14:06 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:14:26 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 195) were adults aged &gt; 60 (mean 69) years, with an indication for long-term oral anticoagulation.</P>
<P>Exclusion criteria included: previous participation in an anticoagulation self-management program; severe cognitive or terminal illness.</P>
<P>The study was based in 3 departments specialising in the treatment of participants receiving long-term oral anticoagulation therapy (Austria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:14:48 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to</P>
<P>a) self-management (n = 99): home self-testing using the Coagucheck<SUP>®</SUP> and self-dosing. INR testing performed once a week, adjusting anticoagulant dosage accordingly. Participants were asked to contact the training centre in case of difficulties.</P>
<P>b) usual care (n = 96): anticoagulant dosage adjusted by usual attending physicians in general practice or at a hospital based specialised anticoagulation clinic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-20 08:23:01 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: composite of all thromboembolic events requiring hospitalisation and all major bleeding complications.</P>
<P>Secondary outcomes: frequency and duration of hospitalisation; mortality; recurrence of stroke; numbers of INR values above 4.5 or lower than 1.7; treatment-related quality of life; cost-effectiveness.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:41:21 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:41:52 -0500" MODIFIED_BY="[Empty name]">
<P>Phenprocoumon (90% participants), acenocoumarol (10% participants)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2015-01-21 03:54:01 -0600" MODIFIED_BY="[Empty name]">
<P>Participants assigned to the self-management group participated in four consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of three to six participants. Participants assigned to the control group participated in a single 90-miute session including basic theoretical information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:16:52 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Soliman-Hamad-2009">
<CHAR_METHODS MODIFIED="2016-06-24 08:15:45 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, parallel-group, randomised controlled study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-13 08:16:09 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were individuals who had undergone elective mechanical aortic valve replacement and who were computer competent (n=58)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:16:02 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to self-management using CoaguChek devices (n = 29) or usual care (conventional clinic care) (n = 29).</P>
<P>In the intervention group, participants received training and self-tested under the supervision of hospital ward staff until discharge, after which time participants self-tested and notified INR dose via the study website. For 4 weeks advice was given from the clinic; subsequently the participant's data were evaluated by the clinic every 3 months.</P>
<P>In the comparison group, participants received conventional care by the thrombosis clinic.</P>
<P>At one year all participants completed a quality of life questionnaire and were evaluated by a study physician.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 08:16:52 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary endpoints were the total number of INR values within the target range as well as the quality of life measurements (SF-36v2)W one-year postoperatively, mortality, postoperative complications up to one year.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:42:41 -0500" MODIFIED_BY="[Empty name]">
<P>12 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:42:46 -0500" MODIFIED_BY="[Empty name]">
<P>Not specified</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:18:05 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sunderji-2004">
<CHAR_METHODS MODIFIED="2016-06-24 08:17:06 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:17:11 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants (n = 139) were adults aged &gt; 18 (mean 60) years, receiving warfarin for at least one month before randomisation and requiring anticoagulation for at least the subsequent year, and competent to manage their own anticoagulation therapy.</P>
<P>Exclusion criteria included: known hypercoagulable disorder, mental incompetence, a language barrier or an inability to attend training sessions.</P>
<P>Based in a tertiary care setting or by referral as an outpatient at the University of British Colombia (Canada).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:17:36 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-management (n = 69): home self-testing using Protime micro coagulation system and self-dosing determining the appropriate dose of oral anticoagulant and the time of the next INR test using a nomogram, recording INR results and warfarin doses in a pocket calendar.</P>
<P>b) usual care (n = 70): conventional care by primary care physician.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-20 10:13:49 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: proportion of INRs within target range; error rate in warfarin dosage adjustments.</P>
<P>Secondary outcomes: concordance between self-monitored values and laboratory INR measures; patient satisfaction; major thromboembolic events; major bleeding events.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:43:45 -0500" MODIFIED_BY="[Empty name]">
<P>Up to 8 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:43:48 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2016-06-24 08:18:05 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants in the self-management group were trained by a pharmacist in a 2-3 session, then required at a second pharmacist appointment to demonstrate competency in self-testing and self-dosing. In a first 2-yo 3-hour visit participants received education from a pharmacist.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:18:27 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Thompson-2013">
<CHAR_METHODS MODIFIED="2016-06-24 08:18:27 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 15:55:48 -0500" MODIFIED_BY="[Empty name]">
<P>200 participants who had received mechanical heart valve prostheses at Mayo Clinic (Rochester, Minnesota, USA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 16:01:15 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were randomised to a) self-testing; once the participant was discharged, dosage decisions using the self-tested INR values were made by the primary care physician. or b) usual care. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 16:07:37 -0500" MODIFIED_BY="[Empty name]">
<P>Primary and secondary outcomes were not specified. Reported outcomes included mean percentage of INR tests within therapeutic range; adverse events within 90 days of hospital discharge; time required to obtain INR result.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2015-01-21 05:54:50 -0600" MODIFIED_BY="[Empty name]">
<P>ClinicalTrials.gov identifier NCT00703963</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-11 15:56:54 -0500" MODIFIED_BY="[Empty name]">
<P>3 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-11 15:57:03 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:19:54 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Verret-2012">
<CHAR_METHODS MODIFIED="2014-03-10 09:33:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, controlled, open-label trial </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:19:03 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants were adults aged 18&#8211;75 years receiving long term warfarin at a specialised anticoagulation clinic (n = 114).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:19:45 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Randomised to pharmacist-led warfarin patient self-management program (n = 58) or conventional anticoagulation clinic care.</P>
<P>All participants attended an educational session on anticoagulation provided by a pharmacist.</P>
<P>Participants randomised to the self-management group also received training to use the CoaguChek XS device and a self-management dosing algorithm.</P>
<P>Participants monitored their INR weekly and adjusted their dose of warfarin according to a written algorithm. Participants recorded their INR results and dose adjustments on a voicemail, reviewed by pharmacists. The participant was contacted by a pharmacist if a contact was missed. If an INR fell outside the algorithm limits (1.5 or 4.5 for a target INR of 2.0&#8211;3.0, or 2.2 or 5.0 for a target INR of 2.5&#8211;3.5), the dose was adjusted by the pharmacist. Each week participants completed a pre-INR questionnaire to identify and inform the pharmacist of new factors that could affect their INR e.g. the addition of prescription or non-prescription drugs, changes in diet. Participants in the self-management group kept a record of their INR, daily doses of warfarin, and adverse events.</P>
<P>Participants in the control group (n = 56) received standard anticoagulation clinic care.</P>
<P>All participants attended clinic at 4 months to check INR and complete quality of life questionnaires.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-24 08:19:54 -0500" MODIFIED_BY="Heather Maxwell">
<P>Primary outcome: anticoagulation-related quality of life.</P>
<P>Secondary outcomes: time in therapeutic range, time in extended therapeutic range, anticoagulation knowledge.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2014-03-10 06:44:09 -0500" MODIFIED_BY="[Empty name]">
<P>Clinicaltrials.gov NCT01033279</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:44:22 -0500" MODIFIED_BY="[Empty name]">
<P>4 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:44:13 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:20:33 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Voller-2005">
<CHAR_METHODS MODIFIED="2016-06-24 08:20:18 -0500" MODIFIED_BY="Heather Maxwell">
<P>Multicentre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-13 08:16:42 -0500" MODIFIED_BY="[Empty name]">
<P>The study enrolled 202 participants, mean age 64 years, with permanent non-valvular atrial fibrillation in long term anticoagulation. The study was based in 33 centres (Germany).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:20:33 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-management vs usual care</B>
</P>
<P>Self-testing using the Coagucheck<SUP>®</SUP> monitor and self-adjusted dosing (regimen not reported).</P>
<P>Usual care by family doctors (regime not reported).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-06-28 07:40:30 -0500" MODIFIED_BY="[Empty name]">
<P>Percentage of INR within therapeutic range. Days within range. Complications.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-10 06:44:52 -0500" MODIFIED_BY="[Empty name]">
<P>Up to 19 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:44:56 -0500" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-06-28 07:41:02 -0500" MODIFIED_BY="[Empty name]">
<P>Stopped early trial due to low number of events.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-06-24 08:21:23 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-White-1989">
<CHAR_METHODS MODIFIED="2016-06-24 08:20:53 -0500" MODIFIED_BY="Heather Maxwell">
<P>Single centre, randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-24 08:21:07 -0500" MODIFIED_BY="Heather Maxwell">
<P>Participants were outpatients discharge from a university hospital or community hospital, who started on warfarin for the first time, who demonstrated ability to self-monitor, and who had not yet achieved stable INR whilst in hospital.</P>
<P>Home monitor mean age 50 ± 14 years. Anticoagulation clinic group 49 ± 16 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-24 08:21:23 -0500" MODIFIED_BY="Heather Maxwell">
<P>
<B>Self-monitoring vs usual care</B>
</P>
<P>Participants were randomised to:</P>
<P>a) self-monitoring (n = 26): using the home monitor Coumatrak to measure INR, dosage adjustments advised by hospital physician, with a telephone contact support for self-testing.</P>
<P>b) usual care (n = 24): conventional management by registered nurse specialists at an anticoagulation clinic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-20 10:24:55 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcome: percentage time within target INR range. </P>
<P>Secondary outcomes: percentage time above therapeutic range; percentage time below therapeutic range; major thromboembolic or haemorrhagic events; differences between self-monitoring measurements and laboratory measurements. </P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1/>
<CHAR_USER_DEF_2 MODIFIED="2014-03-20 10:25:37 -0500" MODIFIED_BY="[Empty name]">
<P>2 months</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2014-03-10 06:47:15 -0500" MODIFIED_BY="[Empty name]">
<P>Warfarin</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2014-03-20 10:26:02 -0500" MODIFIED_BY="[Empty name]">
<P>Participants were trained to use the INR monitor and were required to demonstrate competence to be eligible for randomisation.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>INR: international normalized ratio<BR/>ITT: intention-to-treat<BR/>no. = number<BR/>VKA = vitamin K antagonists</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-06-24 05:54:19 -0500" MODIFIED_BY="Heather Maxwell" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2016-06-24 05:51:52 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Bauman-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-24 05:51:52 -0500" MODIFIED_BY="Heather Maxwell">
<P>No relevant comparison group: the trial compared self-monitoring with self-management</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-17 07:50:03 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bussey-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-17 07:50:03 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-10 08:21:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bussey-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-10 08:21:02 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-10 08:21:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christensen-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-10 08:21:05 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 04:14:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christensen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 04:14:51 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-17 07:50:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarkesmith-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-17 07:50:05 -0500" MODIFIED_BY="[Empty name]">
<P>Intervention was educational and did not comprise self-monitoring or self-management.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-17 07:50:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallagher-2015">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-17 07:50:28 -0500" MODIFIED_BY="[Empty name]">
<P>Secondary report of a trial already included in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-24 05:53:59 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Hambleton-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-24 05:53:59 -0500" MODIFIED_BY="Heather Maxwell">
<P>Not a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 04:14:47 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hasenkam-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 04:14:47 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 04:14:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hasenkam-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 04:14:44 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-10 08:21:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heidinger-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-10 08:21:09 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-21 06:40:06 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horstkotte-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-21 06:40:06 -0600" MODIFIED_BY="[Empty name]">
<P>Non-comparative study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 04:16:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lafata-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 04:16:02 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-24 05:53:11 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Laurence-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-24 05:53:11 -0500" MODIFIED_BY="Heather Maxwell">
<P>No intervention of interest evaluated</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-21 06:40:18 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leger-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-21 06:40:18 -0600" MODIFIED_BY="[Empty name]">
<P>Non-comparative study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-21 06:40:21 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-21 06:40:21 -0600" MODIFIED_BY="[Empty name]">
<P>Non-comparative study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-21 04:17:52 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piso-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-21 04:17:52 -0600" MODIFIED_BY="[Empty name]">
<P>Non-randomised, comparative study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-24 05:54:19 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Rosengart-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-24 05:54:19 -0500" MODIFIED_BY="Heather Maxwell">
<P>Not a clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-03-10 08:21:12 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidtke-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-03-10 08:21:12 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-06-26 08:32:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staresinic-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-06-26 08:32:55 -0500" MODIFIED_BY="[Empty name]">
<P>Self-monitoring/self-management not included in the intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-06-24 05:53:40 -0500" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Sunderji-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-06-24 05:53:40 -0500" MODIFIED_BY="Heather Maxwell">
<P>No intervention of interest evaluated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-18 03:58:23 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watzke-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-18 03:58:23 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-14 11:06:29 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-06-24 08:21:50 -0500" MODIFIED_BY="Heather Maxwell">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-06-24 08:21:40 -0500" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 04:27:16 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azarnoush-2009">
<DESCRIPTION>
<P>Randomisation stated to have been done but no methods reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 04:27:28 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beyth-2000">
<DESCRIPTION>
<P>Randomisation stated to have been done but no method reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:40:51 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Christensen-2006">
<DESCRIPTION>
<P>Computerised randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:42:06 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Christensen-2011">
<DESCRIPTION>
<P>Computer-generated random allocation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-13 07:37:25 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cromheecke-2000">
<DESCRIPTION>
<P>Generation of the randomisation sequence was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-17 08:04:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dignan-2013">
<DESCRIPTION>
<P>Central phone-based randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:48:27 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2002">
<DESCRIPTION>
<P>Computer-generated coding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:59:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2005">
<DESCRIPTION>
<P>Variable block random allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 09:13:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<DESCRIPTION>
<P>Computer-generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-08 15:28:51 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<DESCRIPTION>
<P>Computer-generated list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:51:09 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardiner-2005">
<DESCRIPTION>
<P>Randomisation sequence generation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 07:31:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grunau-2011">
<DESCRIPTION>
<P>Computerised random sequence generation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 08:47:34 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horstkotte-1998">
<DESCRIPTION>
<P>Generation of the randomisation sequence not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 10:11:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaatz-Unpublished">
<DESCRIPTION>
<P>Random sequence was generated using variable block sizes and stratification.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 06:30:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Khan-2004">
<DESCRIPTION>
<P>Random numbers table, computer-generated program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 09:32:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_rtke-2001">
<DESCRIPTION>
<P>Randomisation sequence was generated using a standard randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:11:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matchar-2010">
<DESCRIPTION>
<P>Randomisation stated to have been done but sequence generation not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 08:49:38 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<DESCRIPTION>
<P>Centralised telephone randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:22:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rasmussen-2012">
<DESCRIPTION>
<P>Randomisation was performed by computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:30:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2009">
<DESCRIPTION>
<P>Computer-generated randomisation sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 11:27:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawicki-1999">
<DESCRIPTION>
<P>Computer program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:24:29 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sidhu-2001">
<DESCRIPTION>
<P>Simple random number generator program</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-28 15:56:08 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siebenhofer-2007">
<DESCRIPTION>
<P>Computer-based system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:32:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soliman-Hamad-2009">
<DESCRIPTION>
<P>Randomisation stated to have been done but sequence generation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 04:28:10 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sunderji-2004">
<DESCRIPTION>
<P>Computer-generated randomisation code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 16:02:13 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2013">
<DESCRIPTION>
<P>Generation of randomisation sequence not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:20:03 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Verret-2012">
<DESCRIPTION>
<P>Computer-generated using permuted random blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:20:41 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Voller-2005">
<DESCRIPTION>
<P>Computer-generated randomisation code</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:21:40 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-White-1989">
<DESCRIPTION>
<P>Computer-generated randomisation sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-06-21 05:39:43 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 03:53:47 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azarnoush-2009">
<DESCRIPTION>
<P>Possibly adequate or not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-21 15:23:31 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beyth-2000">
<DESCRIPTION>
<P>Clearly adequate concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-21 05:36:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christensen-2006">
<DESCRIPTION>
<P>Concealment of allocation was not reported, contact with author led to information on appropriate method of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 05:24:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Christensen-2011">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 10:08:35 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cromheecke-2000">
<DESCRIPTION>
<P>Sealed envelopes concealed the allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-17 08:04:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dignan-2013">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-21 05:39:43 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2002">
<DESCRIPTION>
<P>Concealment of allocation was not reported, contact with author led to information on appropriate method of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:59:20 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2005">
<DESCRIPTION>
<P>Central telephone randomisation </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-21 05:36:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<DESCRIPTION>
<P>Concealment of allocation was not reported, contact with author led to information on appropriate method of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-21 05:36:54 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<DESCRIPTION>
<P>Concealment of allocation was not reported, contact with author led to information on appropriate method of concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:51:15 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gardiner-2005">
<DESCRIPTION>
<P>Concealment of allocation was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 08:00:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grunau-2011">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-28 14:58:22 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horstkotte-1998">
<DESCRIPTION>
<P>Possibly adequate or not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 10:12:02 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaatz-Unpublished">
<DESCRIPTION>
<P>Sealed opaque envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 06:30:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2004">
<DESCRIPTION>
<P>Possibly adequate or not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 09:32:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-K_x00f6_rtke-2001">
<DESCRIPTION>
<P>Opaque randomisation envelopes were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 09:11:24 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matchar-2010">
<DESCRIPTION>
<P>Method not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-13 08:14:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<DESCRIPTION>
<P>The sequence of randomisation was concealed until the participant was assigned to a group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 06:44:12 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-2012">
<DESCRIPTION>
<P>Allocation concealment was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:30:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2009">
<DESCRIPTION>
<P>Allocation implemented via sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-27 11:28:21 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sawicki-1999">
<DESCRIPTION>
<P>Possibly adequate or not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:24:29 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sidhu-2001">
<DESCRIPTION>
<P>Possibly adequate or not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:38:06 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siebenhofer-2007">
<DESCRIPTION>
<P>Allocation was done by a central statistical office by fax and without awareness of participant data. The sequence of randomisation was concealed until the participant was assigned to a group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-09 03:34:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soliman-Hamad-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 04:28:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sunderji-2004">
<DESCRIPTION>
<P>Randomisation code concealed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 16:02:31 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thompson-2013">
<DESCRIPTION>
<P>Allocation concealment not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-10 09:13:30 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Verret-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:58:21 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Voller-2005">
<DESCRIPTION>
<P>Allocation concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-06-28 07:43:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1989">
<DESCRIPTION>
<P>Possibly adequate or not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" NO="10">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="GROUP" NO="11">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2016-06-20 08:22:42 -0500" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Intention to treat analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 04:06:43 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Azarnoush-2009">
<DESCRIPTION>
<P>ITT not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 06:01:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beyth-2000">
<DESCRIPTION>
<P>ITT analysis was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-12 10:07:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christensen-2006">
<DESCRIPTION>
<P>ITT analysis was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 08:52:21 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christensen-2011">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-13 07:46:53 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cromheecke-2000">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-17 08:05:05 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dignan-2013">
<DESCRIPTION>
<P>ITT analysis conducted</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-13 08:04:09 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fitzmaurice-2002">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:52:40 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2005">
<DESCRIPTION>
<P>ITT analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:14:46 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:23:54 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:52:45 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gardiner-2005">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-20 08:22:42 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grunau-2011">
<DESCRIPTION>
<P>Outcomes were analysed according to ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 08:47:57 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horstkotte-1998">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 08:53:26 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaatz-Unpublished">
<DESCRIPTION>
<P>ITT analysis was performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 09:19:57 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Khan-2004">
<DESCRIPTION>
<P>ITT analysis was not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 09:24:40 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-K_x00f6_rtke-2001">
<DESCRIPTION>
<P>ITT analysis was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:17:37 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matchar-2010">
<DESCRIPTION>
<P>Analysis was based on ITT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 08:49:33 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<DESCRIPTION>
<P>ITT analysis was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 06:46:49 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-2012">
<DESCRIPTION>
<P>ITT not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:30:18 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ryan-2009">
<DESCRIPTION>
<P>ITT was not performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:10:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawicki-1999">
<DESCRIPTION>
<P>ITT analysis was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:24:25 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sidhu-2001">
<DESCRIPTION>
<P>ITT analysis was not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:43:04 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Siebenhofer-2007">
<DESCRIPTION>
<P>ITT analysis was used for primary outcome; per protocol analyses used for other outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:32:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soliman-Hamad-2009">
<DESCRIPTION>
<P>ITT was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 10:14:13 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sunderji-2004">
<DESCRIPTION>
<P>ITT analysis was used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 16:08:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2013">
<DESCRIPTION>
<P>ITT analysis not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:33:46 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Verret-2012">
<DESCRIPTION>
<P>ITT not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:58:27 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Voller-2005">
<DESCRIPTION>
<P>ITT not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 10:26:28 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-White-1989">
<DESCRIPTION>
<P>ITT analysis was not used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2016-06-24 08:21:50 -0500" MODIFIED_BY="Heather Maxwell" NO="8">
<NAME>Reporting of losses of follow-up</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 04:06:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Azarnoush-2009">
<DESCRIPTION>
<P>7% of participants were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:39:35 -0500" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Beyth-2000">
<DESCRIPTION>
<P>&lt; 20% losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:41:00 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Christensen-2006">
<DESCRIPTION>
<P>4% of participants were lost to follow-up during the relevant period of this trial; reasons were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 08:53:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Christensen-2011">
<DESCRIPTION>
<P>17 participants (12.1%) withdrew; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 06:07:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cromheecke-2000">
<DESCRIPTION>
<P>0% lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-17 08:05:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dignan-2013">
<DESCRIPTION>
<P>Reasons for loss-to-follow-up reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:48:34 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2002">
<DESCRIPTION>
<P>7/56 (12.5%) of participants were lost to follow-up; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:49:55 -0500" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Fitzmaurice-2005">
<DESCRIPTION>
<P>Inadequate report or &gt; 20% losses (41.5% losses to follow-up)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:22:26 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<DESCRIPTION>
<P>Loss to follow-up was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 05:24:04 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<DESCRIPTION>
<P>Loss to follow-up was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:01:25 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Gardiner-2005">
<DESCRIPTION>
<P>15/84 (17.9%) of participants were lost to follow-up; reasons were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 05:56:15 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grunau-2011">
<DESCRIPTION>
<P>There were no losses to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:03:15 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Horstkotte-1998">
<DESCRIPTION>
<P>3/150 (2%) lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:04:09 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Kaatz-Unpublished">
<DESCRIPTION>
<P>No participants were lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:05:25 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Khan-2004">
<DESCRIPTION>
<P>6/85 (7.1%) lost to follow-up; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:06:29 -0500" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-K_x00f6_rtke-2001">
<DESCRIPTION>
<P>90/600 (15%) of participants were lost to follow-up; reasons were not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 06:21:57 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matchar-2010">
<DESCRIPTION>
<P>Loss to follow-up was 1%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:02:07 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<DESCRIPTION>
<P>11.9% of participants were lost to follow-up; reasons not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 06:44:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rasmussen-2012">
<DESCRIPTION>
<P>Losses to follow-up were not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:30:55 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ryan-2009">
<DESCRIPTION>
<P>30 participants (19%) withdrew; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:12:39 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Sawicki-1999">
<DESCRIPTION>
<P>14/179 (7.8%) of participants were lost to follow-up; reasons not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:13:51 -0500" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Sidhu-2001">
<DESCRIPTION>
<P>33.3% of participants were lost to follow-up in intervention group and 2% in the conventional management group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:44:32 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Siebenhofer-2007">
<DESCRIPTION>
<P>19/195 (9.7%) participants lost to follow-up; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:32:38 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soliman-Hamad-2009">
<DESCRIPTION>
<P>Losses to follow-up unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:18:18 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Sunderji-2004">
<DESCRIPTION>
<P>10% of participants were lost to follow-up; reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 16:04:22 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-2013">
<DESCRIPTION>
<P>21 participants withdrew (10.5%); reasons reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:33:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Verret-2012">
<DESCRIPTION>
<P>No participants were lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:20:47 -0500" MODIFIED_BY="Heather Maxwell" RESULT="UNKNOWN" STUDY_ID="STD-Voller-2005">
<DESCRIPTION>
<P>19.8% dropout.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:21:50 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-White-1989">
<DESCRIPTION>
<P>4.1% of participants in intervention group and 11.5% of participants in control group lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-06-24 08:20:09 -0500" MODIFIED_BY="Heather Maxwell" NO="9">
<NAME>Blinding</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 04:06:42 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Azarnoush-2009">
<DESCRIPTION>
<P>Blinding not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 04:19:19 -0600" MODIFIED_BY="Joey Kwong" RESULT="YES" STUDY_ID="STD-Beyth-2000">
<DESCRIPTION>
<P>Blinded data collectors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:41:07 -0500" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Christensen-2006">
<DESCRIPTION>
<P>The trial was open-label to participants and study staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:38:10 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Christensen-2011">
<DESCRIPTION>
<P>The trial was not blinded to participants and study staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-13 07:47:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cromheecke-2000">
<DESCRIPTION>
<P>Blinded outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-17 08:06:04 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dignan-2013">
<DESCRIPTION>
<P>Outcome assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:44:02 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fitzmaurice-2002">
<DESCRIPTION>
<P>Participants and study staff were not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 04:57:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fitzmaurice-2005">
<DESCRIPTION>
<P>Blinded outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 07:51:36 -0500" MODIFIED_BY="Heather Maxwell" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-mge">
<DESCRIPTION>
<P>Participants were not blinded to the intervention (except group D who were unaware of trial participation). Healthcare providers were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:44:47 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gadisseur-2003-Self-monit">
<DESCRIPTION>
<P>Participants were not blinded to the intervention (except group D who were unaware of trial participation). Health care providers were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:48:03 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gardiner-2005">
<DESCRIPTION>
<P>Participants and study staff were not blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:50:32 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grunau-2011">
<DESCRIPTION>
<P>Participants were not blinded; clinic staff were unaware of treatment allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 08:48:28 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horstkotte-1998">
<DESCRIPTION>
<P>Participants were not blinded to the intervention. Blinding of study staff and physicians was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 08:54:13 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaatz-Unpublished">
<DESCRIPTION>
<P>Participants were not blinded to the intervention. It is unclear whether study or medical staff were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-17 09:20:45 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Khan-2004">
<DESCRIPTION>
<P>Participants in groups A and B were not blinded to the allocation; participants in group C were unaware of study participation. It is not reported whether study staff were blinded to the interventions.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 08:40:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-K_x00f6_rtke-2001">
<DESCRIPTION>
<P>Blinding of participants, study staff or medical staff was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:17:27 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Matchar-2010">
<DESCRIPTION>
<P>Participants and study staff were not blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 04:19:21 -0600" MODIFIED_BY="Joey Kwong" RESULT="YES" STUDY_ID="STD-Menendez_x002d_Jandula-2005">
<DESCRIPTION>
<P>Blinded outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-26 06:43:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rasmussen-2012">
<DESCRIPTION>
<P>Study investigators were blinded to computer algorithm group A vs group B allocation; statisticians were blinded to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-04 03:21:52 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ryan-2009">
<DESCRIPTION>
<P>Participants and study staff were not blind to the intervention allocation. It is not reported whether data analysts were blind to allocation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:53:38 -0600" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sawicki-1999">
<DESCRIPTION>
<P>Participants were not blinded to the intervention; data collectors were blinded. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:53:51 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sidhu-2001">
<DESCRIPTION>
<P>Participants were not blinded to the intervention. It was not reported if study or medical staff were blinded to the intervention. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-05 04:19:22 -0600" MODIFIED_BY="Joey Kwong" RESULT="YES" STUDY_ID="STD-Siebenhofer-2007">
<DESCRIPTION>
<P>Blinded outcome assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:32:40 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Soliman-Hamad-2009">
<DESCRIPTION>
<P>Blinding was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:54:32 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sunderji-2004">
<DESCRIPTION>
<P>Participants were not blinded to intervention; it was not reported if study or medical staff were blinded to the intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 16:05:25 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-2013">
<DESCRIPTION>
<P>Participants and study staff were not blind to the intervention allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-24 08:20:09 -0500" MODIFIED_BY="Heather Maxwell" RESULT="NO" STUDY_ID="STD-Verret-2012">
<DESCRIPTION>
<P>The study was open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:58:46 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Voller-2005">
<DESCRIPTION>
<P>Blinding not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-21 05:59:01 -0600" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-White-1989">
<DESCRIPTION>
<P>Participants were not blinded to the intervention. It was not reported if study or medical staff were blinded to the intervention.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-06-24 08:41:04 -0500" MODIFIED_BY="Heather Maxwell">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-06-24 08:28:20 -0500" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2016-03-14 10:08:26 -0500" MODIFIED_BY="[Empty name]">Self-monitoring or self-management of oral anticoagulation vs. standard care</TITLE>
<TABLE COLS="6" ROWS="23">
<TR>
<TD COLSPAN="6">
<P>Self-monitoring or self-management of oral anticoagulation vs. standard care</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>Patients on long-term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment</P>
<P>
<B>Settings: </B>Primary care, specialist clinics (Europe, America, Canada)</P>
<P>
<B>Intervention: </B>Self-monitoring or self-management</P>
<P>
<B>Comparison: </B>Standard care</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Standard care</P>
</TH>
<TH VALIGN="TOP">
<P>Self-monitoring or self-management</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Thromboembolic events</B>
</P>
<P>Follow-up: 3 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.58 </B>
</P>
<P>(0.45 to 0.74)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>7594</P>
<P>(18 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>35 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>21 per 1000 </B>
</P>
<P>(16 to 26)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>22 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>12 per 1000 </B>
</P>
<P>(10 to 16)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
<P>Follow-up: 6 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.85</B>
<BR/>(0.71 to 1.01)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>6358<BR/>(11 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>64 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(45 to 64)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Major haemorrhage</B>
</P>
<P>Follow-up: 4 to 57 months</P>
</TD>
<TD COLSPAN="2">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
</P>
<P>(0.80 to 1.12)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>8018</P>
<P>(20 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>59 per 1000 </B>
</P>
<P>(50 to 69)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 per 1000 </B>
</P>
<P>(14 to 20)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Minor haemorrhage</B>
</P>
<P>Follow-up: 4 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.97</B>
<BR/>(0.67 to 1.41)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>5365<BR/>(13 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>217 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>210 per 1000</B>
<BR/>(145 to 306)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>45 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(30 to 63)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded from high to moderate because of serious risk of bias.</P>
<P>
<SUP>2</SUP> Downgraded from high to low because of serious risk of bias and substantial heterogeneity.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2016-06-24 08:34:36 -0500" MODIFIED_BY="Heather Maxwell" NO="2">
<TITLE MODIFIED="2016-03-14 10:41:30 -0500" MODIFIED_BY="[Empty name]">Self-monitoring of oral anticoagulation vs. standard care</TITLE>
<TABLE COLS="6" ROWS="23">
<TR>
<TD COLSPAN="6">
<P>Self-monitoring of oral anticoagulation vs. standard care</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>Patients on long-term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment</P>
<P>
<B>Settings: </B>Primary care, specialist clinics (Europe, America, Canada)</P>
<P>
<B>Intervention: </B>Self-monitoring</P>
<P>
<B>Comparison: </B>Standard care</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Standard care</P>
</TH>
<TH VALIGN="TOP">
<P>Self-monitoring</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Thromboembolic events</B>
</P>
<P>Follow-up: 3 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.69</B>
<BR/>(0.49 to 0.97)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>4097<BR/>(7 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>35 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>24 per 1000</B>
<BR/>(17 to 34)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>23 per 1000</B>
<BR/>(17 to 33)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
<P>Follow-up: 6 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.94</B>
<BR/>(0.78 to 1.15)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3300<BR/>(3 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>90 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>85 per 1000</B>
<BR/>(70 to 104)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Major haemorrhage</B>
</P>
<P>Follow-up: 4 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.90</B>
<BR/>(0.74 to 1.09)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>4038<BR/>(7 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>91 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>82 per 1000</B>
<BR/>(67 to 99)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>49 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>44 per 1000</B>
<BR/>(36 to 53)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Minor haemorrhage</B>
</P>
<P>Follow-up: 4 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.16</B>
<BR/>(0.95 to 1.42)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3503<BR/>(6 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>275 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>319 per 1000</B>
<BR/>(259 to 391)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>188 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>218 per 1000</B>
<BR/>(177 to 267)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded from high to low because of serious risk of bias and strong suspicion of publication bias.</P>
<P>
<SUP>2</SUP> Downgraded from high to moderate because of serious risk of bias.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2016-06-24 08:41:04 -0500" MODIFIED_BY="Heather Maxwell" NO="3">
<TITLE MODIFIED="2016-03-14 10:07:57 -0500" MODIFIED_BY="[Empty name]">self-management of oral anticoagulation vs. standard care</TITLE>
<TABLE COLS="6" ROWS="23">
<TR>
<TD COLSPAN="6">
<P>Self-management of oral anticoagulation vs. standard care</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population: </B>Patients on long-term anticoagulant therapy (treatment duration longer than two months) irrespective of the indication for treatment</P>
<P>
<B>Settings: </B>Primary care, specialist clinics (Europe, America, Canada)</P>
<P>
<B>Intervention: </B>Self-management</P>
<P>
<B>Comparison: </B>Standard care</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Standard care</P>
</TH>
<TH VALIGN="TOP">
<P>Self-management</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Thromboembolic events</B>
</P>
<P>Follow-up: 3 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.47</B>
<BR/>(0.31 to 0.70)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3497<BR/>(11 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>36 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(12 to 25)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>16 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>7 per 1000</B>
<BR/>(5 to 11)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>All-cause mortality</B>
</P>
<P>Follow-up: 6 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.55</B>
<BR/>(0.36 to 0.84)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3058<BR/>(8 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>Moderate<SUP>2</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(12 to 28)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>17 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>9 per 1000</B>
<BR/>(6 to 14)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Major haemorrhage</B>
</P>
<P>Follow-up:4 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.08</B>
<BR/>(0.79 to 1.47)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>3980<BR/>(13 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low<SUP>1</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>33 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>36 per 1000</B>
<BR/>(22 to 44)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>18 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>19 per 1000</B>
<BR/>(14 to 26)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Minor haemorrhage</B>
</P>
<P>Follow-up: 4 to 57 months</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>Study population</B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.91</B>
<BR/>(0.47 to 1.76)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>1862<BR/>(7 studies)</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>Low<SUP>3</SUP>
</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>137 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>125 per 1000</B>
<BR/>(64 to 241)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<B>Moderate risk population</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2 per 1000</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>2 per 1000</B>
<BR/>(1 to 4)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk Ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> We are very confident that the true effect lies close to that of the estimate of the effect.<BR/>
<B>Moderate quality:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/>
<B>Low quality:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<BR/>
<B>Very low quality:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Downgraded from high to low because of serious risk of bias and imprecision of effect estimate.</P>
<P>
<SUP>2</SUP> Downgraded from high to moderate because of serious risk of bias.</P>
<P>
<SUP>3</SUP> Downgraded from high to low because of serious risk of bias and substantial heterogeneity.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2016-06-30 12:58:07 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-06-30 12:58:07 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-03-24 09:46:13 -0500" MODIFIED_BY="[Empty name]">Tests in range</TITLE>
<TABLE COLS="7" ROWS="28">
<TR>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>
<B>Mean INR within target range, %</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD COLSPAN="2">
<P>
<B>TIme within range, %</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Source</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>P value</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>P value</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-White-1989" TYPE="STUDY">White 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>68</P>
</TD>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Horstkotte-1998" TYPE="STUDY">Horstkotte 1998</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>22.3</P>
</TD>
<TD ALIGN="CENTER">
<P>43.2</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sawicki-1999" TYPE="STUDY">Sawicki 1999</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>43.2</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>0.22</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Beyth-2000" TYPE="STUDY">Beyth 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>32</P>
</TD>
<TD ALIGN="CENTER">
<P>56</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Cromheecke-2000" TYPE="STUDY">Cromheecke 2000</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>49</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>0.06</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sidhu-2001" TYPE="STUDY">Sidhu 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>58</P>
</TD>
<TD ALIGN="CENTER">
<P>67.60</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.0001</P>
</TD>
<TD ALIGN="CENTER">
<P>63.8</P>
</TD>
<TD ALIGN="CENTER">
<P>76.5</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fitzmaurice-2002" TYPE="STUDY">Fitzmaurice 2002</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>66 (61-71)*</P>
</TD>
<TD ALIGN="CENTER">
<P>72 (65-80)*</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
<TD ALIGN="CENTER">
<P>77 (67-86)*</P>
</TD>
<TD ALIGN="CENTER">
<P>74 (67-81)*</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gadisseur-2003-Self-mge" TYPE="STUDY">Gadisseur 2003 Self mge</LINK>; <LINK REF="STD-Gadisseur-2003-Self-monit" TYPE="STUDY">Gadisseur 2003 Self monit</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>61.3</P>
</TD>
<TD ALIGN="CENTER">
<P>65</P>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gardiner-2005" TYPE="STUDY">Gardiner 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>64 (26)</P>
</TD>
<TD ALIGN="CENTER">
<P>61 (20)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kaatz-Unpublished" TYPE="STUDY">Kaatz Unpublished</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>54.2</P>
</TD>
<TD ALIGN="CENTER">
<P>64.6</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.05</P>
</TD>
<TD ALIGN="CENTER">
<P>66.9</P>
</TD>
<TD ALIGN="CENTER">
<P>63.5</P>
</TD>
<TD ALIGN="CENTER">
<P>0.127</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sunderji-2004" TYPE="STUDY">Sunderji 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>58.7 (5.8)**</P>
</TD>
<TD ALIGN="CENTER">
<P>64.8 (5.9)**</P>
</TD>
<TD ALIGN="CENTER">
<P>0.23</P>
</TD>
<TD ALIGN="CENTER">
<P>63.2 (5.8)**</P>
</TD>
<TD ALIGN="CENTER">
<P>71.8 (5.5)**</P>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Khan-2004" TYPE="STUDY">Khan 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>70.4 (24.5)**</P>
</TD>
<TD ALIGN="CENTER">
<P>71.1 (14.5)**</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-K_x00f6_rtke-2001" TYPE="STUDY">Körtke 2001</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>60.5</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>78.3</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Voller-2005" TYPE="STUDY">Voller 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>58.5 (19.8)**</P>
</TD>
<TD ALIGN="CENTER">
<P>67.8 (17.6)**</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0061</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Menendez_x002d_Jandula-2005" TYPE="STUDY">Menendez-Jandula 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>55.6 (19.6)**</P>
</TD>
<TD ALIGN="CENTER">
<P>58.6% (14.3)**</P>
</TD>
<TD ALIGN="CENTER">
<P>0.02</P>
</TD>
<TD ALIGN="CENTER">
<P>64.9 (19.9)</P>
</TD>
<TD ALIGN="CENTER">
<P>64.3 (14.3)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fitzmaurice-2005" TYPE="STUDY">Fitzmaurice 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>- </P>
</TD>
<TD ALIGN="CENTER">
<P>68 (65.2-70.6)</P>
</TD>
<TD ALIGN="CENTER">
<P>70 (68.1-72.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Christensen-2006" TYPE="STUDY">Christensen 2006</LINK>, Denmark</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<I>-</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
<TD ALIGN="CENTER">
<P>68.9 (59.3-78.2)</P>
</TD>
<TD ALIGN="CENTER">
<P>78.7 (69.2-81.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Siebenhofer-2007" TYPE="STUDY">Siebenhofer 2007</LINK>, Austria<SUP>&#8224;</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>57.1 (40.4-72.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>72.4 (53.5-79.4)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
<TD ALIGN="CENTER">
<P>66.5 (47.1-81.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>75.4 (59.4-85.0)</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.029</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Azarnoush-2009" TYPE="STUDY">Azarnoush 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>61.5</P>
</TD>
<TD ALIGN="CENTER">
<P>55.5</P>
</TD>
<TD ALIGN="CENTER">
<P>0.0343</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Christensen-2011" TYPE="STUDY">Christensen 2011</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>79.9</P>
</TD>
<TD ALIGN="CENTER">
<P>72.7</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.0001</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Grunau-2011" TYPE="STUDY">Grunau 2011</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>82.4</P>
</TD>
<TD ALIGN="CENTER">
<P>80.2</P>
</TD>
<TD ALIGN="CENTER">
<P>0.82</P>
</TD>
<TD ALIGN="CENTER">
<P>82.2</P>
</TD>
<TD ALIGN="CENTER">
<P>89.7</P>
</TD>
<TD ALIGN="CENTER">
<P>0.76</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Matchar-2010" TYPE="STUDY">Matchar 2010</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>66.2</P>
</TD>
<TD ALIGN="CENTER">
<P>62.4</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.001</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rasmussen-2012" TYPE="STUDY">Rasmussen 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>Intervention A 49</P>
<P>Intervention B 55</P>
</TD>
<TD ALIGN="CENTER">
<P>55</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Soliman-Hamad-2009" TYPE="STUDY">Soliman Hamad 2009</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>72.9</P>
</TD>
<TD ALIGN="CENTER">
<P>53.9</P>
</TD>
<TD ALIGN="CENTER">
<P>0.01</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Thompson-2013" TYPE="STUDY">Thompson 2013</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>52</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Verret-2012" TYPE="STUDY">Verret 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>80</P>
</TD>
<TD ALIGN="CENTER">
<P>75.5</P>
</TD>
<TD ALIGN="CENTER">
<P>0.79</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>* 95% Confidence intervals</P>
<P>** Standard Deviations</P>
<P>
<SUP>&#8224; </SUP>Used median not mean</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-06-27 05:16:13 -0500" MODIFIED_BY="Heather Maxwell">
<COMPARISON ID="CMP-001" MODIFIED="2016-06-27 03:55:12 -0500" MODIFIED_BY="Heather Maxwell" NO="1">
<NAME>Thromboembolic events</NAME>
<DICH_OUTCOME CHI2="13.559163425675521" CI_END="0.7543404407151669" CI_START="0.45004808003800945" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5826572466200749" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="146" I2="0.0" I2_Q="53.16947394989911" ID="CMP-001.01" LOG_CI_END="-0.12243260883099263" LOG_CI_START="-0.346741086714052" LOG_EFFECT_SIZE="-0.2345868477725223" METHOD="MH" MODIFIED="2016-06-27 03:27:42 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.6315182721087613" P_Q="0.14393679511090285" P_Z="4.1395642537314966E-5" Q="2.1353593144142047" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="18" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3821" TOTAL_2="3773" WEIGHT="100.0" Z="4.099548775152635">
<NAME>Self-monitoring and self-management</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.493229043736482" CI_END="0.6970391198069054" CI_START="0.3121929417547394" DF="9" EFFECT_SIZE="0.4664876132660459" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="69" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.15674284738332006" LOG_CI_START="-0.5055769199527175" LOG_EFFECT_SIZE="-0.3311598836680188" MODIFIED="2016-06-27 03:23:06 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.585907896953706" P_Z="1.981848294736007E-4" STUDIES="11" TAU2="0.0" TOTAL_1="1771" TOTAL_2="1726" WEIGHT="48.13494485700309" Z="3.721319080633478">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="7.9876790726887394" CI_START="0.013910312382356373" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9024206075556674" LOG_CI_START="-1.8566631169949925" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-08-17 15:08:58 -0500" MODIFIED_BY="[Empty name]" ORDER="561" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-Cromheecke-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="0.9978949739722576"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-08-17 15:11:11 -0500" MODIFIED_BY="[Empty name]" ORDER="562" O_E="0.0" SE="0.0" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.908274322255364" CI_START="0.2500373611640465" EFFECT_SIZE="1.1078140454995054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6909288273460112" LOG_CI_START="-0.6019950931876502" LOG_EFFECT_SIZE="0.044466867079180517" MODIFIED="2008-08-17 15:11:11 -0500" MODIFIED_BY="[Empty name]" ORDER="570" O_E="0.0" SE="0.7594699109980985" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.5767945457114596" WEIGHT="2.18016600472383"/>
<DICH_DATA CI_END="0.8963567632673417" CI_START="0.2760240655881018" EFFECT_SIZE="0.49740932642487046" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.047519100293243216" LOG_CI_START="-0.5590530516431674" LOG_EFFECT_SIZE="-0.30328607596820534" ORDER="163" O_E="0.0" SE="0.3004775751568424" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.09028677317213588" WEIGHT="21.34372072468454"/>
<DICH_DATA CI_END="0.5810242715991956" CI_START="0.06921860004621459" EFFECT_SIZE="0.20054347826086957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" LOG_CI_END="-0.23580572509430747" LOG_CI_START="-1.1597771886066446" LOG_EFFECT_SIZE="-0.697791456850476" MODIFIED="2008-09-11 09:29:18 -0500" MODIFIED_BY="[Empty name]" ORDER="564" O_E="0.0" SE="0.5427454113996554" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.29457258159538113" WEIGHT="13.28721304104173"/>
<DICH_DATA CI_END="4.054222754199657" CI_START="0.009632743524367332" EFFECT_SIZE="0.1976190476190476" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6079076067797893" LOG_CI_START="-2.0162500028234422" LOG_EFFECT_SIZE="-0.7041711980218266" MODIFIED="2008-08-17 15:11:14 -0500" MODIFIED_BY="[Empty name]" ORDER="565" O_E="0.0" SE="1.5414431696706024" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="2.3760470453241536" WEIGHT="1.6731173216301323"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2008-08-17 15:11:15 -0500" MODIFIED_BY="[Empty name]" ORDER="566" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.2771930483256271"/>
<DICH_DATA CI_END="2.3839061836393696" CI_START="0.2897939653195134" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.37728916015819763" LOG_CI_START="-0.537910662535387" LOG_EFFECT_SIZE="-0.08031075118859467" MODIFIED="2008-08-17 15:11:16 -0500" MODIFIED_BY="[Empty name]" ORDER="571" O_E="0.0" SE="0.5375929061623979" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.28900613275613274" WEIGHT="4.72848695359162"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-06-17 01:58:58 -0500" MODIFIED_BY="[Empty name]" ORDER="167" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="0.9978949739722576"/>
<DICH_DATA CI_END="4.150007777784805" CI_START="0.009915889948073521" EFFECT_SIZE="0.20285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6180489106508534" LOG_CI_START="-2.003668301913254" LOG_EFFECT_SIZE="-0.6928096956312003" MODIFIED="2008-08-17 15:11:16 -0500" MODIFIED_BY="[Empty name]" ORDER="567" O_E="0.0" SE="1.5400096683696607" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.371629778672032" WEIGHT="1.6513628410888421"/>
<DICH_DATA CI_END="8.08658766065675" CI_START="0.013740172712365944" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9077652987719276" LOG_CI_START="-1.8620078082112528" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-08-17 15:11:17 -0500" MODIFIED_BY="[Empty name]" ORDER="568" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="0.9978949739722576"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.153338637811432" CI_END="0.9697205133890929" CI_START="0.4916381540908497" DF="6" EFFECT_SIZE="0.6904720147744184" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="77" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-0.013353417262426342" LOG_CI_START="-0.3083544206022412" LOG_EFFECT_SIZE="-0.1608539189323338" MODIFIED="2016-06-27 03:27:42 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.6559343050639999" P_Z="0.03256529753934276" STUDIES="7" TAU2="0.0" TOTAL_1="2050" TOTAL_2="2047" WEIGHT="51.86505514299691" Z="2.137402139723161">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.8354105969837315" CI_START="0.005768634986643713" EFFECT_SIZE="0.1028971028971029" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2637332348316947" LOG_CI_START="-2.238926940379988" LOG_EFFECT_SIZE="-0.9875968527741464" MODIFIED="2014-06-17 02:01:05 -0500" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.4700749752870066" STUDY_ID="STD-Azarnoush-2009" TOTAL_1="90" TOTAL_2="102" VAR="2.161120432965093" WEIGHT="3.432621542770549"/>
<DICH_DATA CI_END="1.256992568979038" CI_START="0.34925255498283114" EFFECT_SIZE="0.6625766871165644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09933271025482168" LOG_CI_START="-0.45686040808883793" LOG_EFFECT_SIZE="-0.17876384891700814" MODIFIED="2008-08-17 15:11:20 -0500" MODIFIED_BY="[Empty name]" ORDER="573" O_E="0.0" SE="0.32671059091540455" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.10673981021629282" WEIGHT="14.013515880644254"/>
<DICH_DATA CI_END="3.132442840257882" CI_START="0.03547107378405146" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4958831548818049" LOG_CI_START="-1.45012566432113" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2008-08-17 15:11:22 -0500" MODIFIED_BY="[Empty name]" ORDER="579" O_E="0.0" SE="1.1430952132988164" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="1.3066666666666664" WEIGHT="1.9957899479445151"/>
<DICH_DATA CI_END="1.9939234941193562" CI_START="0.07866268107462225" EFFECT_SIZE="0.39603960396039606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2997084906259765" LOG_CI_START="-1.1042312555353369" LOG_EFFECT_SIZE="-0.4022613824546802" MODIFIED="2008-08-17 15:09:57 -0500" MODIFIED_BY="[Empty name]" ORDER="577" O_E="0.0" SE="0.8246811565089808" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.68009900990099" WEIGHT="3.342865418613533"/>
<DICH_DATA CI_END="1.2892039976286056" CI_START="0.5254278125063275" EFFECT_SIZE="0.8230331927379424" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" LOG_CI_END="0.11032164352456027" LOG_CI_START="-0.27948694240199295" LOG_EFFECT_SIZE="-0.08458264943871631" MODIFIED="2015-11-16 06:08:08 -0600" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.22897549295687764" STUDY_ID="STD-Matchar-2010" TOTAL_1="1463" TOTAL_2="1452" VAR="0.052429776374845125" WEIGHT="27.378723487148278"/>
<DICH_DATA CI_END="21.789947375201727" CI_START="0.18357088849843856" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3382561813849845" LOG_CI_START="-0.7361961900570221" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-06-17 02:01:20 -0500" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="1.2185435916898848" STUDY_ID="STD-Ryan-2009" TOTAL_1="132" TOTAL_2="132" VAR="1.4848484848484849" WEIGHT="0.665263315981505"/>
<DICH_DATA CI_END="7.2316313777687125" CI_START="0.013172666573584721" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8592362804815378" LOG_CI_START="-1.8803263008947622" LOG_EFFECT_SIZE="-0.5105450102066121" MODIFIED="2008-08-17 15:10:01 -0500" MODIFIED_BY="[Empty name]" ORDER="576" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-White-1989" TOTAL_1="26" TOTAL_2="24" VAR="2.5896296296296293" WEIGHT="1.0362755498942675"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.225555738565674" CI_END="0.710376840536192" CI_START="0.3767982895711964" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5173671602112253" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="102" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.14851120571944423" LOG_CI_START="-0.4238910773002778" LOG_EFFECT_SIZE="-0.286201141509861" METHOD="MH" MODIFIED="2016-06-27 03:42:02 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.7953535583154926" P_Q="0.9548876010106883" P_Z="4.6219502102260776E-5" Q="0.09232328493012072" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2421" TOTAL_2="2388" WEIGHT="100.0" Z="4.0739646399967375">
<NAME>Events by Clinical Condition</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.476105701119291" CI_END="0.8965236354484062" CI_START="0.31897853342981036" DF="5" EFFECT_SIZE="0.5347633069129692" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="38" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.04743825645370919" LOG_CI_START="-0.49623854304524634" LOG_EFFECT_SIZE="-0.27183839974947777" MODIFIED="2014-09-10 04:01:33 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6270063027444" P_Z="0.017582213347787635" STUDIES="6" TAU2="0.0" TOTAL_1="893" TOTAL_2="923" WEIGHT="37.28033131749669" Z="2.374300948737519">
<NAME>Mechanical Valve</NAME>
<DICH_DATA CI_END="4.653750598808311" CI_START="0.011011552430563974" EFFECT_SIZE="0.22637362637362637" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6678031051080772" LOG_CI_START="-1.9581514490119574" LOG_EFFECT_SIZE="-0.6451741719519402" MODIFIED="2014-09-09 03:39:39 -0500" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="1.5424987037747913" STUDY_ID="STD-Azarnoush-2009" TOTAL_1="90" TOTAL_2="102" VAR="2.3793022511469113" WEIGHT="2.1954565244491517"/>
<DICH_DATA CI_END="3.132442840257882" CI_START="0.03547107378405146" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4958831548818049" LOG_CI_START="-1.45012566432113" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="581" O_E="0.0" SE="1.1430952132988164" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="1.3066666666666664" WEIGHT="2.8082542796250687"/>
<DICH_DATA CI_END="0.8963567632673417" CI_START="0.2760240655881018" EFFECT_SIZE="0.49740932642487046" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.047519100293243216" LOG_CI_START="-0.5590530516431674" LOG_EFFECT_SIZE="-0.30328607596820534" MODIFIED="2008-08-13 15:53:37 -0500" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.3004775751568424" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.09028677317213588" WEIGHT="30.032516763574755"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" ORDER="580" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.39003531661459284"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-09-09 03:40:23 -0500" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="1.4041271398125343"/>
<DICH_DATA CI_END="78.51557475326187" CI_START="0.1338147223216376" EFFECT_SIZE="3.2413793103448274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8949558141781244" LOG_CI_START="-0.8734961027766389" LOG_EFFECT_SIZE="0.5107298557007426" MODIFIED="2014-09-10 04:01:33 -0500" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="1.626202360077233" STUDY_ID="STD-Thompson-2013" TOTAL_1="86" TOTAL_2="93" VAR="2.644534115920763" WEIGHT="0.4499412934205911"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.08658766065675" CI_START="0.013740172712365944" DF="0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.9077652987719276" LOG_CI_START="-1.8620078082112528" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2016-06-27 03:37:29 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="1.0" P_Z="0.4995188618006836" STUDIES="1" TAU2="0.0" TOTAL_1="101" TOTAL_2="101" WEIGHT="1.4041271398125343" Z="0.6752469891135949">
<NAME>Atrial Fibrillation</NAME>
<DICH_DATA CI_END="8.08658766065675" CI_START="0.013740172712365944" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9077652987719276" LOG_CI_START="-1.8620078082112528" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="583" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="1.4041271398125343"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.715794769287978" CI_END="0.766056199783415" CI_START="0.340870088483611" DF="9" EFFECT_SIZE="0.5110045446017006" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="63" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-0.11573936827795615" LOG_CI_START="-0.46741110665158314" LOG_EFFECT_SIZE="-0.29157523746476965" MODIFIED="2016-06-27 03:42:02 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.563021538722974" P_Z="0.0011538103330248127" STUDIES="10" TAU2="0.0" TOTAL_1="1427" TOTAL_2="1364" WEIGHT="61.315541542690774" Z="3.250059085541344">
<NAME>Any indication</NAME>
<DICH_DATA CI_END="1.256992568979038" CI_START="0.34925255498283114" EFFECT_SIZE="0.6625766871165644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09933271025482168" LOG_CI_START="-0.45686040808883793" LOG_EFFECT_SIZE="-0.17876384891700814" ORDER="585" O_E="0.0" SE="0.32671059091540455" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.10673981021629282" WEIGHT="19.718265434167403"/>
<DICH_DATA CI_END="7.9876790726887394" CI_START="0.013910312382356373" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9024206075556674" LOG_CI_START="-1.8566631169949925" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="586" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-Cromheecke-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="1.4041271398125343"/>
<DICH_DATA CI_END="4.908274322255364" CI_START="0.2500373611640465" EFFECT_SIZE="1.1078140454995054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6909288273460112" LOG_CI_START="-0.6019950931876502" LOG_EFFECT_SIZE="0.044466867079180517" ORDER="596" O_E="0.0" SE="0.7594699109980985" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.5767945457114596" WEIGHT="3.0676878192338672"/>
<DICH_DATA CI_END="1.9939234941193562" CI_START="0.07866268107462225" EFFECT_SIZE="0.39603960396039606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2997084906259765" LOG_CI_START="-1.1042312555353369" LOG_EFFECT_SIZE="-0.4022613824546802" ORDER="597" O_E="0.0" SE="0.8246811565089808" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.68009900990099" WEIGHT="4.7037094899192695"/>
<DICH_DATA CI_END="0.5810242715991956" CI_START="0.06921860004621459" EFFECT_SIZE="0.20054347826086957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" LOG_CI_END="-0.23580572509430747" LOG_CI_START="-1.1597771886066446" LOG_EFFECT_SIZE="-0.697791456850476" ORDER="590" O_E="0.0" SE="0.5427454113996554" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.29457258159538113" WEIGHT="18.696292625997742"/>
<DICH_DATA CI_END="21.789947375201727" CI_START="0.18357088849843856" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3382561813849845" LOG_CI_START="-0.7361961900570221" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-09-09 03:43:46 -0500" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="1.2185435916898848" STUDY_ID="STD-Ryan-2009" TOTAL_1="132" TOTAL_2="132" VAR="1.4848484848484849" WEIGHT="0.9360847598750228"/>
<DICH_DATA CI_END="4.054222754199657" CI_START="0.009632743524367332" EFFECT_SIZE="0.1976190476190476" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6079076067797893" LOG_CI_START="-2.0162500028234422" LOG_EFFECT_SIZE="-0.7041711980218266" ORDER="591" O_E="0.0" SE="1.5414431696706024" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="2.3760470453241536" WEIGHT="2.3542251445958655"/>
<DICH_DATA CI_END="2.3839061836393696" CI_START="0.2897939653195134" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.37728916015819763" LOG_CI_START="-0.537910662535387" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="594" O_E="0.0" SE="0.5375929061623979" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.28900613275613274" WEIGHT="6.6534024471117"/>
<DICH_DATA CI_END="4.150007777784805" CI_START="0.009915889948073521" EFFECT_SIZE="0.20285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6180489106508534" LOG_CI_START="-2.003668301913254" LOG_EFFECT_SIZE="-0.6928096956312003" ORDER="592" O_E="0.0" SE="1.5400096683696607" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.371629778672032" WEIGHT="2.323614652172042"/>
<DICH_DATA CI_END="7.2316313777687125" CI_START="0.013172666573584721" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8592362804815378" LOG_CI_START="-1.8803263008947622" LOG_EFFECT_SIZE="-0.5105450102066121" ORDER="593" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-White-1989" TOTAL_1="26" TOTAL_2="24" VAR="2.5896296296296293" WEIGHT="1.458132029805324"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.947065915213266" CI_END="0.6858214385457149" CI_START="0.36140686119279963" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4978559766072286" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1637889431105778" LOG_CI_START="-0.44200360675603073" LOG_EFFECT_SIZE="-0.3028962749333043" METHOD="MH" MODIFIED="2016-06-27 03:48:17 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.7892532530002929" P_Q="0.32048141838948574" P_Z="1.9751503352800228E-5" Q="0.9869817274126185" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2309" TOTAL_2="2249" WEIGHT="100.00000000000001" Z="4.267681524343848">
<NAME>Events by Self-management (sensitivity)</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.678609403970114" CI_END="0.6627551550362198" CI_START="0.3009046151836064" DF="8" EFFECT_SIZE="0.44657147791493035" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="75" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.17864688555627622" LOG_CI_START="-0.521571151131963" LOG_EFFECT_SIZE="-0.3501090183441196" MODIFIED="2016-06-27 03:46:49 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.6831814054307757" P_Z="6.279441641684764E-5" STUDIES="9" TAU2="0.0" TOTAL_1="1838" TOTAL_2="1780" WEIGHT="71.99342195306397" Z="4.002056054360472">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="7.9876790726887394" CI_START="0.013910312382356373" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9024206075556674" LOG_CI_START="-1.8566631169949925" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="598" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-Cromheecke-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="1.396164098000884"/>
<DICH_DATA CI_END="1.6695606159313081" CI_START="0.11584056876469248" EFFECT_SIZE="0.43977591036414565" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.22260219139673232" LOG_CI_START="-0.9361393188026513" LOG_EFFECT_SIZE="-0.35676856370295945" MODIFIED="2016-06-18 16:18:19 -0500" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.6806504989541002" STUDY_ID="STD-Dignan-2013" TOTAL_1="153" TOTAL_2="157" VAR="0.46328510172646553" WEIGHT="6.43136236111375"/>
<DICH_DATA CI_END="4.908274322255364" CI_START="0.2500373611640465" EFFECT_SIZE="1.1078140454995054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6909288273460112" LOG_CI_START="-0.6019950931876502" LOG_EFFECT_SIZE="0.044466867079180517" ORDER="607" O_E="0.0" SE="0.7594699109980985" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.5767945457114596" WEIGHT="3.0502904442547676"/>
<DICH_DATA CI_END="0.8963567632673417" CI_START="0.2760240655881018" EFFECT_SIZE="0.49740932642487046" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.047519100293243216" LOG_CI_START="-0.5590530516431674" LOG_EFFECT_SIZE="-0.30328607596820534" ORDER="160" O_E="0.0" SE="0.3004775751568424" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.09028677317213588" WEIGHT="29.862197296115873"/>
<DICH_DATA CI_END="0.5810242715991956" CI_START="0.06921860004621459" EFFECT_SIZE="0.20054347826086957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" LOG_CI_END="-0.23580572509430747" LOG_CI_START="-1.1597771886066446" LOG_EFFECT_SIZE="-0.697791456850476" ORDER="601" O_E="0.0" SE="0.5427454113996554" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.29457258159538113" WEIGHT="18.590262797442797"/>
<DICH_DATA CI_END="4.054222754199657" CI_START="0.009632743524367332" EFFECT_SIZE="0.1976190476190476" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6079076067797893" LOG_CI_START="-2.0162500028234422" LOG_EFFECT_SIZE="-0.7041711980218266" ORDER="602" O_E="0.0" SE="1.5414431696706024" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="2.3760470453241536" WEIGHT="2.340873936767949"/>
<DICH_DATA CI_END="2.3839061836393696" CI_START="0.2897939653195134" EFFECT_SIZE="0.8311688311688312" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.37728916015819763" LOG_CI_START="-0.537910662535387" LOG_EFFECT_SIZE="-0.08031075118859467" ORDER="606" O_E="0.0" SE="0.5375929061623979" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.28900613275613274" WEIGHT="6.615669879758035"/>
<DICH_DATA CI_END="4.150007777784805" CI_START="0.009915889948073521" EFFECT_SIZE="0.20285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6180489106508534" LOG_CI_START="-2.003668301913254" LOG_EFFECT_SIZE="-0.6928096956312003" ORDER="604" O_E="0.0" SE="1.5400096683696607" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.371629778672032" WEIGHT="2.3104370416090276"/>
<DICH_DATA CI_END="8.08658766065675" CI_START="0.013740172712365944" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9077652987719276" LOG_CI_START="-1.8620078082112528" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="605" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="1.396164098000884"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5495767510816585" CI_END="1.092598279084548" CI_START="0.36290209044126676" DF="3" EFFECT_SIZE="0.6296873823512054" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="30" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.03846051213621222" LOG_CI_START="-0.4402105301061614" LOG_EFFECT_SIZE="-0.2008750089849746" MODIFIED="2016-06-27 03:48:17 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.6708762416335834" P_Z="0.09996907802625148" STUDIES="4" TAU2="0.0" TOTAL_1="471" TOTAL_2="469" WEIGHT="28.006578046936042" Z="1.6450035546765214">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.256992568979038" CI_START="0.34925255498283114" EFFECT_SIZE="0.6625766871165644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09933271025482168" LOG_CI_START="-0.45686040808883793" LOG_EFFECT_SIZE="-0.17876384891700814" ORDER="610" O_E="0.0" SE="0.32671059091540455" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.10673981021629282" WEIGHT="19.60643982546472"/>
<DICH_DATA CI_END="3.132442840257882" CI_START="0.03547107378405146" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4958831548818049" LOG_CI_START="-1.45012566432113" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2009-02-11 03:42:12 -0600" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="1.1430952132988164" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="1.3066666666666664" WEIGHT="2.792328196001768"/>
<DICH_DATA CI_END="1.9939234941193562" CI_START="0.07866268107462225" EFFECT_SIZE="0.39603960396039606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2997084906259765" LOG_CI_START="-1.1042312555353369" LOG_EFFECT_SIZE="-0.4022613824546802" MODIFIED="2009-02-11 03:42:20 -0600" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.8246811565089808" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.68009900990099" WEIGHT="4.677033960135631"/>
<DICH_DATA CI_END="21.789947375201727" CI_START="0.18357088849843856" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3382561813849845" LOG_CI_START="-0.7361961900570221" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-09-09 03:45:36 -0500" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="1.2185435916898848" STUDY_ID="STD-Ryan-2009" TOTAL_1="132" TOTAL_2="132" VAR="1.4848484848484849" WEIGHT="0.9307760653339227"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.752469146991425" CI_END="0.7802049649216221" CI_START="0.4574860318355234" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5974385938490805" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="134" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.10779129033388804" LOG_CI_START="-0.339622161464993" LOG_EFFECT_SIZE="-0.22370672589944054" METHOD="MH" MODIFIED="2016-06-27 03:55:12 -0500" MODIFIED_BY="Heather Maxwell" NO="4" P_CHI2="0.621410565152021" P_Q="0.6889573367268197" P_Z="1.552234674909749E-4" Q="0.16021665281090122" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3697" TOTAL_2="3647" WEIGHT="100.0" Z="3.7825603097899854">
<NAME>Events by specialty</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="8.120308809436892" CI_END="0.8995209573741197" CI_START="0.4374746715686905" DF="7" EFFECT_SIZE="0.6273098400283524" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="73" I2="13.79638183384039" ID="CMP-001.04.01" LOG_CI_END="-0.045988713846047954" LOG_CI_START="-0.3590470862219646" LOG_EFFECT_SIZE="-0.20251790003400624" MODIFIED="2016-06-27 03:53:08 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.32210505358543606" P_Z="0.01121885772831327" STUDIES="8" TAU2="0.0" TOTAL_1="2507" TOTAL_2="2440" WEIGHT="54.11681888173033" Z="2.5358068993900558">
<NAME>Specialised Care</NAME>
<DICH_DATA CI_END="7.9876790726887394" CI_START="0.013910312382356373" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9024206075556674" LOG_CI_START="-1.8566631169949925" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-09-12 05:54:36 -0500" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.6206994374857624" STUDY_ID="STD-Cromheecke-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.6266666666666665" WEIGHT="1.083133126641825"/>
<DICH_DATA CI_END="4.908274322255364" CI_START="0.2500373611640465" EFFECT_SIZE="1.1078140454995054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6909288273460112" LOG_CI_START="-0.6019950931876502" LOG_EFFECT_SIZE="0.044466867079180517" MODIFIED="2014-09-12 05:55:08 -0500" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.7594699109980985" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.5767945457114596" WEIGHT="2.3663913366502105"/>
<DICH_DATA CI_END="1.9939234941193562" CI_START="0.07866268107462225" EFFECT_SIZE="0.39603960396039606" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2997084906259765" LOG_CI_START="-1.1042312555353369" LOG_EFFECT_SIZE="-0.4022613824546802" MODIFIED="2014-09-12 05:56:43 -0500" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.8246811565089808" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.68009900990099" WEIGHT="3.6284061622163954"/>
<DICH_DATA CI_END="1.2918955660355307" CI_START="0.5265099308673427" EFFECT_SIZE="0.8247398651460918" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="41" LOG_CI_END="0.1112274076779156" LOG_CI_START="-0.27859343287315247" LOG_EFFECT_SIZE="-0.08368301259761847" MODIFIED="2015-11-16 06:21:14 -0600" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.228982691383979" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.05243307295345057" WEIGHT="29.68669461635465"/>
<DICH_DATA CI_END="0.5810242715991956" CI_START="0.06921860004621459" EFFECT_SIZE="0.20054347826086957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="20" LOG_CI_END="-0.23580572509430747" LOG_CI_START="-1.1597771886066446" LOG_EFFECT_SIZE="-0.697791456850476" MODIFIED="2014-09-12 05:58:10 -0500" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.5427454113996554" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.29457258159538113" WEIGHT="14.42217966907975"/>
<DICH_DATA CI_END="21.789947375201727" CI_START="0.18357088849843856" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3382561813849845" LOG_CI_START="-0.7361961900570221" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-09-12 05:58:32 -0500" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.2185435916898848" STUDY_ID="STD-Ryan-2009" TOTAL_1="132" TOTAL_2="132" VAR="1.4848484848484849" WEIGHT="0.72208875109455"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-09-12 05:59:16 -0500" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="1.083133126641825"/>
<DICH_DATA CI_END="7.2316313777687125" CI_START="0.013172666573584721" EFFECT_SIZE="0.30864197530864196" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8592362804815378" LOG_CI_START="-1.8803263008947622" LOG_EFFECT_SIZE="-0.5105450102066121" MODIFIED="2014-09-12 05:59:50 -0500" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="1.6092326213539263" STUDY_ID="STD-White-1989" TOTAL_1="26" TOTAL_2="24" VAR="2.5896296296296293" WEIGHT="1.124792093051126"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.334849550806429" CI_END="0.8365632530956499" CI_START="0.3778276524256448" DF="7" EFFECT_SIZE="0.562207017052162" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="61" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-0.0775012161697902" LOG_CI_START="-0.422706260134698" LOG_EFFECT_SIZE="-0.25010373815224407" MODIFIED="2016-06-27 03:55:12 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.7405019720812386" P_Z="0.004511094741219382" STUDIES="8" TAU2="0.0" TOTAL_1="1190" TOTAL_2="1207" WEIGHT="45.883181118269675" Z="2.840018289113214">
<NAME>Primary Care</NAME>
<DICH_DATA CI_END="1.256992568979038" CI_START="0.34925255498283114" EFFECT_SIZE="0.6625766871165644" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="21" LOG_CI_END="0.09933271025482168" LOG_CI_START="-0.45686040808883793" LOG_EFFECT_SIZE="-0.17876384891700814" MODIFIED="2014-09-12 06:01:16 -0500" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.32671059091540455" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.10673981021629282" WEIGHT="15.210521815363965"/>
<DICH_DATA CI_END="3.132442840257882" CI_START="0.03547107378405146" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4958831548818049" LOG_CI_START="-1.45012566432113" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-09-12 06:02:31 -0500" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="1.1430952132988164" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="1.3066666666666664" WEIGHT="2.16626625328365"/>
<DICH_DATA CI_END="0.8963567632673417" CI_START="0.2760240655881018" EFFECT_SIZE="0.49740932642487046" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" LOG_CI_END="-0.047519100293243216" LOG_CI_START="-0.5590530516431674" LOG_EFFECT_SIZE="-0.30328607596820534" MODIFIED="2014-09-12 06:03:42 -0500" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.3004775751568424" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.09028677317213588" WEIGHT="23.16685780135034"/>
<DICH_DATA CI_END="4.054222754199657" CI_START="0.009632743524367332" EFFECT_SIZE="0.1976190476190476" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6079076067797893" LOG_CI_START="-2.0162500028234422" LOG_EFFECT_SIZE="-0.7041711980218266" MODIFIED="2014-09-12 06:04:08 -0500" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="1.5414431696706024" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="2.3760470453241536" WEIGHT="1.8160315895791075"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2014-09-12 06:04:40 -0500" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.3008703129560625"/>
<DICH_DATA CI_END="4.150007777784805" CI_START="0.009915889948073521" EFFECT_SIZE="0.20285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6180489106508534" LOG_CI_START="-2.003668301913254" LOG_EFFECT_SIZE="-0.6928096956312003" MODIFIED="2014-09-12 06:04:59 -0500" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="1.5400096683696607" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.371629778672032" WEIGHT="1.7924188856956913"/>
<DICH_DATA CI_END="78.51557475326187" CI_START="0.1338147223216376" EFFECT_SIZE="3.2413793103448274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8949558141781244" LOG_CI_START="-0.8734961027766389" LOG_EFFECT_SIZE="0.5107298557007426" MODIFIED="2014-09-12 06:05:27 -0500" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="1.626202360077233" STUDY_ID="STD-Thompson-2013" TOTAL_1="86" TOTAL_2="93" VAR="2.644534115920763" WEIGHT="0.3470813333990378"/>
<DICH_DATA CI_END="8.08658766065675" CI_START="0.013740172712365944" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9077652987719276" LOG_CI_START="-1.8620078082112528" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2014-09-12 06:05:45 -0500" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="1.083133126641825"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-06-27 05:16:13 -0500" MODIFIED_BY="Heather Maxwell" NO="2">
<NAME>All-cause mortality</NAME>
<DICH_OUTCOME CHI2="9.97013369794455" CI_END="1.0131756800446097" CI_START="0.7117438810774757" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8491887839157211" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="242" I2="0.0" I2_Q="80.47021652445456" ID="CMP-002.01" LOG_CI_END="0.005684756573318" LOG_CI_START="-0.14767625783146107" LOG_EFFECT_SIZE="-0.07099575062907154" METHOD="MH" MODIFIED="2016-06-27 04:03:05 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.4431175441969709" P_Q="0.023646414578585517" P_Z="0.06957604518431741" Q="5.12038446945491" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3209" TOTAL_2="3149" WEIGHT="100.0" Z="1.8146608488269211">
<NAME>Events by Self-management</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.6014896914332075" CI_END="0.8421772644114813" CI_START="0.3630347843354321" DF="7" EFFECT_SIZE="0.5529372853749567" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="59" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.0745964870595613" LOG_CI_START="-0.4400517608559347" LOG_EFFECT_SIZE="-0.257324123957748" MODIFIED="2016-06-27 03:59:49 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.7084643135698816" P_Z="0.005778418921995564" STUDIES="8" TAU2="0.0" TOTAL_1="1552" TOTAL_2="1506" WEIGHT="24.38597579037464" Z="2.7600970705461547">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2008-08-17 16:06:27 -0500" MODIFIED_BY="[Empty name]" ORDER="651" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5799844520630385"/>
<DICH_DATA CI_END="18.230061342469895" CI_START="0.15147052205636402" EFFECT_SIZE="1.6617210682492582" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2607881300181887" LOG_CI_START="-0.8196718777484651" LOG_EFFECT_SIZE="0.2205581261348618" MODIFIED="2008-08-17 16:06:27 -0500" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="1.222072507005262" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="1.4934612123781263" WEIGHT="0.44877511154364497"/>
<DICH_DATA CI_END="0.9216082853561328" CI_START="0.3009737677690342" EFFECT_SIZE="0.5266686985675099" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.03545362954990554" LOG_CI_START="-0.521471354936441" LOG_EFFECT_SIZE="-0.27846249224317327" MODIFIED="2009-03-20 05:12:59 -0500" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="0.28548921771859226" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.08150409343357379" WEIGHT="14.004239299878831"/>
<DICH_DATA CI_END="1.022345844713593" CI_START="0.15735452686946552" EFFECT_SIZE="0.40108695652173915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.0095978361537518" LOG_CI_START="-0.8031207585267416" LOG_EFFECT_SIZE="-0.39676146118649486" MODIFIED="2008-09-11 09:29:39 -0500" MODIFIED_BY="[Empty name]" ORDER="652" O_E="0.0" SE="0.47739492553724794" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.2279059149287145" WEIGHT="6.1539734262319685"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" MODIFIED="2008-08-17 16:06:29 -0500" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.4133121524550239"/>
<DICH_DATA CI_END="2.797178608905736" CI_START="0.008650692089220455" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.4467201983649544" LOG_CI_START="-2.0629491458871283" LOG_EFFECT_SIZE="-0.8081144737610868" MODIFIED="2008-08-17 16:06:30 -0500" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="1.474192195877284" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.173242630385488" WEIGHT="1.5405837007924459"/>
<DICH_DATA CI_END="10.343679046785793" CI_START="0.36362776098768446" EFFECT_SIZE="1.9393939393939394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0146750363916348" LOG_CI_START="-0.4393429681796353" LOG_EFFECT_SIZE="0.2876660341059997" MODIFIED="2008-08-17 16:06:30 -0500" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.8540973733903666" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.7294823232323233" WEIGHT="0.8342853271983707"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-17 02:18:36 -0500" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="0.4108223202113189"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7559793782942648" CI_END="1.148758094902902" CI_START="0.7769415741311556" DF="2" EFFECT_SIZE="0.9447316669561617" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="183" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.060228584728683726" LOG_CI_START="-0.10961163883933925" LOG_EFFECT_SIZE="-0.024691527055327758" MODIFIED="2016-06-27 04:03:05 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.685237723293505" P_Z="0.5687572527449367" STUDIES="3" TAU2="0.0" TOTAL_1="1657" TOTAL_2="1643" WEIGHT="75.61402420962536" Z="0.5698827137065818">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.3670029077153973" CI_START="0.47138664633121674" EFFECT_SIZE="0.802737140160453" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" LOG_CI_END="0.13576943834500513" LOG_CI_START="-0.3266227245414562" LOG_EFFECT_SIZE="-0.09542664309822556" MODIFIED="2008-08-17 16:06:33 -0500" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="0.2716114453576282" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.07377277724925986" WEIGHT="10.714246111111198"/>
<DICH_DATA CI_END="58.70843237432536" CI_START="0.10645830159711915" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7687004840521727" LOG_CI_START="-0.9728204667080972" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2008-08-17 16:05:44 -0500" MODIFIED_BY="[Empty name]" ORDER="662" O_E="0.0" SE="1.610382977224155" STUDY_ID="STD-Gardiner-2005" TOTAL_1="29" TOTAL_2="24" VAR="2.5933333333333333" WEIGHT="0.22408490193344666"/>
<DICH_DATA CI_END="1.1889450618251973" CI_START="0.7797761319645866" EFFECT_SIZE="0.962866024651638" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="157" LOG_CI_END="0.07516178742155577" LOG_CI_START="-0.10803006219075444" LOG_EFFECT_SIZE="-0.016434137384599333" MODIFIED="2014-06-17 02:21:22 -0500" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.10760779927655155" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.011579438465142608" WEIGHT="64.67569319658071"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.970133697944553" CI_END="1.01317568004461" CI_START="0.7117438810774757" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8491887839157212" ESTIMABLE="YES" EVENTS_1="206" EVENTS_2="242" I2="0.0" I2_Q="76.59892840198484" ID="CMP-002.02" LOG_CI_END="0.005684756573318094" LOG_CI_START="-0.14767625783146107" LOG_EFFECT_SIZE="-0.07099575062907149" METHOD="MH" MODIFIED="2016-06-27 05:16:13 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.4431175441969707" P_Q="0.038715646865411735" P_Z="0.06957604518431768" Q="4.273308578248264" RANDOM="NO" SCALE="452.17" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3354" TOTAL_2="3291" WEIGHT="100.00000000000001" Z="1.8146608488269194">
<NAME>Events by Clinical Condition</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.904192364031384" CI_END="0.8590075283692625" CI_START="0.2945638371098339" DF="2" EFFECT_SIZE="0.5030234126387007" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="39" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="-0.06600302998144539" LOG_CI_START="-0.5308205715044636" LOG_EFFECT_SIZE="-0.2984118007429545" MODIFIED="2016-06-27 04:06:11 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.6362929958316268" P_Z="0.011849837735984078" STUDIES="3" TAU2="0.0" TOTAL_1="642" TOTAL_2="653" WEIGHT="15.9556453208826" Z="2.5165848091770875">
<NAME>Mechanical Valve</NAME>
<DICH_DATA CI_END="0.9216082853561328" CI_START="0.3009737677690342" EFFECT_SIZE="0.5266686985675099" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.03545362954990554" LOG_CI_START="-0.521471354936441" LOG_EFFECT_SIZE="-0.27846249224317327" MODIFIED="2009-03-20 05:13:47 -0500" MODIFIED_BY="[Empty name]" ORDER="668" O_E="0.0" SE="0.28548921771859226" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.08150409343357379" WEIGHT="14.004239299878835"/>
<DICH_DATA CI_END="2.797178608905736" CI_START="0.008650692089220455" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.4467201983649544" LOG_CI_START="-2.0629491458871283" LOG_EFFECT_SIZE="-0.8081144737610868" ORDER="667" O_E="0.0" SE="1.474192195877284" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.173242630385488" WEIGHT="1.5405837007924463"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-09 03:52:41 -0500" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="0.41082232021131904"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2016-06-27 05:16:13 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Atrial Fibrillation</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-06-27 05:16:12 -0500" MODIFIED_BY="Heather Maxwell" ORDER="671" O_E="0.0" SE="0.0" STUDY_ID="STD-Khan-2004" TOTAL_1="44" TOTAL_2="41" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2016-06-27 05:16:13 -0500" MODIFIED_BY="Heather Maxwell" ORDER="670" O_E="0.0" SE="0.0" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.153447401856462" CI_END="1.1039822750350932" CI_START="0.758214925232213" DF="7" EFFECT_SIZE="0.9149075571463062" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="203" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="0.04296210064295636" LOG_CI_START="-0.12020767086949816" LOG_EFFECT_SIZE="-0.0386227851132709" MODIFIED="2016-06-27 04:09:42 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.641243551956352" P_Z="0.3534807426211951" STUDIES="8" TAU2="0.0" TOTAL_1="2567" TOTAL_2="2496" WEIGHT="84.04435467911742" Z="0.9278589668045556">
<NAME>Any indication</NAME>
<DICH_DATA CI_END="1.3670029077153973" CI_START="0.47138664633121674" EFFECT_SIZE="0.802737140160453" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" LOG_CI_END="0.13576943834500513" LOG_CI_START="-0.3266227245414562" LOG_EFFECT_SIZE="-0.09542664309822556" ORDER="672" O_E="0.0" SE="0.2716114453576282" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.07377277724925986" WEIGHT="10.7142461111112"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="673" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5799844520630387"/>
<DICH_DATA CI_END="18.230061342469895" CI_START="0.15147052205636402" EFFECT_SIZE="1.6617210682492582" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2607881300181887" LOG_CI_START="-0.8196718777484651" LOG_EFFECT_SIZE="0.2205581261348618" ORDER="680" O_E="0.0" SE="1.222072507005262" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="1.4934612123781263" WEIGHT="0.4487751115436451"/>
<DICH_DATA CI_END="58.70843237432536" CI_START="0.10645830159711915" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7687004840521727" LOG_CI_START="-0.9728204667080972" LOG_EFFECT_SIZE="0.3979400086720376" ORDER="674" O_E="0.0" SE="1.610382977224155" STUDY_ID="STD-Gardiner-2005" TOTAL_1="29" TOTAL_2="24" VAR="2.5933333333333333" WEIGHT="0.22408490193344674"/>
<DICH_DATA CI_END="1.1889450618251973" CI_START="0.7797761319645866" EFFECT_SIZE="0.962866024651638" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="157" LOG_CI_END="0.07516178742155577" LOG_CI_START="-0.10803006219075444" LOG_EFFECT_SIZE="-0.016434137384599333" MODIFIED="2014-09-09 03:54:35 -0500" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.10760779927655155" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.011579438465142608" WEIGHT="64.67569319658072"/>
<DICH_DATA CI_END="1.022345844713593" CI_START="0.15735452686946552" EFFECT_SIZE="0.40108695652173915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.0095978361537518" LOG_CI_START="-0.8031207585267416" LOG_EFFECT_SIZE="-0.39676146118649486" ORDER="675" O_E="0.0" SE="0.47739492553724794" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.2279059149287145" WEIGHT="6.15397342623197"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" ORDER="676" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.413312152455024"/>
<DICH_DATA CI_END="10.343679046785793" CI_START="0.36362776098768446" EFFECT_SIZE="1.9393939393939394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0146750363916348" LOG_CI_START="-0.4393429681796353" LOG_EFFECT_SIZE="0.2876660341059997" ORDER="681" O_E="0.0" SE="0.8540973733903666" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.7294823232323233" WEIGHT="0.8342853271983709"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.09041800558926" CI_END="1.0198358951839852" CI_START="0.7145163188981741" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.853633053312186" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="237" I2="13.477894527031182" I2_Q="75.92250864815456" ID="CMP-002.03" LOG_CI_END="0.008530293771858658" LOG_CI_START="-0.14598784787161911" LOG_EFFECT_SIZE="-0.0687287770498802" METHOD="MH" MODIFIED="2016-06-27 04:21:51 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.32468867602922014" P_Q="0.04155465270641767" P_Z="0.08123561250727301" Q="4.153256605461741" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3117" TOTAL_2="3043" WEIGHT="100.0" Z="1.7435613227870344">
<NAME>Events by Self-management (sensitivity)</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6617721707859796" CI_END="0.8816420764533212" CI_START="0.37115799056437937" DF="5" EFFECT_SIZE="0.5720388985841973" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="54" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-0.05470769125155229" LOG_CI_START="-0.43044118519707886" LOG_EFFECT_SIZE="-0.24257443822431557" MODIFIED="2016-06-27 04:21:51 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.5990631878945266" P_Z="0.011383035354476967" STUDIES="6" TAU2="0.0" TOTAL_1="1489" TOTAL_2="1429" WEIGHT="22.90752563949888" Z="2.5307148292647192">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="683" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5922114327453553"/>
<DICH_DATA CI_END="18.230061342469895" CI_START="0.15147052205636402" EFFECT_SIZE="1.6617210682492582" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2607881300181887" LOG_CI_START="-0.8196718777484651" LOG_EFFECT_SIZE="0.2205581261348618" ORDER="690" O_E="0.0" SE="1.222072507005262" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="1.4934612123781263" WEIGHT="0.4582359938139033"/>
<DICH_DATA CI_END="0.9216082853561328" CI_START="0.3009737677690342" EFFECT_SIZE="0.5266686985675099" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.03545362954990554" LOG_CI_START="-0.521471354936441" LOG_EFFECT_SIZE="-0.27846249224317327" MODIFIED="2009-03-20 05:14:14 -0500" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.28548921771859226" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.08150409343357379" WEIGHT="14.299470599237093"/>
<DICH_DATA CI_END="1.022345844713593" CI_START="0.15735452686946552" EFFECT_SIZE="0.40108695652173915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.0095978361537518" LOG_CI_START="-0.8031207585267416" LOG_EFFECT_SIZE="-0.39676146118649486" ORDER="684" O_E="0.0" SE="0.47739492553724794" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.2279059149287145" WEIGHT="6.283708825059264"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" ORDER="685" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.4220254200018668"/>
<DICH_DATA CI_END="10.343679046785793" CI_START="0.36362776098768446" EFFECT_SIZE="1.9393939393939394" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0146750363916348" LOG_CI_START="-0.4393429681796353" LOG_EFFECT_SIZE="0.2876660341059997" ORDER="691" O_E="0.0" SE="0.8540973733903666" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.7294823232323233" WEIGHT="0.8518733686413956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.37315631136339217" CI_END="1.1402458746626594" CI_START="0.7704866812496928" DF="1" EFFECT_SIZE="0.9373069186651113" ESTIMABLE="YES" EVENTS_1="173" EVENTS_2="183" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="0.056998509665895015" LOG_CI_START="-0.11323486416134097" LOG_EFFECT_SIZE="-0.028118177247722982" MODIFIED="2016-06-27 04:14:59 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.541289104576573" P_Z="0.517326946132812" STUDIES="2" TAU2="0.0" TOTAL_1="1628" TOTAL_2="1614" WEIGHT="77.09247436050111" Z="0.6474713327644024">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.3670029077153973" CI_START="0.47138664633121674" EFFECT_SIZE="0.802737140160453" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" LOG_CI_END="0.13576943834500513" LOG_CI_START="-0.3266227245414562" LOG_EFFECT_SIZE="-0.09542664309822556" ORDER="693" O_E="0.0" SE="0.2716114453576282" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.07377277724925986" WEIGHT="10.940119200915863"/>
<DICH_DATA CI_END="1.1848394445884696" CI_START="0.7771168943541638" EFFECT_SIZE="0.9595617486576379" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="157" LOG_CI_END="0.07365950388752963" LOG_CI_START="-0.10951364946855874" LOG_EFFECT_SIZE="-0.01792707279051454" MODIFIED="2015-11-16 06:19:43 -0600" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.10759681700309884" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1452" VAR="0.011577075029198339" WEIGHT="66.15235515958526"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.068065788402631" CI_END="1.0034070850557593" CI_START="0.7032323226784286" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8400168421024385" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="240" I2="0.7506097771112554" I2_Q="70.9358110144557" ID="CMP-002.04" LOG_CI_END="0.001477163255173848" LOG_CI_START="-0.15290117599134848" LOG_EFFECT_SIZE="-0.07571200636808732" METHOD="MH" MODIFIED="2016-06-27 04:23:34 -0500" MODIFIED_BY="Heather Maxwell" NO="4" P_CHI2="0.431015167029441" P_Q="0.06361037296302685" P_Z="0.05454836686440164" Q="3.4406602589095856" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3110" TOTAL_2="3053" WEIGHT="100.0" Z="1.9224563031702815">
<NAME>Events by specialty</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.818108379536161" CI_END="1.132114372433141" CI_START="0.7543958909116828" DF="4" EFFECT_SIZE="0.9241549819189528" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="174" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.05389030389065849" LOG_CI_START="-0.12240068580524807" LOG_EFFECT_SIZE="-0.034255190957294804" MODIFIED="2016-06-27 04:21:10 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.43118161521268616" P_Z="0.4462491245105097" STUDIES="5" TAU2="0.0" TOTAL_1="2228" TOTAL_2="2159" WEIGHT="72.5183589850383" Z="0.7616831770659567">
<NAME>Specialised Care</NAME>
<DICH_DATA CI_END="18.230061342469895" CI_START="0.15147052205636402" EFFECT_SIZE="1.6617210682492582" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2607881300181887" LOG_CI_START="-0.8196718777484651" LOG_EFFECT_SIZE="0.2205581261348618" MODIFIED="2014-09-12 06:31:38 -0500" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.222072507005262" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="1.4934612123781263" WEIGHT="0.4525506754268685"/>
<DICH_DATA CI_END="58.70843237432536" CI_START="0.10645830159711915" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7687004840521727" LOG_CI_START="-0.9728204667080972" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2014-09-12 06:33:28 -0500" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="1.610382977224155" STUDY_ID="STD-Gardiner-2005" TOTAL_1="29" TOTAL_2="24" VAR="2.5933333333333333" WEIGHT="0.22597013763559037"/>
<DICH_DATA CI_END="1.1889450618251973" CI_START="0.7797761319645866" EFFECT_SIZE="0.962866024651638" ESTIMABLE="YES" EVENTS_1="152" EVENTS_2="157" LOG_CI_END="0.07516178742155577" LOG_CI_START="-0.10803006219075444" LOG_EFFECT_SIZE="-0.016434137384599333" MODIFIED="2014-09-12 06:33:53 -0500" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.10760779927655155" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.011579438465142608" WEIGHT="65.21981252288543"/>
<DICH_DATA CI_END="1.022345844713593" CI_START="0.15735452686946552" EFFECT_SIZE="0.40108695652173915" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="0.0095978361537518" LOG_CI_START="-0.8031207585267416" LOG_EFFECT_SIZE="-0.39676146118649486" MODIFIED="2014-09-12 06:34:16 -0500" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.47739492553724794" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.2279059149287145" WEIGHT="6.205747063425169"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-12 06:34:57 -0500" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="0.41427858566524906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3244663929685467" CI_END="0.8979403148180933" CI_START="0.4253247433691726" DF="4" EFFECT_SIZE="0.6179937167648548" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="66" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-0.046752529487042886" LOG_CI_START="-0.37127935136517637" LOG_EFFECT_SIZE="-0.20901594042610963" MODIFIED="2016-06-27 04:23:34 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.6763182331416833" P_Z="0.011580261303153148" STUDIES="5" TAU2="0.0" TOTAL_1="882" TOTAL_2="894" WEIGHT="27.481641014961692" Z="2.5246832484236483">
<NAME>Primary Care</NAME>
<DICH_DATA CI_END="1.3670029077153973" CI_START="0.47138664633121674" EFFECT_SIZE="0.802737140160453" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="26" LOG_CI_END="0.13576943834500513" LOG_CI_START="-0.3266227245414562" LOG_EFFECT_SIZE="-0.09542664309822556" MODIFIED="2014-09-12 06:35:50 -0500" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.2716114453576282" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.07377277724925986" WEIGHT="10.804385514149695"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2014-09-12 06:36:07 -0500" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5848638856450575"/>
<DICH_DATA CI_END="0.9216082853561328" CI_START="0.3009737677690342" EFFECT_SIZE="0.5266686985675099" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="34" LOG_CI_END="-0.03545362954990554" LOG_CI_START="-0.521471354936441" LOG_EFFECT_SIZE="-0.27846249224317327" MODIFIED="2014-09-12 06:37:00 -0500" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.28548921771859226" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.08150409343357379" WEIGHT="14.122057553949945"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" MODIFIED="2014-09-12 06:37:38 -0500" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.41678936497231117"/>
<DICH_DATA CI_END="2.797178608905736" CI_START="0.008650692089220455" EFFECT_SIZE="0.15555555555555556" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.4467201983649544" LOG_CI_START="-2.0629491458871283" LOG_EFFECT_SIZE="-0.8081144737610868" MODIFIED="2014-09-12 06:38:00 -0500" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="1.474192195877284" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.173242630385488" WEIGHT="1.553544696244684"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2016-06-27 04:36:48 -0500" MODIFIED_BY="Heather Maxwell" NO="3">
<NAME>Major haemorrhage</NAME>
<DICH_OUTCOME CHI2="14.402631487197064" CI_END="1.1162670769364167" CI_START="0.8010056370994304" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9455877649031703" ESTIMABLE="YES" EVENTS_1="244" EVENTS_2="260" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.047768115894384844" LOG_CI_START="-0.09636442754552259" LOG_EFFECT_SIZE="-0.024298155825568886" METHOD="MH" MODIFIED="2016-06-27 04:27:23 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.7597344821676164" P_Q="0.31866256609271426" P_Z="0.5087217374068598" Q="0.9944288760117846" RANDOM="NO" SCALE="509.64" SORT_BY="STUDY" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3970" TOTAL_2="4048" WEIGHT="100.00000000000001" Z="0.6608293890090491">
<NAME>Events by Self-management</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.193684920739157" CI_END="1.4746840459290902" CI_START="0.790961428362748" DF="12" EFFECT_SIZE="1.080008425592981" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="70" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.1686989818002805" LOG_CI_START="-0.10184469457774238" LOG_EFFECT_SIZE="0.033427143611269076" MODIFIED="2016-06-27 04:26:24 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.951194731046807" P_Z="0.6281528010806109" STUDIES="13" TAU2="0.0" TOTAL_1="1980" TOTAL_2="2000" WEIGHT="27.140103279864316" Z="0.4843284342199294">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="1.747671667923777" CI_START="0.46907390425027246" EFFECT_SIZE="0.9054209919261822" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.24245984580271493" LOG_CI_START="-0.32875872726463046" LOG_EFFECT_SIZE="-0.04314944073095777" MODIFIED="2016-06-18 13:51:47 -0500" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.33553661739729795" STUDY_ID="STD-Dignan-2013" TOTAL_1="153" TOTAL_2="157" VAR="0.11258482161442071" WEIGHT="6.395907666687184"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2008-08-17 15:32:03 -0500" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5380911531781063"/>
<DICH_DATA CI_END="3.291694204889586" CI_START="0.09320822979113474" EFFECT_SIZE="0.5539070227497527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5174194828896894" LOG_CI_START="-1.0305457400592908" LOG_EFFECT_SIZE="-0.2565631285848007" MODIFIED="2008-08-17 15:32:01 -0500" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.9092824345116646" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.8267945457114596" WEIGHT="1.2490778835321599"/>
<DICH_DATA CI_END="16.123981734890627" CI_START="0.33971705999803836" EFFECT_SIZE="2.3404255319148937" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.207472297516197" LOG_CI_START="-0.4688826430711816" LOG_EFFECT_SIZE="0.36929482722250756" MODIFIED="2015-11-30 02:29:10 -0600" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.9846991901918118" STUDY_ID="STD-Gadisseur-2003-Self-mge" TOTAL_1="47" TOTAL_2="110" VAR="0.9696324951644101" WEIGHT="0.4564064027487334"/>
<DICH_DATA CI_END="1.902776127251359" CI_START="0.7936716948481072" EFFECT_SIZE="1.2288936299908564" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" LOG_CI_END="0.27938769400493735" LOG_CI_START="-0.10035910790209505" LOG_EFFECT_SIZE="0.08951429305142117" MODIFIED="2009-03-20 05:10:23 -0500" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.22306515121717696" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.04975806168754203" WEIGHT="12.992688420266335"/>
<DICH_DATA CI_END="1.940712202941797" CI_START="0.16916864118867395" EFFECT_SIZE="0.5729813664596274" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2879611366550307" LOG_CI_START="-0.7716801390565341" LOG_EFFECT_SIZE="-0.2418595012007517" MODIFIED="2008-08-17 15:29:54 -0500" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.6224385306618831" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.387429724452524" WEIGHT="2.664415171865177"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" MODIFIED="2008-08-17 15:32:05 -0500" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.38345788744156967"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2008-08-17 15:32:05 -0500" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.1588116250699272"/>
<DICH_DATA CI_END="8.514105482407807" CI_START="0.24849380639109928" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9301390264076987" LOG_CI_START="-0.6046844314122993" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2008-08-17 15:32:08 -0500" MODIFIED_BY="[Empty name]" ORDER="519" O_E="0.0" SE="0.901562896622114" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.8128156565656566" WEIGHT="0.774023428033122"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-17 01:51:38 -0500" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="0.38114790016782524"/>
<DICH_DATA CI_END="8.158899051468048" CI_START="0.014010271398333817" EFFECT_SIZE="0.3380952380952381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9116315597182885" LOG_CI_START="-1.8535534517479766" LOG_EFFECT_SIZE="-0.47096094601484395" MODIFIED="2008-08-17 15:32:06 -0500" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="1.6242833636218463" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.638296445338699" WEIGHT="0.5676670853563355"/>
<DICH_DATA CI_END="20.702641733611685" CI_START="0.18011682864360373" EFFECT_SIZE="1.9310344827586208" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3160257665742054" LOG_CI_START="-0.7444457083597167" LOG_EFFECT_SIZE="0.2857900291072443" MODIFIED="2014-06-17 01:52:58 -0500" MODIFIED_BY="[Empty name]" ORDER="163" O_E="0.0" SE="1.2103311438744822" STUDY_ID="STD-Verret-2012" TOTAL_1="58" TOTAL_2="56" VAR="1.4649014778325125" WEIGHT="0.38783470543392745"/>
<DICH_DATA CI_END="72.7792889459108" CI_START="0.12366155441129358" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620078082112528" LOG_CI_START="-0.9077652987719276" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2008-08-17 15:32:07 -0500" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="0.19057395008391262"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.424398258142462" CI_END="1.0897524339418638" CI_START="0.7359008272079638" DF="6" EFFECT_SIZE="0.8955164529977713" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="190" I2="28.77829589548666" ID="CMP-003.01.02" LOG_CI_END="0.037327847679480955" LOG_CI_START="-0.13318070889396524" LOG_EFFECT_SIZE="-0.047926430607242144" MODIFIED="2016-06-27 04:27:23 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.20862977962335738" P_Z="0.27054398553005654" STUDIES="7" TAU2="0.0" TOTAL_1="1990" TOTAL_2="2048" WEIGHT="72.8598967201357" Z="1.1018107218248703">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.8354105969837315" CI_START="0.005768634986643713" EFFECT_SIZE="0.1028971028971029" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2637332348316947" LOG_CI_START="-2.238926940379988" LOG_EFFECT_SIZE="-0.9875968527741464" MODIFIED="2014-06-17 01:54:05 -0500" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="1.4700749752870066" STUDY_ID="STD-Azarnoush-2009" TOTAL_1="90" TOTAL_2="102" VAR="2.161120432965093" WEIGHT="1.9666445776700674"/>
<DICH_DATA CI_END="1.053146935722411" CI_START="0.20770549346437056" EFFECT_SIZE="0.4677011909058102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.022488968451953324" LOG_CI_START="-0.6825520169472676" LOG_EFFECT_SIZE="-0.3300315242476572" MODIFIED="2008-08-17 15:32:10 -0500" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.41414456483266626" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.1715157205804385" WEIGHT="6.499451269938731"/>
<DICH_DATA CI_END="17.00449448308916" CI_START="0.029179515136467153" EFFECT_SIZE="0.7044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.230563725567877" LOG_CI_START="-1.5349219288684166" LOG_EFFECT_SIZE="-0.1521791016502699" MODIFIED="2015-11-30 02:29:18 -0600" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="1.6244599627906477" STUDY_ID="STD-Gadisseur-2003-Self-monit" TOTAL_1="52" TOTAL_2="111" VAR="2.638870170709793" WEIGHT="0.3672879765253589"/>
<DICH_DATA CI_END="1.5801621370908712" CI_START="0.19532297861336032" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19870165127795053" LOG_CI_START="-0.7092466614845627" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2008-08-17 15:32:12 -0500" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.5333333333333334" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.2844444444444445" WEIGHT="3.430331101510427"/>
<DICH_DATA CI_END="1.2943265123017385" CI_START="0.2726565317424484" EFFECT_SIZE="0.594059405940594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11204384712369019" LOG_CI_START="-0.5643840939216881" LOG_EFFECT_SIZE="-0.22617012339899897" MODIFIED="2008-08-17 15:30:34 -0500" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.3973371209423653" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.15787678767876784" WEIGHT="5.745662375664231"/>
<DICH_DATA CI_END="66.85209593841904" CI_START="0.11727381004212385" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8251150277568746" LOG_CI_START="-0.9307989650724365" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2008-08-17 15:30:37 -0500" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="1.6188375213822173" STUDY_ID="STD-Khan-2004" TOTAL_1="44" TOTAL_2="41" VAR="2.6206349206349207" WEIGHT="0.19714546560404755"/>
<DICH_DATA CI_END="1.2720124508132111" CI_START="0.8217034045776466" EFFECT_SIZE="1.0223585288431705" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="143" LOG_CI_END="0.10449136232891121" LOG_CI_START="-0.0852849136029589" LOG_EFFECT_SIZE="0.009603224362976165" MODIFIED="2014-06-17 01:54:25 -0500" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.1114755238900969" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.012426792426571565" WEIGHT="54.65337395322283"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.75220276865131" CI_END="1.1653391715460493" CI_START="0.6633958046661552" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.879250315562515" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="95" I2="0.0" I2_Q="58.150640527126235" ID="CMP-003.02" LOG_CI_END="0.06645234501262468" LOG_CI_START="-0.17822727929844745" LOG_EFFECT_SIZE="-0.05588746714291135" METHOD="MH" MODIFIED="2016-06-27 04:31:55 -0500" MODIFIED_BY="Heather Maxwell" NO="2" P_CHI2="0.769954467085016" P_Q="0.09167366394431731" P_Z="0.37059796813583" Q="4.779045665672315" RANDOM="NO" SCALE="279.59" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2262" TOTAL_2="2332" WEIGHT="100.0" Z="0.895353857892246">
<NAME>Events by Clinical Condition</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.5743682798593173" CI_END="1.6482313870046816" CI_START="0.7548211910736912" DF="3" EFFECT_SIZE="1.115401263538784" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="44" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.21701818008278068" LOG_CI_START="-0.12215591582403489" LOG_EFFECT_SIZE="0.047431132129372895" MODIFIED="2014-06-17 03:08:30 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.46200088901401537" P_Z="0.5835720293486362" STUDIES="4" TAU2="0.0" TOTAL_1="717" TOTAL_2="728" WEIGHT="46.01017646954787" Z="0.5481745914055427">
<NAME>Mechanical Valve</NAME>
<DICH_DATA CI_END="1.5801621370908712" CI_START="0.19532297861336032" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19870165127795053" LOG_CI_START="-0.7092466614845627" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="530" O_E="0.0" SE="0.5333333333333334" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.2844444444444445" WEIGHT="9.304388037739834"/>
<DICH_DATA CI_END="1.902776127251359" CI_START="0.7936716948481072" EFFECT_SIZE="1.2288936299908564" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" LOG_CI_END="0.27938769400493735" LOG_CI_START="-0.10035910790209505" LOG_EFFECT_SIZE="0.08951429305142117" MODIFIED="2009-03-20 05:10:36 -0500" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.22306515121717696" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.04975806168754203" WEIGHT="35.24120883327492"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" ORDER="528" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.4307587054509182"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-06-17 03:08:30 -0500" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="1.0338208930822037"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.03649860469498E-4" CI_END="27.467307689344814" CI_START="0.30582438072449886" DF="1" EFFECT_SIZE="2.8983050847457625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="1.4388160925125268" LOG_CI_START="-0.5145278950125075" LOG_EFFECT_SIZE="0.4621440987500096" NO="2" P_CHI2="0.9760185893223906" P_Z="0.3537081766440302" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="142" WEIGHT="1.0516453912387935" Z="0.9274206642583299">
<NAME>Atrial Fibrillation</NAME>
<DICH_DATA CI_END="66.85209593841904" CI_START="0.11727381004212385" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8251150277568746" LOG_CI_START="-0.9307989650724365" LOG_EFFECT_SIZE="0.4471580313422192" ORDER="532" O_E="0.0" SE="1.6188375213822173" STUDY_ID="STD-Khan-2004" TOTAL_1="44" TOTAL_2="41" VAR="2.6206349206349207" WEIGHT="0.5347349446976916"/>
<DICH_DATA CI_END="72.7792889459108" CI_START="0.12366155441129358" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620078082112528" LOG_CI_START="-0.9077652987719276" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="531" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="0.5169104465411019"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.5553560005895775" CI_END="0.969977676669612" CI_START="0.41425959446730665" DF="9" EFFECT_SIZE="0.6338947538665183" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="51" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="-0.013238260590213794" LOG_CI_START="-0.38272742430644147" LOG_EFFECT_SIZE="-0.19798284244832762" MODIFIED="2016-06-27 04:31:55 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.9381722912231956" P_Z="0.03569285024727813" STUDIES="10" TAU2="0.0" TOTAL_1="1400" TOTAL_2="1462" WEIGHT="52.93817813921333" Z="2.10040931567676">
<NAME>Any indication</NAME>
<DICH_DATA CI_END="1.053146935722411" CI_START="0.20770549346437056" EFFECT_SIZE="0.4677011909058102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.022488968451953324" LOG_CI_START="-0.6825520169472676" LOG_EFFECT_SIZE="-0.3300315242476572" ORDER="533" O_E="0.0" SE="0.41414456483266626" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.1715157205804385" WEIGHT="17.629031967574072"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="535" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="1.4595118490572287"/>
<DICH_DATA CI_END="3.291694204889586" CI_START="0.09320822979113474" EFFECT_SIZE="0.5539070227497527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5174194828896894" LOG_CI_START="-1.0305457400592908" LOG_EFFECT_SIZE="-0.2565631285848007" ORDER="8" O_E="0.0" SE="0.9092824345116646" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.8267945457114596" WEIGHT="3.3879835426454066"/>
<DICH_DATA CI_END="8.767057586948201" CI_START="0.2526258459464993" EFFECT_SIZE="1.4882154882154883" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.9428538592532874" LOG_CI_START="-0.5975222191895283" LOG_EFFECT_SIZE="0.17266582003187958" ORDER="536" O_E="0.0" SE="0.9048245334618724" STUDY_ID="STD-Gadisseur-2003-Self-mge" TOTAL_1="99" TOTAL_2="221" VAR="0.8187074363544952" WEIGHT="1.9190300327838405"/>
<DICH_DATA CI_END="1.2943265123017385" CI_START="0.2726565317424484" EFFECT_SIZE="0.594059405940594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11204384712369019" LOG_CI_START="-0.5643840939216881" LOG_EFFECT_SIZE="-0.22617012339899897" ORDER="545" O_E="0.0" SE="0.3973371209423653" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.15787678767876784" WEIGHT="15.584464209149637"/>
<DICH_DATA CI_END="1.940712202941797" CI_START="0.16916864118867395" EFFECT_SIZE="0.5729813664596274" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2879611366550307" LOG_CI_START="-0.7716801390565341" LOG_EFFECT_SIZE="-0.2418595012007517" ORDER="538" O_E="0.0" SE="0.6224385306618831" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.387429724452524" WEIGHT="7.226927057204224"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" ORDER="539" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="1.040086474252399"/>
<DICH_DATA CI_END="8.514105482407807" CI_START="0.24849380639109928" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9301390264076987" LOG_CI_START="-0.6046844314122993" LOG_EFFECT_SIZE="0.16272729749769976" ORDER="542" O_E="0.0" SE="0.901562896622114" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.8128156565656566" WEIGHT="2.099451659797706"/>
<DICH_DATA CI_END="8.158899051468048" CI_START="0.014010271398333817" EFFECT_SIZE="0.3380952380952381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9116315597182885" LOG_CI_START="-1.8535534517479766" LOG_EFFECT_SIZE="-0.47096094601484395" ORDER="540" O_E="0.0" SE="1.6242833636218463" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.638296445338699" WEIGHT="1.539733245016048"/>
<DICH_DATA CI_END="20.702641733611685" CI_START="0.18011682864360373" EFFECT_SIZE="1.9310344827586208" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3160257665742054" LOG_CI_START="-0.7444457083597167" LOG_EFFECT_SIZE="0.2857900291072443" MODIFIED="2014-06-17 03:11:10 -0500" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="1.2103311438744822" STUDY_ID="STD-Verret-2012" TOTAL_1="58" TOTAL_2="56" VAR="1.4649014778325125" WEIGHT="1.0519581017327688"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.406607503834076" CI_END="1.143145308482089" CI_START="0.8127254305868139" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9638792782601989" ESTIMABLE="YES" EVENTS_1="234" EVENTS_2="244" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.05810143832261327" LOG_CI_START="-0.09005615074214755" LOG_EFFECT_SIZE="-0.015977356209767157" METHOD="MH" MODIFIED="2016-06-27 04:34:13 -0500" MODIFIED_BY="Heather Maxwell" NO="3" P_CHI2="0.7415880921841873" P_Q="0.531361912787081" P_Z="0.6724950838972026" Q="0.39178706566334526" RANDOM="NO" SCALE="427.58" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3640" TOTAL_2="3697" WEIGHT="100.00000000000001" Z="0.4227261382557052">
<NAME>Events by Self-management (sensitivity)</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.242040762030857" CI_END="1.4441239838198925" CI_START="0.7629691680136962" DF="9" EFFECT_SIZE="1.049677128665614" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="68" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.1596044807525491" LOG_CI_START="-0.1174930117594917" LOG_EFFECT_SIZE="0.02105573449652869" MODIFIED="2016-06-27 04:34:13 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.8947719621742084" P_Z="0.7658080810927346" STUDIES="10" TAU2="0.0" TOTAL_1="1859" TOTAL_2="1867" WEIGHT="28.041127665885323" Z="0.29786253861131995">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="1.747671667923777" CI_START="0.46907390425027246" EFFECT_SIZE="0.9054209919261822" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.24245984580271493" LOG_CI_START="-0.32875872726463046" LOG_EFFECT_SIZE="-0.04314944073095777" MODIFIED="2016-06-18 15:59:39 -0500" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.33553661739729795" STUDY_ID="STD-Dignan-2013" TOTAL_1="153" TOTAL_2="157" VAR="0.11258482161442071" WEIGHT="6.842146683232171"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="547" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.5756334817292823"/>
<DICH_DATA CI_END="3.291694204889586" CI_START="0.09320822979113474" EFFECT_SIZE="0.5539070227497527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5174194828896894" LOG_CI_START="-1.0305457400592908" LOG_EFFECT_SIZE="-0.2565631285848007" ORDER="8" O_E="0.0" SE="0.9092824345116646" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.8267945457114596" WEIGHT="1.3362253714858419"/>
<DICH_DATA CI_END="16.123981734890627" CI_START="0.33971705999803836" EFFECT_SIZE="2.3404255319148937" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.207472297516197" LOG_CI_START="-0.4688826430711816" LOG_EFFECT_SIZE="0.36929482722250756" MODIFIED="2008-08-13 15:46:57 -0500" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.9846991901918118" STUDY_ID="STD-Gadisseur-2003-Self-monit" TOTAL_1="47" TOTAL_2="110" VAR="0.9696324951644101" WEIGHT="0.48824963046889225"/>
<DICH_DATA CI_END="1.902776127251359" CI_START="0.7936716948481072" EFFECT_SIZE="1.2288936299908564" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" LOG_CI_END="0.27938769400493735" LOG_CI_START="-0.10035910790209505" LOG_EFFECT_SIZE="0.08951429305142117" MODIFIED="2009-03-20 05:11:00 -0500" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.22306515121717696" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.04975806168754203" WEIGHT="13.899181259919558"/>
<DICH_DATA CI_END="1.940712202941797" CI_START="0.16916864118867395" EFFECT_SIZE="0.5729813664596274" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2879611366550307" LOG_CI_START="-0.7716801390565341" LOG_EFFECT_SIZE="-0.2418595012007517" ORDER="549" O_E="0.0" SE="0.6224385306618831" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.387429724452524" WEIGHT="2.850309976468649"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" ORDER="550" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.41021153672728145"/>
<DICH_DATA CI_END="8.514105482407807" CI_START="0.24849380639109928" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9301390264076987" LOG_CI_START="-0.6046844314122993" LOG_EFFECT_SIZE="0.16272729749769976" ORDER="555" O_E="0.0" SE="0.901562896622114" STUDY_ID="STD-Siebenhofer-2007" TOTAL_1="99" TOTAL_2="96" VAR="0.8128156565656566" WEIGHT="0.8280266237182752"/>
<DICH_DATA CI_END="8.158899051468048" CI_START="0.014010271398333817" EFFECT_SIZE="0.3380952380952381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9116315597182885" LOG_CI_START="-1.8535534517479766" LOG_EFFECT_SIZE="-0.47096094601484395" ORDER="552" O_E="0.0" SE="1.6242833636218463" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.638296445338699" WEIGHT="0.6072729106895797"/>
<DICH_DATA CI_END="72.7792889459108" CI_START="0.12366155441129358" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620078082112528" LOG_CI_START="-0.9077652987719276" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="553" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="0.20387019144578747"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.777080876903359" CI_END="1.138635934568915" CI_START="0.7603207530302841" DF="3" EFFECT_SIZE="0.9304453402531385" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="176" I2="37.2001421515667" ID="CMP-003.03.02" LOG_CI_END="0.05638488572770382" LOG_CI_START="-0.119003155240552" LOG_EFFECT_SIZE="-0.0313091347564241" MODIFIED="2015-11-16 06:16:57 -0600" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1888673923655314" P_Z="0.4840771416297943" STUDIES="4" TAU2="0.0" TOTAL_1="1781" TOTAL_2="1830" WEIGHT="71.95887233411469" Z="0.699760099616018">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="1.053146935722411" CI_START="0.20770549346437056" EFFECT_SIZE="0.4677011909058102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.022488968451953324" LOG_CI_START="-0.6825520169472676" LOG_EFFECT_SIZE="-0.3300315242476572" ORDER="558" O_E="0.0" SE="0.41414456483266626" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.1715157205804385" WEIGHT="6.952914467646488"/>
<DICH_DATA CI_END="17.00449448308916" CI_START="0.029179515136467153" EFFECT_SIZE="0.7044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.230563725567877" LOG_CI_START="-1.5349219288684166" LOG_EFFECT_SIZE="-0.1521791016502699" MODIFIED="2008-08-13 15:48:17 -0500" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="1.6244599627906477" STUDY_ID="STD-Gadisseur-2003-Self-mge" TOTAL_1="52" TOTAL_2="111" VAR="2.638870170709793" WEIGHT="0.39291345987733584"/>
<DICH_DATA CI_END="1.2943265123017385" CI_START="0.2726565317424484" EFFECT_SIZE="0.594059405940594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11204384712369019" LOG_CI_START="-0.5643840939216881" LOG_EFFECT_SIZE="-0.22617012339899897" ORDER="560" O_E="0.0" SE="0.3973371209423653" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.15787678767876784" WEIGHT="6.146534130156577"/>
<DICH_DATA CI_END="1.2720124508132111" CI_START="0.8217034045776466" EFFECT_SIZE="1.0223585288431705" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="143" LOG_CI_END="0.10449136232891121" LOG_CI_START="-0.0852849136029589" LOG_EFFECT_SIZE="0.009603224362976165" MODIFIED="2015-11-16 06:16:57 -0600" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.1114755238900969" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.012426792426571565" WEIGHT="58.46651027643429"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.82410029975722" CI_END="1.144293734631868" CI_START="0.8092828514862168" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9623187083813192" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="236" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.05853752004739588" LOG_CI_START="-0.09189966210814443" LOG_EFFECT_SIZE="-0.01668107103037428" METHOD="MH" MODIFIED="2016-06-27 04:36:48 -0500" MODIFIED_BY="Heather Maxwell" NO="4" P_CHI2="0.7559971698856098" P_Q="0.7929484139207882" P_Z="0.6638113067293718" Q="0.06889778905216237" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3628" TOTAL_2="3693" WEIGHT="99.99999999999999" Z="0.43465715024208185">
<NAME>Events by specialty</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.426111667710758" CI_END="1.1938150558947846" CI_START="0.7979315495814417" DF="8" EFFECT_SIZE="0.9760034310717258" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="173" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.07693705173005098" LOG_CI_START="-0.09803436292761333" LOG_EFFECT_SIZE="-0.010548655598781164" MODIFIED="2016-06-27 04:36:48 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.8167791805627849" P_Z="0.8131811520189565" STUDIES="9" TAU2="0.0" TOTAL_1="2501" TOTAL_2="2553" WEIGHT="72.7491312636767" Z="0.23632414585409817">
<NAME>Specialised Care</NAME>
<DICH_DATA CI_END="3.291694204889586" CI_START="0.09320822979113474" EFFECT_SIZE="0.5539070227497527" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5174194828896894" LOG_CI_START="-1.0305457400592908" LOG_EFFECT_SIZE="-0.2565631285848007" MODIFIED="2014-09-12 06:54:07 -0500" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.9092824345116646" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="0.8267945457114596" WEIGHT="1.3746762162832296"/>
<DICH_DATA CI_END="16.123981734890627" CI_START="0.33971705999803836" EFFECT_SIZE="2.3404255319148937" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="1.207472297516197" LOG_CI_START="-0.4688826430711816" LOG_EFFECT_SIZE="0.36929482722250756" MODIFIED="2014-09-12 06:55:10 -0500" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.9846991901918118" STUDY_ID="STD-Gadisseur-2003-Self-mge" TOTAL_1="47" TOTAL_2="110" VAR="0.9696324951644101" WEIGHT="0.5022993642669159"/>
<DICH_DATA CI_END="17.00449448308916" CI_START="0.029179515136467153" EFFECT_SIZE="0.7044025157232704" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.230563725567877" LOG_CI_START="-1.5349219288684166" LOG_EFFECT_SIZE="-0.1521791016502699" MODIFIED="2014-09-12 06:55:33 -0500" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="1.6244599627906477" STUDY_ID="STD-Gadisseur-2003-Self-monit" TOTAL_1="52" TOTAL_2="111" VAR="2.638870170709793" WEIGHT="0.404219826892167"/>
<DICH_DATA CI_END="1.2943265123017385" CI_START="0.2726565317424484" EFFECT_SIZE="0.594059405940594" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.11204384712369019" LOG_CI_START="-0.5643840939216881" LOG_EFFECT_SIZE="-0.22617012339899897" MODIFIED="2014-09-12 06:56:08 -0500" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.3973371209423653" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.15787678767876784" WEIGHT="6.323405064449417"/>
<DICH_DATA CI_END="66.85209593841904" CI_START="0.11727381004212385" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8251150277568746" LOG_CI_START="-0.9307989650724365" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2014-09-12 06:56:08 -0500" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="1.6188375213822173" STUDY_ID="STD-Khan-2004" TOTAL_1="44" TOTAL_2="41" VAR="2.6206349206349207" WEIGHT="0.2169690027235119"/>
<DICH_DATA CI_END="1.2720124508132111" CI_START="0.8217034045776466" EFFECT_SIZE="1.0223585288431705" ESTIMABLE="YES" EVENTS_1="147" EVENTS_2="143" LOG_CI_END="0.10449136232891121" LOG_CI_START="-0.0852849136029589" LOG_EFFECT_SIZE="0.009603224362976165" MODIFIED="2014-09-12 06:56:25 -0500" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.1114755238900969" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.012426792426571565" WEIGHT="60.14892610272881"/>
<DICH_DATA CI_END="1.940712202941797" CI_START="0.16916864118867395" EFFECT_SIZE="0.5729813664596274" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.2879611366550307" LOG_CI_START="-0.7716801390565341" LOG_EFFECT_SIZE="-0.2418595012007517" MODIFIED="2014-09-12 06:56:51 -0500" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.6224385306618831" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.387429724452524" WEIGHT="2.932329693253231"/>
<DICH_DATA CI_END="15.235048878454709" CI_START="0.06563812219954164" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1828438519035636" LOG_CI_START="-1.1828438519035636" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-09-12 06:57:23 -0500" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="1.3896166675593022" STUDY_ID="STD-Soliman-Hamad-2009" TOTAL_1="29" TOTAL_2="29" VAR="1.9310344827586206" WEIGHT="0.41947340526545634"/>
<DICH_DATA CI_END="20.702641733611685" CI_START="0.18011682864360373" EFFECT_SIZE="1.9310344827586208" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3160257665742054" LOG_CI_START="-0.7444457083597167" LOG_EFFECT_SIZE="0.2857900291072443" MODIFIED="2014-09-12 06:57:59 -0500" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="1.2103311438744822" STUDY_ID="STD-Verret-2012" TOTAL_1="58" TOTAL_2="56" VAR="1.4649014778325125" WEIGHT="0.42683258781397315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.345397039552859" CI_END="1.299523217841574" CI_START="0.659533787666948" DF="7" EFFECT_SIZE="0.9257858661829925" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="63" I2="4.702224232304868" ID="CMP-003.04.02" LOG_CI_END="0.11378404319863186" LOG_CI_START="-0.18076295080535063" LOG_EFFECT_SIZE="-0.033489453803359395" MODIFIED="2014-10-03 05:36:10 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3938244739324588" P_Z="0.6558221791326737" STUDIES="8" TAU2="0.0" TOTAL_1="1127" TOTAL_2="1140" WEIGHT="27.250868736323287" Z="0.4456886313741493">
<NAME>Primary Care</NAME>
<DICH_DATA CI_END="1.053146935722411" CI_START="0.20770549346437056" EFFECT_SIZE="0.4677011909058102" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.022488968451953324" LOG_CI_START="-0.6825520169472676" LOG_EFFECT_SIZE="-0.3300315242476572" MODIFIED="2014-09-12 07:00:07 -0500" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.41414456483266626" STUDY_ID="STD-Beyth-2000" TOTAL_1="163" TOTAL_2="162" VAR="0.1715157205804385" WEIGHT="7.152989575326644"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2014-09-12 07:00:45 -0500" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.592197748610056"/>
<DICH_DATA CI_END="1.5801621370908712" CI_START="0.19532297861336032" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.19870165127795053" LOG_CI_START="-0.7092466614845627" LOG_EFFECT_SIZE="-0.25527250510330607" MODIFIED="2014-09-12 07:01:58 -0500" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.5333333333333334" STUDY_ID="STD-Horstkotte-1998" TOTAL_1="75" TOTAL_2="75" VAR="0.2844444444444445" WEIGHT="3.775260647389107"/>
<DICH_DATA CI_END="1.902776127251359" CI_START="0.7936716948481072" EFFECT_SIZE="1.2288936299908564" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="34" LOG_CI_END="0.27938769400493735" LOG_CI_START="-0.10035910790209505" LOG_EFFECT_SIZE="0.08951429305142117" MODIFIED="2014-09-12 07:02:19 -0500" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.22306515121717696" STUDY_ID="STD-K_x00f6_rtke-2001" TOTAL_1="579" TOTAL_2="576" VAR="0.04975806168754203" WEIGHT="14.299140183646362"/>
<DICH_DATA CI_END="15.530962571524665" CI_START="0.06284534966277124" EFFECT_SIZE="0.9879518072289156" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1911983730850808" LOG_CI_START="-1.2017268530697955" LOG_EFFECT_SIZE="-0.0052642399923572315" MODIFIED="2014-09-12 07:03:11 -0500" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="1.4056161230142803" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="1.9757566852776962" WEIGHT="0.42201566832767123"/>
<DICH_DATA CI_END="100.09930561649661" CI_START="0.1762249986786411" EFFECT_SIZE="4.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0004310648122874" LOG_CI_START="-0.7539324840164864" LOG_EFFECT_SIZE="0.6232492903979004" MODIFIED="2014-09-12 07:03:34 -0500" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="1.6179267829014798" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="2.617687074829932" WEIGHT="0.1747805855272735"/>
<DICH_DATA CI_END="8.158899051468048" CI_START="0.014010271398333817" EFFECT_SIZE="0.3380952380952381" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9116315597182885" LOG_CI_START="-1.8535534517479766" LOG_EFFECT_SIZE="-0.47096094601484395" MODIFIED="2014-09-12 07:03:55 -0500" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="1.6242833636218463" STUDY_ID="STD-Sunderji-2004" TOTAL_1="69" TOTAL_2="70" VAR="2.638296445338699" WEIGHT="0.6247476248634456"/>
<DICH_DATA CI_END="72.7792889459108" CI_START="0.12366155441129358" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8620078082112528" LOG_CI_START="-0.9077652987719276" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-09-12 07:04:35 -0500" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="1.6269784336399213" STUDY_ID="STD-Voller-2005" TOTAL_1="101" TOTAL_2="101" VAR="2.6470588235294117" WEIGHT="0.20973670263272817"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2016-06-27 04:39:58 -0500" MODIFIED_BY="Heather Maxwell" NO="4">
<NAME>Minor haemorrhage</NAME>
<DICH_OUTCOME CHI2="66.8577702235549" CI_END="1.4076480577004955" CI_START="0.6657518186796879" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9680621129220145" ESTIMABLE="YES" EVENTS_1="719" EVENTS_2="653" I2="82.05145047482867" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.14849408541369286" LOG_CI_START="-0.17668763849551913" LOG_EFFECT_SIZE="-0.014096776540913136" METHOD="MH" MODIFIED="2016-06-27 04:39:58 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="1.2340418686918042E-9" P_Q="0.4867332058476789" P_Z="0.8650646597696238" Q="0.48373989620369134" RANDOM="YES" SCALE="647.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2271937022637969" TOTALS="YES" TOTAL_1="2707" TOTAL_2="2658" WEIGHT="100.0" Z="0.16993067129450803">
<NAME>Events by Self-management</NAME>
<GROUP_LABEL_1>Self-management</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.11068394560015" CI_END="1.7579382926067133" CI_START="0.4685578226184812" DF="6" EFFECT_SIZE="0.9075768500140646" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="172" I2="72.86379736256892" ID="CMP-004.01.01" LOG_CI_END="0.24500362634028675" LOG_CI_START="-0.3292368071356704" LOG_EFFECT_SIZE="-0.04211659039769185" MODIFIED="2016-06-27 04:39:58 -0500" MODIFIED_BY="Heather Maxwell" NO="1" P_CHI2="0.0011562026780980172" P_Z="0.7737296675666139" STUDIES="7" TAU2="0.39032414699670354" TOTAL_1="952" TOTAL_2="910" WEIGHT="46.44702578738839" Z="0.2874997841285156">
<NAME>Self-management</NAME>
<DICH_DATA CI_END="3.0945718416929227" CI_START="0.0359051645252244" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4906005694617424" LOG_CI_START="-1.4448430789010676" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="612" O_E="0.0" SE="1.1368891796488878" STUDY_ID="STD-Cromheecke-2000" TOTAL_1="49" TOTAL_2="49" VAR="1.292517006802721" WEIGHT="2.400858354367926"/>
<DICH_DATA CI_END="212.30870061611492" CI_START="0.7213111123359031" EFFECT_SIZE="12.375" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.32696779233906" LOG_CI_START="-0.14187737712784695" LOG_EFFECT_SIZE="1.0925452076056064" ORDER="613" O_E="0.0" SE="1.4502118735255474" STUDY_ID="STD-Fitzmaurice-2002" TOTAL_1="23" TOTAL_2="26" VAR="2.103114478114478" WEIGHT="1.5657200119739016"/>
<DICH_DATA CI_END="18.230061342469895" CI_START="0.15147052205636402" EFFECT_SIZE="1.6617210682492582" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2607881300181887" LOG_CI_START="-0.8196718777484651" LOG_EFFECT_SIZE="0.2205581261348618" ORDER="620" O_E="0.0" SE="1.222072507005262" STUDY_ID="STD-Fitzmaurice-2005" TOTAL_1="337" TOTAL_2="280" VAR="1.4934612123781263" WEIGHT="2.1204775699281035"/>
<DICH_DATA CI_END="0.5438336332960747" CI_START="0.31146325236552164" EFFECT_SIZE="0.41156310837118754" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="134" LOG_CI_END="-0.2645339370515565" LOG_CI_START="-0.5065931857184857" LOG_EFFECT_SIZE="-0.38556356138502107" ORDER="614" O_E="0.0" SE="0.14218680087955962" STUDY_ID="STD-Menendez_x002d_Jandula-2005" TOTAL_1="368" TOTAL_2="369" VAR="0.020217086344363533" WEIGHT="14.74717482050987"/>
<DICH_DATA CI_END="2.590764996937807" CI_START="0.5425078057512632" EFFECT_SIZE="1.1855421686746987" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.41342802079676527" LOG_CI_START="-0.26559400868623007" LOG_EFFECT_SIZE="0.0739170060552676" ORDER="615" O_E="0.0" SE="0.3988609013315663" STUDY_ID="STD-Sawicki-1999" TOTAL_1="83" TOTAL_2="82" VAR="0.15909001861102948" WEIGHT="9.44541526063189"/>
<DICH_DATA CI_END="9.534631841197745" CI_START="0.2090358199425469" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9793039283811716" LOG_CI_START="-0.6797792877145075" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="616" O_E="0.0" SE="0.9745536937289727" STUDY_ID="STD-Sidhu-2001" TOTAL_1="34" TOTAL_2="48" VAR="0.9497549019607843" WEIGHT="3.1000590331542965"/>
<DICH_DATA CI_END="1.6470043800302214" CI_START="0.673600552230797" EFFECT_SIZE="1.0532915360501567" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.2166947541305475" LOG_CI_START="-0.17159756546522173" LOG_EFFECT_SIZE="0.0225485943326629" MODIFIED="2014-06-17 02:23:42 -0500" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.22808483060853574" STUDY_ID="STD-Verret-2012" TOTAL_1="58" TOTAL_2="56" VAR="0.05202268995372444" WEIGHT="13.067320736822404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.072484196907629" CI_END="1.4207014437861485" CI_START="0.9471214988441873" DF="5" EFFECT_SIZE="1.1599900348058332" ESTIMABLE="YES" EVENTS_1="618" EVENTS_2="481" I2="29.303482895215257" ID="CMP-004.01.02" LOG_CI_END="0.1525028218125994" LOG_CI_START="-0.023594305164671744" LOG_EFFECT_SIZE="0.06445425832396386" MODIFIED="2014-06-17 02:24:56 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21530524029423093" P_Z="0.1513572222754434" STUDIES="6" TAU2="0.01674376184103681" TOTAL_1="1755" TOTAL_2="1748" WEIGHT="53.5529742126116" Z="1.4347539580417494">
<NAME>Self-monitoring</NAME>
<DICH_DATA CI_END="2.1847897746149876" CI_START="0.6591023158069121" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.33940965452517824" LOG_CI_START="-0.18104716242992858" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2014-06-17 02:24:39 -0500" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.3057189105822237" STUDY_ID="STD-Azarnoush-2009" TOTAL_1="90" TOTAL_2="102" VAR="0.0934640522875817" WEIGHT="11.378518374487468"/>
<DICH_DATA CI_END="2.5247240518704244" CI_START="0.27127674778478045" EFFECT_SIZE="0.8275862068965517" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.40221391738575585" LOG_CI_START="-0.566587429760456" LOG_EFFECT_SIZE="-0.08218675618735007" ORDER="622" O_E="0.0" SE="0.5690787069576964" STUDY_ID="STD-Gardiner-2005" TOTAL_1="29" TOTAL_2="24" VAR="0.32385057471264367" WEIGHT="6.621264941003547"/>
<DICH_DATA CI_END="1.2132770018745163" CI_START="0.7222351071787757" EFFECT_SIZE="0.9360936093609361" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="55" LOG_CI_END="0.08395996545990589" LOG_CI_START="-0.14132140474408036" LOG_EFFECT_SIZE="-0.028680719642087255" ORDER="624" O_E="0.0" SE="0.1323313920185891" STUDY_ID="STD-Kaatz-Unpublished" TOTAL_1="101" TOTAL_2="100" VAR="0.017511597313577508" WEIGHT="14.91022122686429"/>
<DICH_DATA CI_END="6.313025197492252" CI_START="0.13753867548506762" EFFECT_SIZE="0.9318181818181818" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8002375227520337" LOG_CI_START="-0.8615751622849377" LOG_EFFECT_SIZE="-0.03066881976645196" ORDER="625" O_E="0.0" SE="0.9761569972961769" STUDY_ID="STD-Khan-2004" TOTAL_1="44" TOTAL_2="41" VAR="0.9528824833702882" WEIGHT="3.0918428797241275"/>
<DICH_DATA CI_END="1.4904314228252318" CI_START="1.2034571467553727" EFFECT_SIZE="1.3392797868809205" ESTIMABLE="YES" EVENTS_1="540" EVENTS_2="401" LOG_CI_END="0.17331199823262083" LOG_CI_START="0.0804306303326753" LOG_EFFECT_SIZE="0.12687131428264808" MODIFIED="2014-06-17 02:24:56 -0500" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.054558975274614195" STUDY_ID="STD-Matchar-2010" TOTAL_1="1465" TOTAL_2="1457" VAR="0.002976681783015963" WEIGHT="15.851779398963362"/>
<DICH_DATA CI_END="13.952690829387027" CI_START="0.06106857926806031" EFFECT_SIZE="0.9230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.14465797102622" LOG_CI_START="-1.2141821835446438" LOG_EFFECT_SIZE="-0.03476210625921192" ORDER="623" O_E="0.0" SE="1.385594383242006" STUDY_ID="STD-White-1989" TOTAL_1="26" TOTAL_2="24" VAR="1.9198717948717947" WEIGHT="1.699347391568808"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-06-27 09:20:03 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-06-27 09:20:03 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flowchart showing the results of combined searches</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAt8AAAK/CAYAAACx/qGeAABpSElEQVR42uzdD8QV6d8/8IckSRLJ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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-06-24 04:20:37 -0500" MODIFIED_BY="Heather Maxwell" NO="2" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 Major haemorrhage, outcome </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-06-24 04:20:37 -0500" MODIFIED_BY="Heather Maxwell" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 2 Thromboembolic events </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2016-06-24 08:21:51 -0500" MODIFIED_BY="Heather Maxwell" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiIAAADOCAMAAAA0c5nIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2016-06-26 04:05:00 -0500" MODIFIED_BY="Heather Maxwell" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUIAAAR/CAIAAADhE3gfAAA9ZklEQVR42u3dvW4kxdvG4ZGQEIED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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2016-06-30 12:55:46 -0500" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2016-06-30 12:55:46 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-03-27 07:56:06 -0500" MODIFIED_BY="[Empty name]">New Feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2016-06-27 05:25:05 -0500" MODIFIED_BY="Heather Maxwell">
<P>Date of Submission: 20th October 2011<BR/>Name: Dominique Roberfroid<BR/>Email Address: dominique.roberfroid@kce.fgov.be<BR/>Personal Description: Occupation epidemiologist<BR/>
<BR/>Feedback: Revisiting the 'unbelievable' protective effects of Patient Self-Management with POC Anticoagulation?<BR/>
</P>
<P>Dear Authors,<BR/>
<BR/>You conclude that the Point of Care approach (POC) associated with Patient Self Management (PSM) reduces all-cause mortality by 45% (RR 0.55, 95% CI 0.36 to 0.84) over a follow-up period of 2 years, in comparison to patients with a laboratory-based monitoring of coagulation parameters.<BR/>
<BR/>However, we believe that such statement is not supported by available evidence.<BR/>To date, fourteen studies on POC+PSM reported all-cause mortality as an outcome. However, the results are estimable in only 7 of them. On the basis of these 7 studies, the all cause mortality rate would decrease by 45% (95%CI: 16%-64%) for patients using POC+PSM (Figure 9 of your review). Similar results were reported by other authors [1]. As displayed in the forest plot (figure 9 of your review), one specific study is very influential in the analysis of POC+PSM, the one by Koertke et al. [2], which is the long-term follow-up of another study by the same authors [3]. That study bears a 59.0% weight in the meta-analysis POC+PSM. Thus the quality of that study determines the strength or the weakness of the analysis. Strikingly, that study presents a number of important flaws:</P>
<P>
<BR/>1. The randomization procedure is unclear and allocation concealment is not described.</P>
<P>
<BR/>2. Only 930 patients over the 1,155 patients (80.5%) in the initial trial 4 participated in the follow- up study (442 in the control group and 488 in the PSM group). How the patient selection was   done is not described. We don&#8217;t know how much the 930 follow-up patients differed from the 1,155 patients of the initial study. There are indirect clues of selection bias. In the 2001 paper, no differences at baseline between groups were reported (although the results were not displayed). In contradiction, in the follow-up study, important and clinically relevant differences between groups at baseline were obvious (table 1 in [2)]. Patients in the control group were significantly in   worse health condition at baseline than PSM patients: 5.9% were in NYHA functional class vs. 2.0% of PSM patients (p=0.04), and 10.2 % had undergone a double valve replacement vs. 5.3% of the PSM patients (p=0.01). Authors of the paper acknowledged that a double valve replacement bears a higher mortality risk. Age difference between groups at baseline is not reported in the paper, although being also a determinant of lethality. As the patient selection is not described in the follow-up study, we cannot conclude if such differences were due to selection bias or differential lost to follow-up, but this question is of secondary interest.<BR/>
</P>
<P>3. The authors reported 236 deaths over the follow-up period (94 in PSM patients, 142 in controls).  However, when these numbers are subtracted from the initial numbers of participants, 300 and 394 participants should remain at months 120 in the control and PSM group, respectively. In figure 2 of the paper by Koertke et al. [2], these numbers are 260 and 305. So, 40 were lost to follow-up in the control group and 89 in the PSM group. Such difference could explain some or most of the mortality difference between groups. However, the authors did not discuss the fact nor provide a description of these lost to follow-ups, in particular if they presented differential  characteristics between groups. Authors laconically reported that &#8220;122 patients were either noncompliant within the first two years of the study or switched over from INR self-management to INR measurement by a GP and vice-versa during follow-up (p27 in [2]).<BR/>
<BR/>On the basis of these elements, the study can be rated low quality. Christensen et al. also categorized the study by Koertke et al. in ?lower quality trials? [1]. We argue that when a study presents such potential flaws and bears a dominant weight in the meta-analysis, a sensitivity analysis should be performed for a more realistic appraisal of evidence, and results of such sensitivity analysis should be fully discussed. Not surprisingly in this case, when the study by Koerkte et al. is removed from the meta-analysis, there is no more statistically significant evidence that POC+PSM confers an improved survival to patients (RR=0.72; 95%CI: 0.42-1.24). Christensen et al. also reached a non significant RR=0.49 (95%CI: 0.21-1.14) when analysing only high quality trials [1].<BR/>
</P>
<P>Also noteworthy, Koerkte et al. reported 4 baseline factors associated to an excess mortality in their study: age; being a control; atrial fibrillation; and other than aortic surgery. When adjusting for these factors in a multivariate analysis, the &#8220;protective effect&#8221; of PSM fell to 23% (95%: 0%-42%), a much lower value than the one used in previous meta-analyzes [1, 4, 5].<BR/>I would appreciate receiving your thoughts on my comments.<BR/>
<BR/>Best regards,<BR/>
<BR/>Dominique Roberfroid, MD, MSc, MPhil</P>
<P>Belgian Health Care Knowledge Centre (https://kce.fgov.be/)<BR/>
<BR/>
</P>
<P>
<B>Bibliography<BR/>
</B>1. Christensen TD, Johnsen SP, Hjortdal VE, Hasenkam JM. Self-management of oral anticoagulant therapy: a systematic review and meta-analysis. Int J Cardiol. 2007;118(1):54-61.<BR/>2. Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg. 2007;83(1):24-9.<BR/>3. Kortke H, Minami K, Breymann T, Seifert D, Baraktaris A, Wagner O, et al. [INR self-management after mechanical heart valve replacement: ESCAT (Early Self-Controlled Anticoagulation Trial)]. Z Kardiol. 2001;90 Suppl 6:118-24.<BR/>4. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11(38):iii-iv, ix-66.<BR/>5. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367(9508):404-11.<BR/>
<BR/>
</P>
<P>
<BR/>Submitter agrees with default conflict of interest statement:<BR/>I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.<BR/>
<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2016-06-30 12:55:46 -0500" MODIFIED_BY="[Empty name]">
<P>In response to comments by Dominique Roberfroid submitted 2nd April 2012:</P>
<P>Dear Dominique,</P>
<P>In terms of mortality we report a reduction in all-cause mortality of 36% (RR 0.64, 95% CI 0.46 to 0.89) and as stated for self-management of 45% (RR 0.55, 95% CI 0.36 to 0.84) over a follow-up period of 2 years.[1]</P>
<P>It is correct that the study by Koertke et al [2] provides a substantial amount of data to the mortality analysis for self-management. In terms of the GRADE of the paper we therefore judged the evidence to be of moderate quality around the reported effects, particularly due to an absence of information on allocation concealment and also because there was a few number of events. However, in terms of study quality we confirmed in a subsequent publication, [3] and with direct communication with the authors for this Cochrane review that randomization and allocation concealment were clear in this study.    </P>
<P>In terms of the baseline difference in this trial these imbalances could have led to differences in the outcomes. We stated in the discussion that the 36% reduction in mortality from all causes was largely influenced by one study. In addition we applied the logic of early stopping of randomized controlled trials to determine whether our meta-analysis could be considered definitive. It is not, the calculated optimal information size needed to reliably detect a plausible treatment effect is 2,300 patients per group for thromboembolic events alone.</P>
<P>Further to the publication of this review a large RCT was published in the US.[4] We have analysed this in our subsequent publication &#8216;Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data&#8217; [3] including individual patient data from 11 trials of 6,417 participants including the Koertke data. </P>
<P>This allowed us to verify the trial methods as well as undertake time-to-event outcomes analysed with hazard ratios (HR) with 5 years of follow-up data, which take into account the number of people randomized and timing of events, and the time until last follow-up for each patient not experiencing an event. In this study [3] we reported a significant reduction in thromboembolic events in the self-monitoring group (HR 0.51; 95% CI 0.31 to 0.85) but a non-significant reduction in death for the self-monitoring group (HR 0·82, 95% CI 0.62 to 1.09) and a non-significant effect in terms of death for the self-management group alone (HR 0.75, 95% CI, to 0.42 to 1.33).  </P>
<P>Therefore, the protective effect is lower than previously estimated in our previous review.[1] Reasons for this could include lower quality trial methodology but could also results as improvements in the control group care occur over time. The increase in the number of trials and participants allows us to improve the confidence around our estimated and we will incorporate this additional data into our updated review.</P>
<P>
<B>References </B>
</P>
<P>[1] Garcia-Alamino JM, Ward AM, Alonso-Coello P, Perera R, Bankhead C, Fitzmaurice D, Heneghan CJ <A HREF="http://www.ncbi.nlm.nih.gov/pubmed/20393937">Self-monitoring and self-management of oral anticoagulation.</A> Cochrane Database Syst Rev. 2010 Apr 14;(4):CD003839. Review.</P>
<P>[2] Koertke H, Zittermann A, Wagner O, Koerfer R. Self-management of oral anticoagulation therapy improves long-term survival in patients with mechanical heart valve replacement. Ann Thorac Surg. 2007;83(1):24-9.<BR/>
</P>
<P>[3] Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379(9813):322-34.</P>
<P>[4] Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med 2010;363(17):1608-20.<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2016-06-27 05:25:27 -0500" MODIFIED_BY="Heather Maxwell">
<P>Heneghan CJ, Garcia-Alamino JM, Ward AM and Perera R</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2016-06-27 05:23:23 -0500" MODIFIED_BY="Heather Maxwell">
<APPENDIX ID="APP-01" MODIFIED="2016-06-27 05:23:23 -0500" MODIFIED_BY="Heather Maxwell" NO="1">
<TITLE MODIFIED="2014-10-16 10:22:05 -0500" MODIFIED_BY="[Empty name]">Search strategies 2007</TITLE>
<APPENDIX_BODY MODIFIED="2016-06-27 05:23:23 -0500" MODIFIED_BY="Heather Maxwell">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL,The Cochrane Library (Spanish version platform)</HEADING>
<P>#1. ANTICOAGULANTS*:TA<BR/>#2. ANTICOAGULANT*:TA<BR/>#3. ANTI-COAGULANT*:TA<BR/>#4. WARFARIN*:TA<BR/>#5. (VITAMIN ANTAGONIST*):TA<BR/>#6. VITAMIN-K*:TA<BR/>#7. COUMARINS*:TA<BR/>#8. COUMARIN*:TA<BR/>#9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8<BR/>#10. SELF-CARE:TA<BR/>#11. SELF-ADMINISTRATION:TA<BR/>#12. CONSUMER-PARTICIPATION:TA<BR/>#13. CONSUMER-PARTICIPATION*:TA<BR/>#14. (PATIENT CENTRED):TA<BR/>#15. (PATIENT CENTERED):TA<BR/>#16. (PATIENT* PARTICIPAT*):TA<BR/>#17. SELF*:TA<BR/>#18. HOME*:TA<BR/>#19. COAGUCHECK:TA<BR/>#20. COAGUCHEK:TA<BR/>#21. (PROTHROMBIN MONITOR*):TA<BR/>#22. COAGULOMETER*:TA<BR/>#23. CONSUMER*:TA<BR/>#24. (PATIENT* MONITOR*):TA<BR/>#25. (PATIENT* MANAGE*):TA<BR/>#26. (PATIENT* MEASUR*):TA<BR/>#27. (PATIENT* TEST*):TA<BR/>#28. (PATIENT* ADJUST*):TA<BR/>#29. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20<BR/>#30. #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28<BR/>#31. #29 OR #30<BR/>#32. #9 AND #31</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE on PubMed</HEADING>
<P>#1. "Anticoagulants"[Mesh]<BR/>#2. Anticoagulant*<BR/>#3. Anti-coagulant*<BR/>#4. warfarin*<BR/>#5. vitamin antagonist*<BR/>#6. "Vitamin K"[Mesh]<BR/>#7. "Coumarins"[Mesh]<BR/>#8. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7<BR/>#9. "Self Care"[Mesh]<BR/>#10. "Self Administration"[Mesh]<BR/>#11. "Consumer Participation"[Mesh]<BR/>#12. patient centred<BR/>#13. patient centered<BR/>#14. patient* participat*<BR/>#15. self*<BR/>#16. home*<BR/>#17. coagucheck<BR/>#18. coaguchek<BR/>#19. prothrombin monitor*<BR/>#20. coagulometer*<BR/>#21. consumer*<BR/>#22. patient* monitor*<BR/>#23. patient* manage*<BR/>#24. patient* measur*<BR/>#25. patient* test*<BR/>#26. patient* adjust*<BR/>#27. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26<BR/>#28. #8 AND #27</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>#1. fondaparinux/ or low molecular weight heparin/ or hirudin/ or enoxaparin/ or heparin/ or new drug/ or warfarin/ or ximelagatran/ or anticoagulant agent/ or acetylsalicylic acid/<BR/>#2. anticoagulant protein/ or lupus anticoagulant/ or anticoagulant agent/ or coumarin anticoagulant/ or anticoagulant therapy/ or tick anticoagulant peptide/<BR/>#3. rivaroxaban/ or acetylsalicylic acid/ or bleeding/ or antithrombocytic agent/ or warfarin/ or dabigatran etexilate/ or heparin/ or anticoagulation/ or anticoagulant agent/ or anticoagulant therapy/<BR/>#4. anticoagulation/ or bleeding/ or stroke/ or anticoagulant agent/ or thromboembolism/ or herbaceous agent/ or acetylsalicylic acid/ or heart atrium fibrillation/ or warfarin/ or phytomenadione/<BR/>#5. (vitamin adj antagonist*).mp.<BR/>#6. antivitamin K/ or phytomenadione/ or menadione/ or oral drug administration/ or warfarin/ or anticoagulant agent/ or vitamin K deficiency/ or bleeding/ or vitamin K group/ or brain hemorrhage/<BR/>#7. coumarin/ or plant extract/ or phytochemistry/ or osthole/ or drug isolation/ or cytotoxic agent/ or unclassified drug/ or drug synthesis/ or coumarin derivative/ or drug identification/<BR/>#8. coumarin 7 hydroxylase/ or coumarin/ or coumarin derivative/ or coumarin anticoagulant/<BR/>#9. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8).mp.<BR/>#10. self care/<BR/>#11. drug self administration/<BR/>#12. disability/ or health care policy/ or medical research/ or drug dependence/ or health care planning/ or mental disease/ or mental health service/ or health care system/ or consumer/ or health care delivery/<BR/>#13. (patient adj centred).mp.<BR/>#14. (patient adj centered).mp.<BR/>#15. (patient* adj participat*).mp.<BR/>#16. self monitoring/ or self control/ or self care/ or patient self-determination act/ or self examination/ or self medication/ or self injection/ or self-directed learning/ or self evaluation/<BR/>#17. home diagnostic test/ or home monitoring/ or home/ or home delivery/ or home care/ or home safety/<BR/>#18. warfarin/ or anticoagulant therapy/ or international normalized ratio/ or acenocoumarol/ or prothrombin time/ or thromboembolism/ or prothrombin complex/ or vitamin K group/ or anticoagulant agent/ or anticoagulation/<BR/>#19. thrombosis/ or anticoagulation/ or device/ or anticoagulant therapy/ or international normalized ratio/ or coumarin anticoagulant/ or anticoagulant agent/ or international standard unit/ or prothrombin time/ or warfarin/<BR/>#20. (prothrombin adj monitor*).mp.<BR/>#21. international standard unit/ or blood clotting/ or warfarin/ or thromboembolism/ or blood clotting test/ or laboratory test/ or anticoagulant agent/ or thromboplastin/ or prothrombin time/ or coagulometer/<BR/>#22. consumer advocacy/ or consumer/ or consumer health information/ or consumer attitude/<BR/>#23. (patient* adj monitor*).mp.<BR/>#24. (patient* adj manage*).mp.<BR/>#25. (patient* adj measur*).mp.<BR/>#26. (patient* adj test*).mp.<BR/>#27. (patient* adj adjust*).mp.<BR/>#28. (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19).mp.<BR/>#29. (#20 or #21 or #22 or #23 or #24 or #25 or #26 or #27).mp.<BR/>#30. (#28 or #29).mp.<BR/>#31. (#9 and #30).mp.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL (EBSCO host)</HEADING>
<P>#1. anticoagulants*<BR/>#2. anticoagulant*<BR/>#3. anti-coagulant*<BR/>#4. warfarin*<BR/>#5. vitamin NEAR antagonist*<BR/>#6. vitamin-k*<BR/>#7. coumarins*<BR/>#8. coumarin*<BR/>#9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8<BR/>#10. self-care<BR/>#11. self-administration<BR/>#12. consumer-participation*<BR/>#13. patient NEAR centred<BR/>#14. patient NEAR centered<BR/>#15. patient* NEAR participat*<BR/>#16. self*<BR/>#17. home*<BR/>#18. coaguchek<BR/>#19. prothrombin NEAR monitor*<BR/>#20. coagulometer*<BR/>#21. consumer*<BR/>#22. patient* NEAR monitor*<BR/>#23. patient* NEAR manage*<BR/>#24. patient* NEAR measur*<BR/>#25. patient* NEAR test*<BR/>#26. patient* NEAR adjust*<BR/>#27. #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18<BR/>#28. #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26<BR/>#29. #27 OR #28<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-10-16 11:22:57 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-10-16 10:22:19 -0500" MODIFIED_BY="[Empty name]">Search strategies 2013</TITLE>
<APPENDIX_BODY MODIFIED="2014-10-16 11:22:57 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1MeSH descriptor: [Anticoagulants] explode all trees<BR/>#2MeSH descriptor: [Coumarins] explode all trees<BR/>#3anticoagulant*<BR/>#4anti-coagulant*<BR/>#5warfarin*<BR/>#6vitamin antagonist*<BR/>#7vitamin-K*<BR/>#8coumarin*<BR/>#9#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8<BR/>#10MeSH descriptor: [Self Care] explode all trees<BR/>#11MeSH descriptor: [Consumer Participation] explode all trees<BR/>#12self near/3 admin*<BR/>#13self near/3 car*<BR/>#14consumer near/3 participat*<BR/>#15patient near/3 participat*<BR/>#16patient next cent*<BR/>#17self*<BR/>#18home*<BR/>#19coagucheck*<BR/>#20coaguchek*<BR/>#21prothrombin next monitor*<BR/>#22coagulometer*<BR/>#23consumer*<BR/>#24patient* near/2 monitor*<BR/>#25patient* near/2 manag*<BR/>#26patient* near/2 measur*<BR/>#27patient* near/2 test*<BR/>#28patient* near/2 adjust*<BR/>#29#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28<BR/>#30#9 and #29 from 2007 to 2013</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE OVID</HEADING>
<P>1. exp Anticoagulants/<BR/>2. anticoagulant*.tw.<BR/>3. anti-coagulant*.tw.<BR/>4. (thrombin adj2 inhibit*).tw.<BR/>5. antithrombin*.tw.<BR/>6. Warfarin/<BR/>7. warfarin*.tw.<BR/>8. coumadin*.tw.<BR/>9. (vitamin adj2 antagonist*).tw.<BR/>10. Coumarins/<BR/>11. vitamin k.tw.<BR/>12. or/1-11<BR/>13. exp Self Care/<BR/>14. exp Consumer Participation/<BR/>15. (patient adj2 cent*).tw.<BR/>16. (patient* adj2 participat*).tw.<BR/>17. self*.tw.<BR/>18. home*.tw.<BR/>19. coagucheck.tw.<BR/>20. coaguchek.tw.<BR/>21. prothrombin monitor*.tw.<BR/>22. coagulometer*.tw.<BR/>23. consumer*.tw.<BR/>24. (patient* adj2 monitor*).tw.<BR/>25. (patient* adj2 manage*).tw.<BR/>26. (patient* adj2 measur*).tw.<BR/>27. (patient* adj2 test*).tw.<BR/>28. (patient* adj2 adjust*).tw.<BR/>29. or/13-28<BR/>30. 12 and 29<BR/>31. randomized controlled trial.pt.<BR/>32. controlled clinical trial.pt.<BR/>33. randomized.ab.<BR/>34. placebo.ab.<BR/>35. drug therapy.fs.<BR/>36. randomly.ab.<BR/>37. trial.ab.<BR/>38. groups.ab.<BR/>39. 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38<BR/>40. exp animals/ not humans.sh.<BR/>41. 39 not 40<BR/>42. 30 and 41<BR/>43. (200711* or 200712* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013*).ed.<BR/>44. 42 and 43</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE OVID</HEADING>
<P>1. exp anticoagulant agent/<BR/>2. anticoagulant protein/<BR/>3. lupus anticoagulant/<BR/>4. anticoagulant therapy/<BR/>5. tick anticoagulant peptide/<BR/>6. fondaparinux/<BR/>7. low molecular weight heparin/<BR/>8. hirudin/<BR/>9. enoxaparin/<BR/>10. heparin/<BR/>11. warfarin/<BR/>12. ximelagatran/<BR/>13. acetylsalicylic acid/<BR/>14. rivaroxaban/<BR/>15. antithrombocytic agent/<BR/>16. dabigatran etexilate/<BR/>17. anticoagulation/<BR/>18. exp thromboembolism/<BR/>19. herbaceous agent/<BR/>20. phytomenadione/<BR/>21. exp vitamin K group/<BR/>22. vitamin K deficiency/<BR/>23. coumarin/<BR/>24. osthole/<BR/>25. coumarin derivative/<BR/>26. coumarin 7 hydroxylase/<BR/>27. (vitamin adj2 antagonist*).tw.<BR/>28. anticoagulant*.tw.<BR/>29. anti-coagulant*.tw.<BR/>30. (thrombin adj2 inhibit*).tw.<BR/>31. antithrombin*.tw.<BR/>32. warfarin*.tw.<BR/>33. coumadin*.tw.<BR/>34. vitamin k.tw.<BR/>35. or/1-34<BR/>36. exp self care/<BR/>37. drug self administration/<BR/>38. (patient adj2 cent*).tw.<BR/>39. (patient* adj2 participat*).tw.<BR/>40. self monitoring/<BR/>41. home monitoring/<BR/>42. self*.tw.<BR/>43. home*.tw.<BR/>44. coagucheck.tw.<BR/>45. coaguchek.tw.<BR/>46. prothrombin monitor*.tw.<BR/>47. coagulometer*.tw.<BR/>48. consumer*.tw.<BR/>49. (patient* adj2 monitor*).tw.<BR/>50. (patient* adj2 manage*).tw.<BR/>51. (patient* adj2 measur*).tw.<BR/>52. (patient* adj2 test*).tw.<BR/>53. (patient* adj2 adjust*).tw.<BR/>54. or/36-53<BR/>55. 35 and 54<BR/>56. random$.tw.<BR/>57. factorial$.tw.<BR/>58. crossover$.tw.<BR/>59. cross over$.tw.<BR/>60. cross-over$.tw.<BR/>61. placebo$.tw.<BR/>62. (doubl$ adj blind$).tw.<BR/>63. (singl$ adj blind$).tw.<BR/>64. assign$.tw.<BR/>65. allocat$.tw.<BR/>66. volunteer$.tw.<BR/>67. crossover procedure/<BR/>68. double blind procedure/<BR/>69. randomized controlled trial/<BR/>70. single blind procedure/<BR/>71. 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70<BR/>72. (animal/ or nonhuman/) not human/<BR/>73. 71 not 72<BR/>74. 55 and 73<BR/>75. (20074* or 20075* or 2008* or 2009* or 2010* or 2011* or 2012* or 2013*).em.<BR/>76. 74 and 75</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">CINAHL</HEADING>
<P>S22S20 AND S21<BR/>S21EM 2007-2013<BR/>S20S7 AND S19<BR/>S19S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18<BR/>S18(patient* N2 adjust*)<BR/>S17(patient* N2 test*)<BR/>S16(patient* N2 measur*)<BR/>S15(patient* N2 manage*)<BR/>S14(patient* N2 monitor*)<BR/>S13"prothrombin monitor*"<BR/>S12self* or home* or coagucheck or coaguchek or coagulometer* or consumer*<BR/>S11(patient* N2 participat*)<BR/>S10(patient N2 cent*)<BR/>S9(MH "Consumer Participation")<BR/>S8(MH "Self Care+")<BR/>S7S1 OR S2 OR S3 OR S4 OR S5 OR S6<BR/>S6vitamin N2 k<BR/>S5(MH "Warfarin")<BR/>S4(vitamin N2 antagonist*)<BR/>S3(thrombin N2 inhibit*)<BR/>S2anticoagulant* or anti-coagulant* or antithrombin* or warfarin* or coumadin*<BR/>S1(MH "Anticoagulants+")<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;studies included in quantitative synthesis (meta-analysis), n = 28 (27 articles)&lt;/p&gt;" WIDTH="286">
<FLOWCHARTBOX TEXT="&lt;p&gt;studies included in qualitative synthesis, n = 28 (27 articles)&lt;/p&gt;" WIDTH="220">
<FLOWCHARTBOX TEXT="&lt;p&gt;full-text articles assessed for eligibility, n = 69&lt;/p&gt;" WIDTH="192">
<FLOWCHARTBOX TEXT="&lt;p&gt;records screened, n = 5136&lt;/p&gt;" WIDTH="224">
<FLOWCHARTBOX TEXT="&lt;p&gt;records after duplicates removed, n = 5136&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;records identified through database searching, n = 5894&lt;/p&gt;" WIDTH="207"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;additional records identified through other sources, n = 1&lt;/p&gt;" WIDTH="221"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;records excluded, n = 5067&lt;/p&gt;" WIDTH="210"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Full-text articles excluded, with reasons, n = 22&lt;/p&gt;&lt;p&gt;Non-randomised: 12&lt;/p&gt;&lt;p&gt;No intervention of interest: 4&lt;/p&gt;&lt;p&gt;Non-clinical trial: 2&lt;/p&gt;&lt;p&gt;Non-comparative: 3&lt;/p&gt;&lt;p&gt;No controls: 1&lt;/p&gt;&lt;p&gt;Secondary publications of primary studies already included in the review, n = 20&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="328"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>